IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
US009550837B2
lI2~ United States Patent
Sleeman et al.
(Io) Patent No. : US 9,550,837 B2
(45) Date of Patent: *Jan. 24, 2017
(54) THERAPEUTIC USES OF ANTI-PCSK9
ANTIBODIES
(71) Applicant: REGENERON
PHARMACEUTICALS, INC. ,
Tarrytown, NY (US)
(72) Inventors: Mark W. Sleeman, Melbourne (AU);
Joel H. Martin, Putnam Valley, NY
(US); Tammy T. Huang, Goldens
Bridge, NY (US); Douglas MacDonald,
New York, NY (US)
(73) Assignee: Regeneron Pharmaceuticals, Inc. ,
Tarrytown, NY (US)
(56) References Cited
U.S. PATENT DOCUMENTS
5,260,440 A 11/1993 Hirai
5,273,995 A 12/1993 Roth
(Continued)
FOREIGN PATENT DOCUMENTS
(52) U.S. Cl.
CPC ......... C07K 16/40 (2013.01); A6/K 2039/505
(2013.01); C07K 23/7/2/ (2013.01);
(Continued)
(58) Field of Classification Search
CPC ...... C07K 16/40; A61K 39/3955; A61K 31/40
See application file for complete search history.
( * ) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35 CN
U.S.C. 154(b) by 0 days.
This patent is subject to a terminal dis-
claimer.
101489565 7/2009
0409281 I/1991
(Continued)
OTHER PUBLICATIONS
(21) Appl. No. : 14/737, 4SS
(22) Filed: Jun. 12, 2015
LaGace et al, lI Clin Invest Am So Clin Invest. Nov. I,
2006; II6lt ti:2995-30051.*
(Continued)
(65) Prior Publication Data
US 2015/0284474 Al Oct. 8, 2015
Primary Examiner Cherie M Stanfield
(74) Attorney, Agent, or Firm Swanson k Bratschun,
L.L.C.
(51) Int. Cl.
A 61K 39/395
C07K 16/40
A6/K 39/00
(2006.01)
(2006.01)
(2006.01)
Related U.S. Application Data
(60) Continuation of application No. 13/690, 585, filed on
Nov. 30, 2012, now abandoned, which is a
(Continued)
(57) ABSTRACT
An human antibody or antigen-binding fragment of a human
antibody that specifically binds and inhibits human propro-
tein convertase subtilisin/kexin type 9 (hPCSK9) character-
ized by the ability to reduce serum LDL cholesterol by
40-80% over a 24, 60 or 90 day period relative to predose
levels, with little or no reduction in serum HDL cholesterol
and/or with little or no measurable efiect on liver function,
as determined by ALT and AST measurements.
10 Claims, 14 Drawing Sheets
US 9,550,837 B2
Page 2
Related U.S. Application Data
continuation of application No. 12/949, 846, filed on
Nov. 19, 2010, now Pat. No. 8,501,184, which is a
division of application No. 12/637, 942, filed on Dec.
15, 2009, now Pat. No. 8,062,640.
(60) Provisional application No. 61/122, 482, filed on Dec.
15, 2008, provisional application No. 61/210, 566,
filed on Mar. 18, 2009, provisional application No.
61/168,753, filed on Apr. 13, 2009, provisional
application No. 61/218, 136, filed on Jun. 18, 2009,
provisional application No. 61/249, 135, filed on Oct.
6, 2009, provisional application No. 61/261, 776, filed
on Nov. 17, 2009.
(56) References Cited
U.S. PATENT DOCUMENTS
5,399,670
5,851,999
5,939,598
6,011,003
6, 171,586
6,267,958
6,270,993
6,596,541
6,629,949
6,659,982
6,875,432
7,001,892
7,029,895
7,060,268
7, 129,338
7,300,754
7,482, 147
7,572,618
7,608,693
7,754,208
8,030,457
8,062,640
8,080,243
8,092,803
8, 168,762
8, 188,233
8, I gg, 234
8,357,371
2003/0092606
2003/0113316
2003/0118592
2003/0133939
2004/0101920
2004/0197324
2005/0281831
2006/0147945
2007/0082345
2007/0224663
2008/0008697
2009/01423 52
2009/0232795
2009/0246192
2009/0269350
2009/0318536
2009/0326202
2010/0040610
2010/0040611
2010/0041102
A 3/1995
A 12/1998
A 8/1999
A I/2000
BI I/2001
BI 7/2001
BI 8/2001
B2 7/2003
BI 10/2003
B2 12/2003
B2 4/2005
BI 2/2006
B2 4/2006
B2 6/2006
BI 10/2006
B2 11/2007
B2 I/2009
B2 8/2009
B2 10/2009
B2 7/2010
B2 * 10/2011
B2 11/2011
B2 12/2011
B2 I/2012
B2 5/2012
B2 5/2012
B2 5/2012
B2 I/2013
Al 5/2003
Al 6/2003
Al 6/2003
Al 7/2003
Al 5/2004
A I 10/2004
Al 12/2005
Al 7/2006
Al 4/2007
Al 9/2007
Al * I/2008
Al 6/2009
Al 9/2009
A I 10/2009
A I 10/2009
A I 12/2009
A I 12/2009
Al 2/2010
Al 2/2010
Al 2/2010
Bhattacharya
Ulrich
Kucherlapati
Charmock- Jones
Lam
Andya
Shibuya
Murphy
Douglas
Douglas
Liu
Chmielewski
Glue ksmann
Andya
Ota
Abi Fadel et al.
Glue ksmann
Mintier
Martin
Ledbetter
Jackson
Sleeman
Liang
Furfine
Jackson
Condra
Condra
Sleeman
L'Italien
Kaisheva
Ledbetter
Ledbetter
Radziej ewski
Liu
Davis-Smyth
Edmonds
Ota
Rosen
Mintier .... ... ... .
Jackson
Condra
Condra
Glue ksmann
Freier
Jackson
Sitlani
Sparrow
Sitlani
A61K 31/22
424/130. 1
C12N 9/6424
424/94. 63
(52) U.S. Cl.
CPC .... COD 23/7/56 (2013.01); COD 23/7/565
(2013.01); COD 23/7/76 (2013.01); COD
23/ 7/92 (2013.01)
2010/0068199 Al
2010/0136028 Al
2010/0150937 Al
2010/0166768 Al
2010/0233177 Al
2011/0027287 Al
2011/0033465 Al
2011/0065902 Al
2011/0098450 Al
2011/0111406 Al
2011/0142849 Al
2011/0171241 Al
2011/0229489 Al
2011/0256148 Al
2012/0014951 Al
2012/0015435 Al
2012/0020975 Al
2012/0027765 Al
2012/0076799 Al
2012/0077964 Al
2012/0082679 Al
2012/0082680 Al
2012/0093818 Al
2012/0097565 Al
2012/0195910 Al
2012/0213794 Al
2012/0213797 Al
2012/0219558 Al
2012/0231005 Al
2012/0251544 Al
2013/0011866 Al
2013/0064825 Al
2013/0064834 Al
3/2010
6/2010
6/2010
7/2010
9/2010
2/2011
2/2011
3/2011
4/2011
5/2011
6/2011
7/2011
9/2011
10/2011
I/2012
I/2012
I/2012
2/2012
3/2012
3/2012
4/2012
4/2012
4/2012
4/2012
8/2012
8/2012
8/2012
8/2012
9/2012
10/2012
I/2013
3/2013
3/2013
Liang
Sparrow
Sparrow
Sleeman
Yowe
Jackson
Hedrick
Sleeman
Igawa
Igawa
Rue
Dix
Pons
Sleeman
Liang
Liange
Jackson
Jackson
Sparrow
Sparrow
Sparrow
Sitlani
Jackson
Dix
WU
Luo
Jackson
Ni
Luo
Jackson
Igawa
Chan
Sleeman
EP
EP
EP
EP
EP
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
Wo
0521471
1067182
1514933
1317537
1618212
Wo 93/00807
WO97/35620
Wo 98/22136
Wo 99/38495
Wo 01/57081
Wo 2004/055164
Wo 2005103081
Wo 2007/143315
Wo 2007/149334
Wo 2008/057457
Wo 2008/057458
Wo 2008/057459
Wo 2008/063382
Wo 2008057457 A2
Wo 2008057458 A2
Wo 2008057459 A2
Wo 2008063382 A2
Wo 2008/125623
Wo 2008125623 A2
Wo 2008/133647
Wo 2009/026558
Wo 2009/055783
Wo 2009/100297
Wo 2009/100318
Wo 2010/029513
Wo 2010/077854
Wo 2010/102241
Wo 2011/028938
Wo 2011/039578
Wo 2011/053759
Wo 2011/061712
Wo 2011/111007
Wo 2012/054438
Wo 2012/064792
Wo 2012/101251
Wo 2012/101252
Wo 2012/101253
Wo 2012/109530
I/1993
I/2001
3/2005
12/2006
11/2007
I/1993
10/1997
5/1998
8/1999
8/2001
7/2004
11/2005
12/2007
12/2007
5/2008
5/2008
5/2008
5/2008
5/2008
5/2008
5/2008
5/2008
10/2008
10/2008
11/2008
2/2009
4/2009
8/2009
8/2009
3/2010
7/2010
9/2010
3/2011
4/2011
5/2011
5/2011
9/2011
4/2012
5/2012
8/2012
8/2012
8/2012
8/2012
FOREIGN PATENT DOCUMENTS
US 9,550,837 B2
Page 3
References Cited
FOREIGN PATENT DOCUMENTS
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO 2012/146776
WO 2012/154999
WO 2013/039969
WO 2013158984
WO 2013/166448
WO 2014/194111
WO 2014/197752
WO 2015/054619
WO 2015/073494
WO 2015/123423
WO 2015/140079
WO 2015/142668
WO 2016/011256
WO 2016/011260
11/2012
11/2012
3/2013
10/2013
11/2013
12/2014
12/2014
4/2015
5/2015
g/2015
9/2015
9/2015
I/2016
I/2016
OTHER PUBLICATIONS
Anonymous; A Randomized, Double-Blind, Placebo-Controlled,
Parallel Group Study to Evaluate the Eflect of Alirocumab
iSAR236553/REGN727i on the Occurrence of Cardiovascular
Events in Patients Who Have Recently Experienced an Acute
Coronary Syndrome. Archive from ClinicalTrials. gov for
NCT01663402 on Mar. 11, 2014 i3 pages).
Anonymous: Long-term Safety and Tolerability of Alirocumab
SAR236553 iREGN727i in High Cardiovascular Risk Patients
With Hypercholesterolemia Not Adequately Controlled With Their
Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-
Controlled Study. Archive from ClinicalTrials. gov for
NCTOI507831 on Jun. 27, 2013 i3 pages).
Blom, Dirk J, et als "A 52-Week Placebo-Controlled Trial of
Evolocumab in Hyperlipidemia" vol. 370, No. 19, May g, 2014 pp.
1809-1819.
Costet. PCSK9 inhibitors as LDL cholesterol-lowering agents;
Rationale, concerns and preliminary outcomes. Drugs of the Future.
May I, 2012, vol, 37, No. 5, pp. 331-341.
Gonnet et als Exhaustive Matching of the Entire Protein Sequence
Database; Science; 1992, vol. 256, pp. 1443-1445.
Gusarova V, Sleeman M, Swergold G, Sasiela B, Stahl N,
Yancopoulos G, Murphy A. Fully human antibody that blocks
PCSK9 demonstrates reduction in LDL-C preclinically and in early
clinical trials. Abstract of oral presentation at the Keystone Sym-
posia on Molecular and Cellular Biology, Mar. 25-30, 2012, Mon-
tana, USA.
Haddley et al. ALIROCUMAB Anti-Proprotein Convertase 9
iPCSK9i Mab Treatment of Hypercholesterolemia. Drugs of the
Future; Apr. I, 2013, vol, 3g, No. 4, pp, 215-216.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M,
Stroes E, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor N,
Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. Long-term
safety, tolerability and efficacy of alirocumab versus placebo in high
cardiovascular risk patients: first results from the Odyssey Long
Term study in 2,341 patients; presented at ESC Congress Aug. 31,
2014, abstract not published.
Roth et al. Alirocumab for hyperlipidemia; physiology of PCSK9
inhibition, pharmacodynamics and Phase I and H clinical trial
results of a PCSK9 monoclonal antibody. Future Cardiology. Mar.
2014; vol. 10, No. 2, pp, 187-197. 183-199.
Shao W. New Therapies for Lowering LDL-C; Targeting PCSK9.
Abstract of oral presentation at the Sino-American Pharmaceutical
Professionals Association 2014 Scientific Symposium, Apr. 26,
2014, New Jersey, USA.
Swergold GD, et al. Identification and characterization of patients
with autosomal dominant hypercholesterolemia caused by gain-of-
function mutations in proprotein convertase subtilisin/kexin type 9
and comparison with patients with Familial Hypercholesterolemia
iFHi and Familial Defective apolipoprotein B iFDBi. Abstract of a
poster presentation at the American Society of Human Genetics
iASHGi, Oct. 22-26, 2013, Boston, USA.
Chinese Patent Application No. 201280015477.6, Office Action
dated Dec. 2, 2014 with English summary, 12 pages.
Chinese Patent Application No. 201280015571.I, Office Action
dated Sep. 3, 2014 with English summary, 12 pages.
European Patent Application No. 12701015.5, Communication pur-
suant to Article 94i3i EPC dated Apr. 24, 2015, 9 pages.
European Patent Application No. 12701015.5, Communication pur-
suant to Article 94i3i EPC dated May 30, 2014, g pages.
European Patent Application No. 12701742.4, Communication pur-
suant to Article 94i3i EPC dated May 2g, 2014, g pages.
Dube, et al, i2012i Curr Opin Lipidol 23i2i;133-140,
"Lipoproteiniai; more interesting than ever after 50 years".
Koschinsky and Bofla i2014i Endocrinology and Metabolism Clin-
ics of North America 43i4i:949-962, "Lipoproteiniai: An Important
Cardiovascular Risk Factor and a Clinical Conundrum".
Lamon-Fava, et al, i20IIi Journal of Lipid Research 52:I ISI-I I 87
"Lipoproteiniai levels, apoiai isoform size, and coronary heart
disease risk in the Framingham Ofl'spring Study".
Third Party Observation for European Patent Application No.
12761864.3 dated Feb. 24, 2016.
Tsimikas, et al, i2015i The Lancet 386iI0002i:1472-1483, "Anti-
sense therapy targeting apolipoproteiniai; a randomised, double-
blind, placebo-controlled phase I study".
Davidson et al, i20IIi Journal of Clinical Lipidology 5;338-367,
"Clinical utility of inflammatory markers and advanced lipoprotein
testing: Advice from an expert panel of lipid specialists".
Rader, et al, iI995i The Journal of Clinical Investigation, Inc.
95;1403-1408, "The Low Density Lipoprotein Receptor Is Not
Required for Normal Catabolism of Lpiai in Humans".
Kostner et al, i2013i European Heart Journal 34:3268-3276, "When
should we measure lipoprotein iai?".
Abifadel, et al. , 2012 Atherosclerosis 223i2i:394-400, "Identifica-
tion and characterization of new gain-of-function mutations in the
PCSK9 gene responsible for autosomal dominant
hyperchole sterol emia".
Abifadel, et al. , 2009 Human Mutation 30i4i;520-529, "Mutations
and polymorphisms in the proprotein convertase subtilisin kexin 9
iPCSK9i gene in cholesterol metabolism and disease".
Abifadel, et al, i2003i Nature Genetics 34i2i;154-156, "Mutations
in PCSK9 cause autosomal dominant hypercholesterolemia".
Alborn, et al, i2007i Clinical Chemistry 53iIOi; IS 14-1819,"Serum
proprotein convertase subtilisin Kexin type 9 is correlated directly
with serum LDL cholesterol".
Al-Mashhadi et al. , 2013 Science Translation Medicine, American
Association for the Advancement of Science 5iI66i:44-53, "Ath-
erosclerosis; Familial hypercholesterolemia and atherosclerosis in
clones minipigs created by DNA transposition of a human PCSK9
gain-of-function mutant".
Almagro et al. , 'Humanization of antibodies. ' Frontiers in Biosci-
ence. 2008, vol. 13, pp. 1619-1633.
Altschul et al. , 'Basic local alignment search tool. ' Journal of
Molecular Biology. 1990, vol. 215, No. 3, pp. 403-410.
Altschul et al. , 'Gapped BLAST and PSI-BLAST; a new generation
of protein database search programs. ' Nucleic Acids Research.
1997, vol. 25, No. 17, pp. 3389-3402.
AMGen; 'Ascending Multiple Dose Study to Evaluate the Safety,
Tolerability, Pharmacokinetics and Pharmacodynamics of AMG
145 in Subjects With Hyperlipidemia on Stable Doses of a Statin'.
May 27, 2010, XP002682099. Retrieved from the Internet;
clinic altrials, gov/ct2/show/nct01133 522?term=amg+ 145&rank=2
Accessed on Aug. 6, 2014.
Angal et al. ,
'A single amino acid substitution abolishes the het-
erogeneity of chimeric mouse/human iigG4i antibody. ' Molecular
Immunology. 1993, vol. 30, No. I, pp. 105-108.
Attic and Seidah i2005i Cell Metabolism 5:290-292, "Dual regu-
lation of the LDL receptor Some clarity and new questions".
Annex to Form PCT/ISA/206 Communication Relating to the
Results of the Partial International Search for PCT/US2009/068013,
mailed Mar. 10, 2010.
Benjannet, et al, i2006i J. Biological Chemistry 2gli4Ii; 30561-
30572, "The Proprotein Convertase iPCi PCSK9 Is Inactivated by
Furin and/or PC5/6A".
US 9,550,837 B2
Page 4
References Cited
OTHER PUBLICATIONS
Bird et al. , 'Single-chain antigen-binding proteins. ' Science. 19gg,
vol. 242, No. 4877, pp. 423-426.
Chan, et al. (2009i PNAS 106(24i;9820-9825, "A proprotein
convertase subtilisin/kexin type 9 neutralizing antibody reduces
serum cholesterol in mice and nonhuman primates".
Chaparro-Riggers, et al. (2012i J. Biological Chemistry
287(14i; 11090-11097, "Increasing serum half-life and extending
cholesterol lowering in vivo by engineering antibody with pH-
sensitive binding to PCSK9".
Fallon, et al. (2000i J. Biological Chemistry 275(IOi:6790-6797,
"Increased endosomal sorting of ligand to recycling enhances
potency of an intereukin-2 analog".
Farnier, 2011 American Journal of Cardiovascular Drugs I I(3i:145-
152, "The role of proprotein convertase subtilisin/kexin type 9 in
hyperlipidemia: Focus on therapeutic implications".
Fasano, et al. , 2008 NMCD Nutrition Metabolism and Cardiovas-
cular Diseases Ig(li; S46, "45 Activity of Gain-of-Function PCSK9
Mutants on LDLR Correlates with Total-Cholesterol Values in ADH
patients".
Foote and Winter (1992i J. Mol. Biol. 224;487-499, "Antibody
Framework Residues Afiecting the Conformation of the Hypervari-
able Loops".
Grozdanov, et al. (2006i Biochem. Cell. Biol. 84:80-92, Expression
and localization of PCSK9 in rat hepatic cells.
Heap et al. , 'Analysis of a 17-amino acid residue, virus-neutralizing
microantibody. ' Journal of General Virology. 2005, vol. 86, No. 6,
pp. 1791-1800.
Holliger et al. , 'Diabodies: small bivalent and bispecific antibody
fragments. ' Proceedings of the National Academy of Sciences.
1993, vol. 90,No. 14, pp. 6444-6448.
Huston et al. 'Protein engineering of antibody binding sites: recov-
ery of specific activity in an anti-digoxin single-chain Fv analogue
produced in Escherichia coh. ' Proceedings of the National Acad-
emy of Sciences. 19gg, vol. 85, No. 16, pp. 5879.
Hopkins, et al. , 2011 Journal of Clinical Lipidology 5(3i:S9-SI7,
"Familial Hypercholesterolemias; Prevalence, genetics, diagnosis
and screening recommendations from the National Lipid Associa-
tion Expert Panel on Familial Hypercholesterolemia".
Horton, et al. (2007i Trends Biochem Sci. 32(2i; 71-77, "Molecular
biology of PCSK9; its role in LDL metabolism".
Igawa, et al. (2010i Nature Biotechnology 2g(IIi:1203-1208,
"Antibody recycling by engineered pH-dependent antigen binding
improves the duration of antigen neutralization".
Ito, et al. (1992i Federation of European Biochemical Societies
309(li;85-gg, "The His-probe method: efiects of histidine residues
introduced into the complementarity-determining regions of anti-
bodies on antigen-antibody interactions at difierent pH values".
Jorgensen et al. (2013i European Heart Journal 34;1826-1833,
"Genetically elevated non-fasting triglycerides and calculated rem-
nant cholesterol as casual risk factors for myocardial infarction".
Kawashiri, et al. (2012i Circulation 126(2 I i:13869, "Statin Therapy
Improves Fractional Catabolic Rate of LDL without Afiecting
Impaired VLDL and VLDL Remnant Catabolism in Homozygous
FH Patient Due to PCSK9 Gene Mutation; Evidence from Kinetic
Study with Stable Isotope".
Lagace, et al. (2006i J Clin Invest Am Soc Clin Invest
II6(IIi:2995-3005, "Secreted PCSK9 decreases the number of
LDL receptors in hepatocytes and in liver of parabiotic mice".
Langer et al. , 'New methods of drug delivery. ' Science. 1990, vol.
249, No. 4976, pp. 1527-1533.
Langer et al. , 'Medical Applications of Controlled Release. ' CRC
Press, Boca Raton, Florida. 1984, pp. II5-138.
Leuenberger et al. ,
'A Multilingual Glossary of Biotechnological
Terms. ' Recueil des Travaux Chimiques des Pays Bas. 1996, vol.
115, No. 7, pp. 382.
Lippi and Guidi (2000i QJ Med 93;75-84, "Lipoprotein(ai; from
ancestral benefit to modern pathogen?".
Lopez, Dayami (200gi Drug News & Perspectives Abstract 21(6i;
323, "Inhibition of PCSK9 as a Novel Strategy for the Treatment of
Hypercholesterolemia".
Lose, et al. , 2013 Pharmacotherapy: The Journal of Human Phar-
macology and Drug Therapy 33(4i;447-460, "Evaluation of
Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential
Clinical and Therapeutic Implications for Low-Density Lipoprotein
Cholesterol Lowering".
Marcovina and Koschinsky (199gi The American Journal of Car-
diology 82(12Ai:57U-66U, "Lipoprotein(ai as a Risk Factor for
Coronary Artery Disease".
Maxwell and Breslow (2004i PNAS IOI(lgi:7100-7105,
"Adenoviral-mediated expression of Pcsk9 in mice results in a
low-density lipoprotein receptor knockout phenotype".
McKenney, et a. (2012i Journal of the American College of Car-
diology 59(25i;2335-2353, "Safety and Efficacy of a Monoclonal
Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine
Protease, SAR236553/REGN727, in Patients With Primary
Hypercholesterolemia Receiving Ongoing Stable Atorvastatin
Therapy".
Nakasako, et a. (1999i J. Mol. Biol. 291:117-134, "The pH-
dependent structural variation of complementarity-determining
region H3 in the crystal structures of the Fv fragment from an
anti-dansyl monoclonal antibody".
Naureckiene, et al. (2003i Archives of Biochemistry and Biophysics
420;55-67, "Functional characterization of Narc I, a novel
proteinase related to proteinase K".
Noguchi, et al. , 2010 Atherosclerosis 210(li;166-172, "The E32K
variant of PCSK9 exacerbates the phenotype of familial
hypercholesterolemia by increasing PCSK9 function and concen-
tration in the circulation".
Nordestgaard, et al. (2010) European Hear Journal 31;2844-2853,
"Lipoprotein(si as cardiovascular risk factor: current status".
Padlan et al. , 'Identification of specificity-determining residues in
antibodies. ' The FASEB Journal. 1995, vol. 9, No. I, pp. 133-139.
Parhofer (20 IIi Current Pharmaceutical Design 17;871-876,
"Lipoprotein(ai: Medical Treatment Options for an Elusive Mol-
ecule".
Park, et al. (2004i J. Biol. Chem. 279; 50630-50638, "Lipids and
Lipoproteins: Post-transcriptional Regulation of Low Density Lipo-
protein Receptor Protein by Proprotein Convertase Subtilisin/Kexin
Type 9a in Mouse Liver".
Partial International Search Report mailed Nov. 6, 2014 for Inter-
national Application No. PCT/US2014/040163.
Pfizer: 'Safety and Tolerability of Multiple Doses of PF-04950615
(RN316i in Subjects With Hypercholesterolemia. ' Nov. 3, 2012,
XP002682100. Retrieved from the Internet; clinicaltrials. gov/ct2/
show? term=rn3 16&rank=2.
Pearson, William R., 'Using the FASTA program to search protein
and DNA sequence databases. ' Computer Analysis of Sequence
Data. 1994, pp. 307-331.
Powell et al. , 'Compendium of Excipients for Parenteral Formula-
tions PDA. ' Journal of Pharmaceutical Science and Technology.
1998, vol. 52, No. 5, pp. 238-3II.
Qui et al. , 'Small antibody mimetics comprising two complemen-
tarity-determining regions and a framework region for tumor tar-
geting. ' Nature Biotechnology. 2007, vol. 25, No. g, pp. 921-929.
Rhainds, et al. , 2012 Clinical Lipidology 7(6i:621-640, "PCSK9
inhibition and LDL cholesterol lowering: The biology of an attrac-
tive therapeutic target and critical review of the latest clinical trials".
Rashid, et al. (2005i PNAS 102(15i;5374-5379, "Decreased plasma
cholesterol and hypersensitivity to statins in mice lacking Pcsk9".
Reddy et al. , 'Elimination of Fc receptor-dependent efiector func-
tions of a modified IgG4 monoclonal antibody to human CD4. ' The
Journal of Immunology. 2000, vol. 164, No. 4, pp. 1925-1933.
Reineke, Ulrich, 'Antibody epitope mapping using arrays of syn-
thetic peptides. ' Antibody Engineering. Humana Press. 2004, pp.
443-463.
Sarkar, et al. (2002i Nature Biotechnology 20;908-913, "Rational
cytokine design for increased lifetime and enhanced potency using
pH-activated histidine switching".
US 9,550,837 B2
Page 5
References Cited
OTHER PUBLICATIONS
Seidah, et al, i2003i PNAS 100i3i:928-933, "The secretory
proprotein convertase neural apoptosis-regulated convertase I
iNARC-Ii; liver regeneration and neuronal ditferentiation".
Sefton, Michael V., 'Implantable Pumps. ' Critical Reviews in Bio-
medical Engineering. 1986, vol. 14, No. 3, pp. 201-240.
Seidah et al. , 'The secretory proprotein convertase neural apoptosis-
regulated convertase I iNARC-I i: liver regeneration and neuronal
difierentiation. ' PNAS. 2003, 100i3i;928-933.
Soutar, Anne, 'Unexpected Roles for PCSK9 in Lipid Metabolism. '
Current Opinion in Lipidology. 2011, vol. 22, pp. 192-196.
Stein and Swergold, 2013 Current Atherosclerosis Reports
15i310i:1-14, "Potential of proprotein Convertase Subtilisin/Kexin
Type 9 Based Therapeutics".
Stein, et al. , 2012 Obstetrical and Gynecological Survey 67i7i:413-
414, "Etfect of a monoclonal antibody to PCSK9 on LDL choles-
terol".
Stein, et al, i2012i New England Journal of Medicine 366:IIOg-
IIIg, "Efiect of a Monoclonal Antibody to PCSK9 on D Choles-
terol".
Stein, et al, i2012i The Lancet 380:29-36, "Efiect of a monoclonal
antibody to PCSK9, REGN727/SAR236553, to reduce low-density
lipoprotein cholesterol in patients with heterozygofamilial
hypercholesterolemia on stable statin dose with or without
ezetimibe therapy; a phase 2 randomized controlled trial".
Timms, et al, i2004i Human Genetics I 14i4i;349-353, "A mutation
in PCSK9 causing autosomal-dominant hypercholesterolemia in a
Utah pedigree".
Toth, et al. , i2013i Circulation 12gi22i;17492, "Alirocumab, a
Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Anti-
body, Reduces Cholesterol Concentrations of Serum Remnant Lipo-
protein Fractions, Very Low-Density Lipoproteins and
Triglycerides".
Tiwari et al. , 'Statins therapy: a review on conventional and novel
formulation approaches. ' Journal of Pharmacy and Pharmacology.
2011, vol. 63, No. g, pp. 983-998.
Tutt et al. , 'Trispecific F iab'i 3 derivatives that use cooperative
signaling via the TCR/CD3 complex and CD2 to activate and
redirect resting cytotoxic T cells. ' The Journal of Immunology.
1991, vol. 147, No. I, pp. 60-69.
Varbo, et al. , i2013i Journal of the American College of Cardiology
6Ii4i;427-436, "Remnant Cholesterol as a Casual Risk Factor for
Ischemic Heart Disease".
Vajdos, et al, i2002i Journal of Molecular Biology 320:415-428,
"Comprehensive functional maps of the antigen-binding site of an
annti-ErbB2 antibody obtained with shotgun scanning
mutagenesi s".
Watanabe, et al, i2009i J. Biological Chemistry 284ilgi;12373-
12383, "Optimizing pH response of atfinity between protein G and
IgG Fc".
Winter and Harris i 1993] Immunology Today 14i6i:243-246,
"Humanized Antibodies".
Ward et al. , 'Binding activities of a repertoire of single immuno-
globulin variable domains secreted from Escheri chi a coh. ' Nature.
1989, vol. 341, No. 6242, pp. 544-546.
Wu et al. , 'Receptor-mediated in vitro gene transformation by a
soluble DNA carrier system. ' Journal of Biological Chemistry.
1987, vol. 262, No. 10, pp. 4429-4432.
Colhoun, et al. , i2014i BMC Cardiovascular Disorders, Biomed
Central 14ili:121, "Efficacy and safety of alirocumab, a fully
human PCSKO monoclonal antibody, in high cardiovascular risk
patients with poorly controlled hypercholesterolemia on maximally
tolerated doses of statins: rationale and design of the ODYSSEY
COMBO I and H trials".
Kastelein et al. , i2014i Cardiovascular Drugs and Therapy
2gi3i:281-289, "Efficacy and Safety of Alirocumab in Patients with
Heterozygous Familial Hypercholesterolemia not Adequately Con-
trolled with Current Lipid-Lowering Therapy; Design and Rationale
of the ODYSSEY FH Studies".
Robinson et al. , i2014i Clinical Cardiology 37iIOi;597-604, "Etfi-
cacy and Safety of Alirocumab as Add-on Therapy in High-
Cardiovascular-Risk Patients with Hypercholesterolemia Not
Adequately Controlled with Atorvastatin i20 or 40 mgi or
Rosuvastatin i IO or 20 mgi: Design and Rationale of the ODYSSEY
OPTIONS Studies".
International Search Report dated Aug. 19, 2015 for International
Application No. PCT/US2015/015633.
Bays H, Farnier M, Gaudet D, Weiss R, Lima Ruiz J, Watts GF,
Gouni-Berthold I, Robinson J, Jones P, Severance R, Averna M,
Steinhagen-Thiessen E, Colhoun HM, Zhao J, Du Y, Hanotin C,
Donahue S. Efficacy and safety of combining alirocumab with
atorvastatin or rosuvastatin versus statin intensification or adding
ezetimibe in high cardiovascular risk patients: ODYSSEY
OPTIONS I and H, Circulation. 2014;130;2105-2126.
Bays H; Gaudet D; Weiss R; Lima Ruiz J; Watts GF; Gouni-
Berthold I; Robinson J; Zhao J; Hanotin C; Donahue S. PCSK9
Inhibitor Alirocumab as Add-on to Atorvastatin versus Other Lipid
Treatment Strategies in Patients at High CVD Risk; ODYSSEY
OPTIONS I. Circulation. 2014;130:A16194.
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy
R, Chaudhari U, Colhoun HM. Efficacy and safety of alirocumab in
high cardiovascular risk patients with inadequately controlled
hypercholesterolaemia on maximally tolerated daily statin: results
from the ODYSSEY COMBO H study; presented at ESC Congress
Aug. 31, 2014, abstract not published.
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy
R, Chaudhari U, Colhoun HM; for the ODYSSEY COMBO H
Investigators. Efficacy and safety of alirocumab in high cardiovas-
cular risk patients with inadequately controlled
hypercholesterolaemia on maximally tolerated doses of statins: the
ODYSSEY COMBO H randomized controlled trial Eur Heart J.
2015, doi: 10.1093/eurheartj/ehv02g [epub ahead of print].
Catapano AL, Papadopoulos N. The safety of therapeutic monoclo-
nal antibodies; implications for cardiovascular disease and targeting
the PCSK9 pathway. Atherosclerosis 2013;22gili; Ig-2g.
Dutf et al. Biochem Journal, the Biochemical Society, vol. 419, No.
3, May I, 2009 pp. 577-584.
Dufour R, Moriarty PM, Genestin E, Sasiela WJ, Du Y, Ferrand
A-C; Ginsberg HN. Efiect of REGN727/SAR236553 PCSK9 fully
human monoclonal antibody in patients with elevated triglycerides/
low high-density lipoprotein cholesterol: data from three phase 2
studies. Circulation 2012;126:Abstract A16127.
Farnier M, Kastelein JJP, Roth E, Taskinen MR, Ginsberg HN,
Colhoun HM, Robinson JG, Merlet L, Brunet A, Pordy R, Baccara-
Dinet MT. Relationship between alirocumab, PCSK9 and LDL-C
levels; results from the ODYSSEY MONO Phase 3 trial of
alirocumab 75 mg every 2 weeks. Atherosclerosis.
2014;235i2i:e34-e35. [Abstract MP02E].
Foody J, Khan I, Lewis B. Attainment of low-density lipoprotein
cholesterol goals in patients at high cardiovascular risk; results from
a managed care population study. Circulation. 2013;128;AI7254.
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D,
Du Y, Ferrand A-C, Ginsberg H, Stein E. Alirocumab, a fully human
monoclonal antibody to PCSK9, reduces high plasma Lpiai con-
centration: pooled analysis of 352 patients from phase 2. J Clin
Lipidol 2013:7i3i;283-284.
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D,
Du Y, Ferrand A-C, Ginsberg H, Stein E. Efiect of Alirocumab, a
Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on
Lipoproteiniai Concentrations ia Pooled Analysis of 150 mg Every
2 Weeks Dosing from Phase 2 Trials). Am J Cardiol.
2014; II4i5i:711-715.
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D,
Du Y, Ferrand A-C, Ginsberg H, Stein E. Efiect of SAR236553/
REGN727 fully human monoclonal anti-proprotein convertase
subtilisin/kexin type 9 antibody on plasma lipoproteiniai concen-
trations: pooled analysis from three phase 2 studies
iNCT;01266876; 01288469; 012gg443i. Circulation
2012;126;Abstract A14725.
US 9,550,837 B2
Page 6
(56) References Cited
OTHER PUBLICATIONS
Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Lorenzato C, Pordy
R, Baccara-Dinet MT, Stroes E. ODYSSEY HIGH FH; efficacy and
safety of alirocumab in patients with severe heterozygous familial
hypercholesterolemia. Circulation. 2014;130;2119.
Gusarova V, Howard VG, Okamoto H, Koehler-Stec EM
Papadopoulos N, Murphy AJ, Yancopoulos GD, Stahl N, Sleeman
MW. Reduction of LDL cholesterol by a monoclonal antibody to
PCSK9 in rodents and nonhuman primates. Clin Lipidol
2012;7i6i;737-743.
Hochleitner et al. , Characterization of a discontinuous epitope of the
human immunodeficiency virus -HIV! core protein p24 by epitope
excision and difierential chemical modification followed by mass
spectrometric peptide mapping analysis; Protein Science 2000,
9:487-496. Cambridge University Press.
Hopkins PN, Swergold GD, Mellis S, Bruckert E, Luc G, Mendoza
J, Du Y, Krempf M. A randomized placebo-phase clinical trial with
the monoclonal antibody alirocumab demonstrates reductions in
low-density lipoprotein cholesterol in patients with proprotein
convertase subtilisin/kexin type 9 gain-of-function mutations. Cir-
culation. 2013;12g;A17156.
Hovingh GK, Davidson MH, Kastelein JJ, O' Connor AM. Diagno-
sis and treatment of familial hypercholesterolaemia. Eur Heart J
2013;34iI3i;962-971.
International Preliminary Report on Patentability dated Jul. 30,
2013 for International application No. PCT/EP12/051321, 7 pages.
International Search Report and Written Opinion dated Aug. 19,
2015 for International application No. PCT/US2015/015633, 23
pages.
International Search Report and Written Opinion mailed Apr. 16,
2015 for International Application No. PCT/US2014/060109 i 19
pages).
International Search Report and Written Opinion mailed Feb. 3,
2015 for International Application No. PCT/US2014/065149 i 17
pages).
International Search Report and Written Opinion mailed Jun. 12,
2015 for International Application No. PCT/US2015/020564 i20
pages).
International Search Report dated Aug. 2, 2012 for International
application No. PCT/EP12/051321, i4 pages).
Jones P, Bays H, Chaudhari U, Pordy R, Lorenzato C, Miller K,
Robinson J. Pooled safety and adverse events in nine randomized,
placebo-controlled, phase 2 and 3 clinical trials of alirocumab. J Am
Coll Cardiol 2015;65iI0 Si:AI363.
Junghans et al. : Anti-Tac-H, a Humanized Antibody to the
Interleukin 2 Receptor with New Features for Immunotherapy in
Malignant and Immune Disorders; Cancer Research, 50. 1495-
1502; Mar. I, 1990.
Kastelein JJP, Ginsberg HN, Langslet G, Kees Hovingh G, Ceska R,
Dufour R, Blom D, Civeira F, Krempf M, Farnier M. Efficacy and
safety of alirocumab in patients with heterozygous familial
hypercholesterolaemia not adequately controlled with current lipid-
lowering therapy: results of ODYSSEY FH I and FH H studies;
presented at ESC Congress Aug. 31, 2014, abstract not published.
Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R,
Chaudhari U, Colhoun HM. Efficacy and safety of alirocumab in
high cardiovascular risk patients with suboptimally controlled
hypercholesterolemia on maximally tolerated doses of statins: the
ODYSSEY COMBO I study. Circulation. 2014;130:2119.
Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R,
Chaudhari U, Colhoun HM. Efficacy and safety of the PCSK9
inhibitor alirocumab among high cardiovascular risk patients on
maximally tolerated statin therapy; the ODYSSEY COMBO I study.
Am Heart J. 2015. In press. DOI: dx.doi. org/10. 1016/j.ahj. 2015.03.
004.
Koren M, Stein E, McKenney JM, Gipe D, Hanotin C, Ferrand A-C,
Wu R, Dufour R. Efficacy, safety and tolerability of 150 mg Q2W
dose of the anti-PCSK9 mAb, REGN727/SAR236553: data from 3
phase 2 studies. Eur Heart J 2012;33iAbstract Supplementi;37.
Abstract 429.
Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P,
Hamon S, Hanotin C, McKenney JM. Efiects of alirocumab, a fully
human monoclonal antibody to proprotein convertase subtilisin/
kexin type 9, on lipoprotein particle concentrations determined by
nuclear magnetic resonance: substudy of a randomized double-blind
phase H clinical trial. J Am Coll Cardiol 2014;63iI2 Suppl Ii;
A1373.
Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand
AC, Wu R, Dufour R. Safety and efficacy of alirocumab 150 mg
every 2 weeks, a fully human proprotein convertase subtilisin/kexin
type 9 monoclonal antibody; a Phase H pooled analysis. Postgrad
Med 2015;22:I-g.
Koren MJ, Stein E, Roth E, McKenney JM, Gipe D, Hanotin C,
Ferrand A-C, Wu R, Dufour R. Efficacy, safety and tolerability of
alirocumab 150 mg Q2W, a fully human PCSK9 monoclonal
antibody: a pooled analysis of 352 patients from phase 2. J Clin
Lipidol 2013;7i3i279-280.
Krauss RM, Banerjee P, Hamon S, Hanotin C, Sasiela B, Koren MJ,
McKenney JM. Alirocumab, a fully human monoclonal antibody to
proprotein convertase subtilisin/kexin type 9, and its efiects on
lipoprotein subfractions determined by ion mobility. Circulation.
2014;130:A15525.
Kiihnast S, van der Hoorn JW, Pieterman E, Sasiela WJ, Gusarova
V, Peyman A, Schafer H-L, Schwahn U, Jukema JW, Princen HM.
PCSK-9 monoclonal antibody alirocumab dose-dependently
decreases atherosclerosis development and enhances the efiects of
atorvastatin in APOE*3Leiden. CETP mice. Circulation.
2013;12g:A15823.
Kiihnast S, van der Hoorn JWA, Pieterman EJ, van den Hock AM,
Sasiela WJ, Gusarova V, Peyman A, Schafer H-L, Schwahn U,
Jukema JW, Princen HMG. Alirocumab inhibits atherosclerosis,
improves the plaque morphology, and enhances the efiects of a
statin. J Lipid Res. 2014;55iIOi;2103-2112.
Lambert G, Chatelais M, Petrides F, Passard M, Thedrez A, Rye KA,
Schwahn U, Gusarova V, Blom DJ, Sasiela W, Marais AD. Nor-
malization of Low-Density Lipoprotein Receptor Expression in
Receptor Defective Homozygous Familial Hypercholesterolemia by
Inhibition of PCSK9 With Alirocumab. J Am Coll Cardiol.
2014;64i2Ii:2299-2300.
Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The
PCSK9 decade. J Lipid Res 2012;53iI2i:2515-2524.
Lunven C, Paehler T, Lewanczyk P, Poitiers F, Brunet A, Rey J,
Hanotin C, Sasiela WJ. A randomized study of the relative bioavail-
ability, pharmacodynamics, and safety of alirocumab, a fully human
monoclonal antibody to proprotein convertase subtilisin/ kexin type
9, after single subcutaneous administration at three difierent injec-
tion sites in healthy subjects. J Am Coll Cardiol 2014;63iI2 Suppl
Ii: A1377.
Lunven C, Paehler T, Poitiers F, Brunet A, Rey J, Hanotin C, Sasiela
WJ. A randomized study of the relative pharmacokinetics,
pharmacodynamics and safety of alirocumab, a fully human mono-
clonal antibody to PCSK9, after single subcutaneous administration
at three difierent injection sites in healthy subjects. Cardiovasc Ther.
Dec. 2014;32i6i:297-301.
McKenney J, Koren M, Kereiakes D, Hanotin C, Ferrand A-C. A
randomized, double-blind, placebo-controlled trial of the safety and
efficacy of a monoclonal antibody to proprotein convertase
subtilisin/kexin type 9 serine protease, REGN727/SAR236553, in
patients with primary hypercholesterolemia iNCT; 012gg443i. Pre-
sented as a late-breaking oral presentation at the American College
of Cardiology iACCi Annual Scientific Session, Mar. 24-27, 2012,
Chicago, Illinois, USA.
Missouri DU Report, Drug Use Review Newsletter, vol. g, No. 6,
Oct./Nov. 2003 "Statin Therapy" pp. 1-9.
Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR,
Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a
monoclonal antibody to PCSK9, in statin-intolerant patients: Design
and rationale of ODYSSEY ALTERNATIVE, a randomized Phase
3 trial. J Clin Lipidol. 2014;gi6i;554-561.
US 9,550,837 B2
Page 7
References Cited
OTHER PUBLICATIONS
Moriarty PM, Lecorps G, Hanotin C, Pordy R, Roth EM. Homo-
geneity of treatment efiect of REGN727/SAR236553, a fully human
monoclonal antibody against PCSK9, in lowering LDL-C; data
from three phase 2 studies. Eur Heart J. 2013;34iSuppl Ii;doh IO.
1093/eurheartj/eht307. 142.
Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J,
Zieve FJ, Bruckert E, Jacobson TA, BaccaraDinet MT, Zhao J,
Pordy R, Gipe R. ODYSSEY ALTERNATIVE; Efficacy and safety
of the proprotein convertase subtilisin/kexin type 9 monoclonal
antibody, alirocumab, versus ezetimibe, in patients with statin
intolerance as defined by a placebo run-in and statin rechallenge
arm. Circulation. 2014;130:210g.
Pordy R, Lecorps G, Bessac L, Sasiela WJ, Ginsberg H.
Alirocumab, a fully human monoclonal antibody to proprotein
convertase subtilisin/kexin type 9: therapeutic dosing in phase 3
studies. J Clin Lipidol 2013;7i3i;279.
Ramanathan A, Gusarova V, Kyratsous C. Role of alirocumab
iproprotein convertase subtilisin/kexin type 9 antibody) on CDgl
levels and hepatitis C virus entry into hepatocytes. Circulation.
2013;12g:A12052.
Ray KK, Foody J, Khan I, Lewis BE. Attainment of low-density
lipoprotein cholesterol goals in patients at very high cardiovascular
risk in the United Kingdom; results from a general practice popu-
lation study. Value Health 2013;16i7i:A513.
Rey J, Poitiers F, Paehler T, Brunet A, Pinquier JL, Hanotin C,
Sasiela B. Randomized, partial blind study of the pharmacodynam-
ics, pharmacokinetics and safety of multiple subcutaneous doses of
alirocumab, a fully human monoclonal antibody to proprotein
convertase subtilisin/kexin type 9, administered every 4 weeks
alone or in combination with ezetimibe or fenofibrate in healthy
subjects. J Am Coll Cardiol 2014;63iI2 Suppl Ii:AI375.
Robinson J, Farnier M, Chaudhari U, Sasiela B, Lorenzato C, Miller
K, Kastelein JJP. Adverse events in patients with low-density
lipoprotein cholesterol levels &25 or &15 mg/dL on at least two
consecutive visits in fourteen randomized, controlled, clinical trials
of alirocumab. J Am Coll Cardiol 2015;65iIO Si;AI350.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M,
Stroes E, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor N,
Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. Long-term
safety, tolerability and efficacy of alirocumab versus placebo in high
cardiovascular risk patients: first results from the ODYSSEY LONG
TERM study in 2,341 patients. Circulation. 2014;130;2120.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M,
Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE,
Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY
LONG TERM Investigators. Efficacy and Safety of Alirocumab in
Reducing Lipids and Cardiovascular Events. N Eng J Med. 2015.
Roth E, Taskinen M-R, Ginsberg HN, Kastelein JJP, Colhoun HM,
Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. A 24-week
study of alirocumab monotherapy versus ezetimibe; The first phase
3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. J
Am Coll Cardiol 2014;63iI2 Suppl Ii; A.
Roth EM, McKenney J, Hanotin C, Asset G, Stein E. The efiects of
co-administering a monoclonal antibody to proprotein convertase
subtilisin/kexin type 9 serine protease, REGN727/SAR236553,
with 10 and g0 mg atorvastatin compared to g0 mg atorvastatin
alone in patients with primary hypercholesterolemia iNCT:
012gg469i. J Am Coll Cardiol 2012;59;E1620.
Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA.
Atorvastatin with or without an antibody to PCSK9 in primary
hypercholesterolemia. N Engl J Med. 2012;367i20i:Ig91-1900.
Roth EM, McKenney JM. ODYSSEY MONO; efiect of alirocumab
75 mg subcutaneously every 2 weeks as monotherapy versus
ezetimibe over 24 weeks. Future Cardiol 2015;Ilili;27-37.
Roth EM, Taskinen M-R, Ginsberg H, Kastelein JJP, Colhoun HM,
Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy
with the PCSK9 inhibitor alirocumab versus ezetimibe in patients
with hypercholesterolemia: Results of a 24 week, double-blind,
randomized Phase 3 trial. Int J Cardiol. 2014;176ili;55-61.
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R,
Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahafiey
KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ,
Shirodaria C, Szarek M, Tamby J-F, Tricoci P, White H, Zeiher A,
Steg PG. Efiect of alirocumab, a monoclonal antibody to pcsk9, on
long-term cardiovascular outcomes following acute coronary syn-
dromes: Rationale and design of the odyssey outcomes trial. Am
Heart J. 2014;16gi5i:682-689.el.
Steen D, Khan I, Becker L, Gorcyca K, Foody J. Attainment of
Lipid Levels in Patients at High Cardiovascular Risk; Results from
a U.S. Managed Care Population Study. Circulation.
2014;130:A19949.
Steen D, Khan I, Song X, Sanchez R, Gorcyca K, Hollenbeak CS,
Foody J. Cardiovascular Event Rates in a High-Risk Managed Care
Population in the United States. J Am Coll Cardiol 2015;65iIO
Si:A1647.
Stein E, Bergeron J, Gaudet D, Weiss R, Gipe D, Wu R, Dufour R,
Pordy R. Safety and efficacy of a monoclonal antibody to PCSK9,
REGN727/SAR236553, in statin-treated heterozygous familial
hypercholesterolemia patients. Presented as an oral presentation at
the 80th European Atherosclerosis Society iEASi Congress, May
25-2g, 2012, Milan, Italy. Abstract 139g.
Stein EA, Bergeron J, Gaudet D, Weiss R, Dufour R, Du Y, Yang F,
Andisik M, Toni A, Pordy R, Gipe D. One year open-label treatment
with alirocumab 150 mg every two weeks in heterozygous familial
hypercholesterolemic patients. Lancet 2012 380;29-36.
Stroes E, Guyton JR, Farnier M, Rader D, Moriarty PM, Bergeron
J, Langslet G, Lepor N, Civeira F, Gaudet D, Watts GF, Manvelian
G, Lecorps G, Zhao J, Baccara-Dinet M, Roth EM. Efficacy and
safety of difierent dosing regimens of alirocumab istarting doses of
75 mg every two weeks and 150 mg every four weeks) versus
placebo in patients with hypercholesterolemia not treated using
statins; the ODYSSEY CHOICE H study. J Am Coll Cardiol
2015;65iio Si:AI370.
Sullivan, et al. Efiect of a Monoclonal Antibody to PCSK9 on
Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant
Patients. JAMA. Dec. 19, 2012, vol, 30g, No. 23, pp, 2497-2506.
Swergold G, Biedermann S, Renard R, Du Y, Nadler D, Wu R,
Mellis S, Lisbon E. REGN727/SAR236553, a fully-human mono-
clonal antibody to proprotein convertase subtilisin kexin 9
iPCSK9i, decreases ApoB and non-HDL-C when administered
intravenously to healthy volunteers. J Clin Lipidol 20 II;5i3i;219.
Swergold G, Biedermann S, Renard R, Nadler D, Wu R, Lisbon EA,
Gutierrez MJ, Mellis S. REGN727/SAR236553, a fully human
proprotein convertase subtilisin kexin 9 iPCSK9i monoclonal anti-
body; efiects on safety and lipid and lipoprotein profiles when
administered subcutaneously. J Am Coll Cardiol
201 I;57iI4sli:E2023.
Swergold G, Biedermann S, Renard R, Nadler D, Wu R, Mellis S.
Safety, lipid, and lipoprotein efiects of REGN727/SAR236553, a
fully human proprotein convertase subtilisin kexin 9 iPCSK9i
neutralizing monoclonal antibody administered intravenously to
healthy volunteers. Circulation 2010;122:Abstract A23251.
Swergold G, Smith W, Mellis S, Logan D, Webb C, Wu R, Du Y,
Krans T, Gasparino E, Stein EA. Inhibition of proprotein convertase
subtilisin/kexin type 9 with a monoclonal antibody REGN727/
SAR236553, efiectively reduces low-density-lipoprotein choles-
terol, as mono or add-on therapy in heterozygous familial and
non-familial hypercholesterolemia. Circulation 2011;124:Abstract
A16265.
Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka 0, Sugimoto
M, Inoue S, Minami F, Baccara-Dinet MT. Efficacy and safety of
alirocumab in Japanese patients with hypercholesterolemia on
stable statin therapy; first data with the 75 mg every two weeks dose.
Circulation. 2014;130:A13651.
Toth PP, Hamon S, Jones SR, Joshi PH, Martin SS, Pordy R,
Hanotin C. Alirocumab, a proprotein convertase subtilisin/kexin
type 9 monoclonal antibody, reduces cholesterol concentrations of
all serum low-density lipoprotein cholesterol fractions. Circulation.
2013;12g:A17313.
US 9,550,837 B2
Page 8
References Cited
OTHER PUBLICATIONS
Toth PP, Hamon S, Jones SR, Martin SS, Joshi PH, Kulkarni K,
Banerjee P, Hanotin C. Proprotein convertase subtilisin/kexin 9
monoclonal antibody therapy significantly reduces apoprotein CH
and CHI levels in serum. Atherosclerosis. 2014;235i2i;eI07-eIOg.
[Abstract 593].
Van der Hoorn JWA, Kuhnast S, Pieterman E, van der Hock AM,
Sasiela WJ, Gusarova V, Peyman A, Schafer H-L, Schwahn U,
Jukema JW, Princen HMG. Alirocumab, a monoclonal antibody to
PCSK-9, dose-dependently decreases atherosclerosis, improves
plaque stability and shows additive efiects with atorvastatin in
APOE*3Leiden. CETP mice. Atherosclerosis. 2014;235i2i;e19.
[Abstract WS16].
Wong ND, Chuang J. Residual Dyslipidemia According to LDL-C,
non-HDL-C and Apolipoprotein B by Cardiovascular Risk Cat-
egory in Statin Treated US Adults. J Clin Lipidol. 2014;8;323-324.
Presented as a poster presentation at the National Lipid Association
Scientific Sessions, May 1-4, 2014, Orlando, Florida, USA.
Romagnuolo, et al, i2015i The Journal of Biological Chemistry
290ilgi;11649-11662, "Lipoproteiniai Catabolism is Regulated by
Proprotein Convertase Subtilisin/Kexin Type 9 through the Low
Density Lipoprotein Receptor".
Bee, et al, i2009i Journal of Pharmaceutical Sciences 9gi9i: 3290-
3301, "Precipitation of a monoclonal antibody by soluble tungsten".
Breen, et al, i200Ii Pharmaceutical Research Igi9i: 1345-1353,
"Efiect of moisture on the stability of a lyophilized humanized
monoclonal antibody formulation".
Carpenter, 1997 Pharm. Res. 14igi: 969-975, Rational Design of
Stable Lyophilized Protein Formulations: Some Practical Advice.
Daugherty, et al. , 2006 Advanced Drug Delivery Reviews 58:
686-706, "Formulation and delivery issues for monoclonal antibody
therapeutics".
Katayama, et al. 2004 J. Pharm. Sci. 93iIOi: 2609-2623, "Retro-
spective statistical analysis of lyophilized Protein Formulations of
Progenipoietin Using PLS: Determination of the Critical Parameters
for Long-Term Storage Stability".
Lefranc, M. -P. , et al. , IMGT, the international ImMunoGeneTics
information system, Nucl. Acids Res, 37, D1006-D1012 i2009i.
Majumdar, et al, i20 I I i Journal of Pharmaceutical Sciences
100i7i;2563-2573, "Evaluation of the efiect of syringe surfaces on
protein formulations".
Meehan et al. , 1996, J. Controlled Release 46; 107-116, "A
microinfusor device for the delivery of therapeutic levels of
peptides and macromolecules".
Robinson, N. , 2002, PNAS, 99igi;5283-52gg "Protein Deamida-
tion".
Scaviner, D, et al. , 1999 Exp. Clin. Immunogenet. 16:234-240
"Protein Displays of the Human Immunoglobulin Heavy, Kappa and
Lambda Variable and Joining Regions".
Varret, et al. , 1999 Am. J. Hum. Genet. 64: 1378-1387, "A third
major locus for autosomal dominant hypercholesterolemia Maps to
Ip34. I-p32".
Wang, 1999 International J. Pharmaceutics 185i2i; 129-1gg, "Insta-
bility, stabilization, and formulation of liquid protein pharmaceuti-
cals".
Webb, et al. 2002 J. Pharm. Sci. 9 Ii2i: 543-558, "Anew mechanism
for decreasing aggregation of Recombinant Human Interferon-7 by
a Surfactant: Slowed Dissolution of Lyophilized Formulations in a
Solution Containing 0,03% Polysorbate 20".
Anthem iSep. 21, 2015i "Proprotein Convertase Subtilisin Kexin 9
iPCSK9i Inhibitors, "Policy No. DRUG. 00078. American Medical
Association. Accessible on the Internet at URL: www. anthem. corn/
ca/medicalpolicies/policies/mp pw c182635.htm. [Last Accessed
Apr. 27, 2016].
Defesche et al. iJun, 2-5, 2013i "Natural history of autosomal
dominant hypercholesterolemia caused by gain-of-function muta-
tions in proprotein convertase subtilisin/kexin type 9 iPCSK9i
ifunded by Regeneron/Sanofii, " Abstract of a presentation pre-
sented at the 81st European Atherosclerosis Society iEASi Con-
gress, Jun. 2-5, 2013, Lyon, France.
Hiriyama et al. iJan, I, 2014i "Efiects of evolocumab iAMG 145i,
a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-
treated Japanese patients at high cardiovascular risk primary
results from the phase 2 YUKAWA study,
" Circulation Journal.
7gi5i;1073-1082.
International Search Report with Written Opinion corresponding to
International Patent Application No. PCT/EP2012/051321, mailed
Apr. 19, 2012, 10 pages.
International Search Report with Written Opinion corresponding to
International Patent Application No. PCT/EP2012/057890, mailed
Aug. 28, 2012, 14 pages.
International Search Report with Written Opinion corresponding to
International Patent Application No. PCT/US2015/040754, mailed
Oct. 14, 2015, 15 pages.
International Search Report with Written Opinion corresponding to
International Patent Application No. PCT/US2015/040765, mailed
Nov. 26, 2015, 15 pages.
McKenney et al. iJun, 2-5, 2013i "Dynamics between the mono-
clonal antibody SAR236553/REGN727, proprotein convertase
subtilisin/kexin type 9 iPCSK9i and low-density lipoprotein cho-
lesterol iLDL-Ci levels ifunding: Regeneron/Sanofii, "Presented as
a poster presentation at the 81st European Atherosclerosis Society
iEASi Congress, Jun. 2-5, 2013, Lyon, France.
Schafer et al. iMar, 14-16, 20IIi "Cholesterol lowering etfect of
SAR236553/REGN727, a fully human PCSK9 blocking monoclo-
nal antibody in male Syrian hamster, " Presented as a poster at the
Drugs Afiecting Lipid Metabolism iDALMi XVH International
Symposium, Mar. 14-16, 2011, Doha, Qatar.
* cited by examiner
U.S. Patent Jan. 24, 2017 Sheet 1 of 14 US 9,550,837 B2
O O
CO CO
L L'
CO CO
C U
0 0
Q Q
(3 Q
0 0
Q 0
Q Q
OD
CI
CO
K CL
CO CO
x x
Q Q
U
CO
x
CO
Cl C5
K CL
CO CO
I-
0 C
CO CO
G) Ci
I
I
s Q
s
s
s
I
s
Ch Cl
C 2
CO
Q b
hC E
Z
IX 2!
X Q
CO
M CO
CO CO
Q Q
CO CO
CO CO
U V
X CO
I- CO
CL CL
LLI lll
0 0
CL
CO I-
CL
CO CO
Q U
CO CO
Q Q
I- I-
x x
Cl Ci
Q 0)
LLI LLI
Q LU
CO CL
CO CO
I- I-
Cl Ch
0 Q
CO
Q V
CO CO
Q C
CO CO
CL CL
Cl 6!
Q G
CO CO
LU Q
CL' CL
CO CO
& 0"
2."Q
CL CL
CL CO
Q Q
0 0
CL CL
R hC
U.S. Patent Jan. 24, 2017 Sheet 2 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 3 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 4 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 5 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 6 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 7 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 8 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 9 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 10 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 11 of 14 US 9,550,837 B2
U.S. Patent Jan. 24, 2017 Sheet 12 of 14 US 9,550,837 B2
C)
C)
C)
C)
C)
C)
C)
(~uj~6ouj) uogej~ueauog
U.S. Patent Jan. 24, 2017 Sheet 13 of 14 US 9,550,837 B2
C)
C)
C3
C)
C)
C)
C)
C)
C)
C)
C)
(~uj~6om} uoges~ueauog
U.S. Patent Jan. 24, 2017 Sheet 14 of 14 US 9,550,837 B2
US 9,550,837 B2
1
THERAPEUTIC USES OF ANTI-PCSK9
ANTIBODIES
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation of U.S. application Ser.
No. 13/690, 585, filed on 30 Nov. 2012, which is a continu-
ation of U.S. application Ser. No. 12/949, 846 filed on 19
Nov. 2010, now U.S. Pat. No. 8,501,184, Issued 6 Aug.
2013, which is a divisional of U.S. application Ser. No.
12/637, 942, filed 15 Dec. 2009, now U.S. Pat. No. 8,062,
640, Issued 22 Nov. 2011, which claims the benefit under 35
USC )119(e)of U.S. Provisional 61/261,776 filed 17 Nov.
2009, 61/249, 135 filed 6 Oct. 2009, 61/218, 136 filed 18 Jun.
2009, 61/168, 753 filed 13 Apr. 2009, 61/210, 566 filed 18
Mar. 2009 and 61/122, 482 filed 15 Dec. 2008, which appli-
cations are herein specifically incorporated by reference in
their entirety.
FIELD OF THE INVENTION
The present invention is related to human antibodies and
antigen-binding fragments of human antibodies that specifi-
cally bind human proprotein convertase subtilisin/kexin type
9 (PCSK9), and therapeutic methods of using those anti-
bodies.
STATEMENT OF RELATED ART
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is
a proprotein convertase belonging to the proteinase K sub-
family of the secretory subtilase family. The encoded protein
is synthesized as a soluble zymogen that undergoes auto-
catalytic intramolecular processing in the endoplasmic
reticulum. Evidence suggest that PCSK9 increases plasma
LDL cholesterol by promoting degradation of the LDL
receptor, which mediates LDL endocytosis in the liver, the
major route of LDL clearance from circulation. The structure
of PCSK9 protein shows that it has a signal sequence,
followed by a prodomain, a catalytic domain that contains a
conserved triad of residues (D186, H226 and S386), and a
C-terminal domain. It is synthesized as a soluble 74-kDa
precursor that undergoes autocatalytic cleavage in the ER,
generating a 14-kDa prodomain and 60-kDa catalytic frag-
ment. The autocatalytic activity has been shown to be
required for secretion. After cleavage the prodomain
remains tightly associated with the catalytic domain.
Antibodies to PCSK9 are described in, for example, WO
2008/057457, WO 2008/057458, WO 2008/057459, WO
2008/063382, WO 2008/125623, and US 2008/0008697.
BRIEF SUMMARY OF THE INVENTION
In a first aspect, the invention provides fully human
monoclonal antibodies (mAbs) and antigen-binding frag-
ments thereof that specifically bind and neutralize human
PCSK9 (hPCSK9) activity.
In one embodiment, the invention comprises an antibody
or antigen-binding fragment of an antibody that specifically
binds hPCSK9 and is characterized by at least one of:
(I) capable of reducing serum total cholesterol at least
about 25-35% and sustaining the reduction over at least a 24
day period relative to a predose level, preferably the reduc-
tion in serum total cholesterol is at least about 30-40%;
6
10
16
20
26
30
36
40
46
60
66
60
66
(ii) capable of reducing serum LDL cholesterol at least
about 65-80% and sustaining the reduction over at least a 24
day period relative to a predose level;
(iii) capable of reducing serum triglyceride at least about
25-40% relative to predose level;
(iv) does not reduce serum HDL cholesterol or reduces
serum HDL cholesterol no more than 5% relative to predose
level.
In one embodiment, the invention comprises an antibody
or antigen-binding fragment of an antibody that specifically
binds hPCSK9 and is characterized by at least one of:
(I) capable of reducing serum LDL cholesterol at least
about 40-70% and sustaining the reduction over at least a 60
or 90 day period relative to a predose level;
(ii) capable of reducing serum triglyceride at least about
25-40% relative to predose level;
(iii) does not reduce serum HDL cholesterol or reduces
serum HDL cholesterol no more than 5% relative to predose
level.
In one embodiment, the antibody or antigen-binding
fragment is characterized as binding an epitope comprising
amino acid residue 238 of hPCSK9 (SEQ ID NO:755). In a
more specific embodiment, the antibody or antigen-binding
fragment binds an epitope comprising one or more of amino
acid residue 238, 153, 159 and 343 of hPCSK9 (SEQ ID
NO:755).). In a more specific embodiment, the antibody or
fragment thereof is characterized as binding an epitope
which does not comprise an amino acid residue at position
192, 194, 197 and/or 237 of SEQ ID NO:755.
In one embodiment, the antibody or antigen-binding
fragment is characterized as binding an epitope comprising
amino acid residue 366 of hPCSK9 (SEQ ID NO:755). In a
more specific embodiment, the antibody or antigen-binding
fragment binds an epitope comprising one or more of amino
acid residue at position 147, 366 and 380 of SEQ ID
NO:755. In a more specific embodiment, the antibody or
antigen-binding fragment of an antibody is characterized as
binding an epitope which does not comprise an amino acid
residue at position 215 or 238 of SEQ ID NO:755.
In one embodiment, the antibody or antigen-binding
fragment is characterized as exhibiting an enhanced binding
affinity (K~) for hPCSK9 at pH 5.5 relative to the K~ at pH
7.4, as measured by plasmon surface resonance. In a specific
embodiment, the antibody or fragment thereof exhibits at
least a 20-fold, at least a 40-fold or at least a 50-fold
enhanced affinity for PCSK9 at an acidic pH relative to a
neutral pH, as measured by surface plasmon resonance.
In one embodiment, the antibody or antigen-binding
fragment is characterized as not exhibiting an enhanced
binding affinity for PCSK9 at an acidic pH relative to a
neutral pH, as measured by surface plasmon resonance. In a
specific embodiment, the antibody or fragment thereof
exhibits a decreased binding affinity at an acidic pH.
In another embodiment, the antibody or antigen-binding
fragment binds human, human GOF mutation D374Y, cyno-
molgus monkey, rhesus monkey, mouse, rat and hamster
PCSK9.
In one embodiment, the antibody or antigen-binding
fragment binds human and monkey PCSK9, but does not
bind mouse, rat or hamster PCSK9.
The mAbs can be full-length (e.g. , an IgGI or IgG4
antibody) or may comprise only an antigen-binding portion
(e.g. , a Fab, F(ab')~ or scFv fragment), and may be modified
to afi'ect functionality, e.g. , to eliminate residual efiector
functions (Reddy et al. (2000) J. Immunol. 164:1925-1933).
In one embodiment, the invention comprises an antibody
or antigen-binding fragment of an antibody comprising a
US 9,550,837 B2
heavy chain variable region (HCVR) selected from the
group consisting of SEQ ID NO:2, 18, 22, 26, 42, 46, 50, 66,
70, 74, 90, 94, 98, 114, 118, 122, 138, 142, 146, 162, 166,
170, 186, 190, 194, 210, 214, 218, 234, 238, 242, 258, 262,
266, 282, 286, 290, 306, 310, 314, 330, 334, 338, 354, 358,
362, 378, 382, 386, 402, 406, 410, 426, 430, 434, 450, 454,
458, 474, 478, 482, 498, 502, 506, 522, 526, 530, 546, 550,
554, 570, 574, 578, 594, 598, 602, 618, 622, 626, 642, 646,
650, 666, 670, 674, 690, 694, 698, 714, 718, 722, 738 and
742, or a substantially similar sequence thereof having at
least 90%, at least 95%, at least 98% or at least 99%
sequence identity. In one embodiment, the HCVR comprises
an amino acid sequence selected from the group consisting
of SEQ ID NO:50, 66, 70, 74, 90, 94, 122, 138, 142, 218,
234, 238, 242, 258, 262, 314, 330 and 334. In a more specific
embodiment, the HCVR comprises SEQ ID NO:90 or 218.
In one embodiment, the antibody or fragment thereof
further comprises a light chain variable region (LCVR)
selected from the group consisting of SEQ ID NO:10, 20,
24, 34, 44, 48, 58, 68, 72, 82, 92, 96, 106, 116, 120, 130,
140, 144, 154, 164, 168, 178, 188, 192, 202, 212, 216, 226,
236, 240, 250, 260, 264, 274, 284, 288, 298, 308, 312, 322,
332, 336, 346, 356, 360, 370, 380, 384, 394, 404, 408, 418,
428, 432, 442, 452, 456, 466, 476, 480, 490, 500, 504, 514,
524, 528, 538, 548, 552, 562, 572, 576, 586, 596, 600, 610,
620, 624, 634, 644, 648, 658, 668, 672, 682, 692, 696, 706,
716, 720, 730, 740 and 744, or a substantially similar
sequence thereof having at least 90%, at least 95%, at least
98% or at least 99% sequence identity. In one embodiment,
the LCVR comprises an amino acid sequence selected from
the group consisting of SEQ ID NO: 58, 68, 72, 82, 92, 96,
130, 140, 144, 226, 236, 240, 250, 260, 264, 322, 332 and
336. In a more specific embodiment, the LCVR comprises
SEQ ID NO:92 or 226.
In specific embodiments, the antibody or fragment thereof
comprises a HCVR and LCVR (HCVR/LCVR) sequence
pair selected from the group consisting of SEQ ID NO: 2/10,
18/20, 22/24, 26/34, 42/44, 46/48, 50/58, 66/68, 70/72,
74/82, 90/92, 94/96, 98/106, 114/116, 118/120, 122/130,
138/140, 142/144, 146/154, 162/164, 166/168, 170/178,
186/188, 190/192, 194/202, 210/212, 214/216, 218/226,
234/236, 238/240, 242/250, 258/260, 262/264, 266/274,
282/284, 286/288, 290/298, 306/308, 310/312, 314/322,
330/332, 334/336, 338/346, 354/356, 358/360, 362/370,
378/380, 382/384, 386/394, 402/404, 406/408, 410/418,
426/428, 430/432, 434/442, 450/452, 454/456, 458/466,
474/476, 478/480, 482/490, 498/500, 502/504, 506/514,
522/524, 526/528, 530/538, 546/548, 550/552, 554/562,
570/572, 574/576, 578/586, 594/596, 598/600, 602/610,
618/620, 622/624, 626/634, 642/644, 646/648, 650/658,
666/668, 670/672, 674/682, 690/692, 694/696, 698/706,
714/716, 718/720, 722/730, 738/740 and 742/744. In one
embodiment, the HCVR and LCVR sequence pair com-
prises one of SEQ ID NO: 50/58, 66/68, 70/72, 74/82, 90/92,
94/96, 122/130, 138/140, 142/144, 218/226, 234/236, 238/
240, 242/250, 258/260, 262/264, 314/322, 330/332 and
334/336. In a more specific embodiment, the HCVR/LCVR
pair comprises SEQ ID NO:90/92 or 218/226.
In a second aspect, the invention features an antibody or
antigen-binding fragment of an antibody comprising a heavy
chain CDR3 (HCDR3) domain selected from the group
consisting of SEQ ID NO:8, 32, 56, 80, 104, 128, 152, 176,
200, 224, 248, 272, 296, 320, 344, 368, 392, 416, 440, 464,
488, 512, 536, 560, 584, 608, 632, 656, 680, 704 and 728,
or a substantially similar sequence thereof having at least
90%, at least 95%, at least 98% or at least 99% sequence
identity; and a light chain CDR3 (LCDR3) domain selected
5
10
15
20
25
30
35
40
45
50
55
60
65
from the group consisting of SEQ ID NO:16, 40, 64, 88, 112,
136, 160, 184, 208, 232, 256, 280, 304, 328, 352, 376, 400,
424, 448, 472, 496, 520, 544, 568, 592, 616, 640, 664, 688,
712 and 736, or substantially similar sequences thereof
having at least 90%, at least 95%, at least 98% or at least
99% sequence identity. In one embodiment, the HCDR3/
LCDR3 sequence pair is selected from the group consisting
of SEQ ID NO:56/64, 80/88, 128/136, 224/232, 248/256 and
320/328. In a more specific embodiment, the HCDR3/
LCDR3 sequence pair comprises SEQ ID NO:80/88 or
224/232.
In a further embodiment, the invention comprising an
antibody or fragment thereof further comprising a heavy
chain CDRI (HCDRI) domain selected from the group
consisting of SEQ ID NO:4, 28, 52, 76, 100, 124, 148, 172,
196, 220, 244, 268, 292, 316, 340, 364, 388, 412, 436, 460,
484, 508, 532, 556, 580, 604, 628, 652, 676, 700 and 724,
or a substantially similar sequence thereof having at least
90%, at least 95%, at least 98% or at least 99% sequence
identity; a heavy chain CDR2 (HCDR2) domain selected
from the group consisting of SEQ ID NO:6, 30, 54, 78, 102,
126, 150, 174, 198, 222, 246, 270, 294, 318, 342, 366, 390,
414, 438, 462, 486, 510, 534, 558, 582, 606, 630, 654, 678,
702 and 726, or a substantially similar sequence thereof
having at least 90%, at least 95%, at least 98% or at least
99% sequence identity; a light chain CDRI (LCDRI)
domain selected from the group consisting of SEQ ID
NO:12, 36, 60, 84, 108, 132, 156, 180, 204, 228, 252, 276,
300, 324, 348, 372, 396, 420, 444, 468, 492, 516, 540, 564,
588, 612, 636, 660, 684, 708 and 732, or a substantially
similar sequence thereof having at least 90%, at least 95%,
at least 98% or at least 99% sequence identity; and a light
chain CDR2 (LCDR2) domain selected from the group
consisting of SEQ ID NO:14, 38, 62, 86, 110, 134, 158, 182,
206, 230, 254, 278, 302, 326, 350, 374, 398, 422, 446, 470,
494, 518, 542, 566, 590, 614, 638, 662, 686, 710 and 734,
or a substantially similar sequence thereof having at least
90%, at least 95%, at least 98% or at least 99% sequence
identity. In one embodiment, the heavy and light chain CDR
sequences comprise a sequence selected from the group
consisting of SEQ ID NO:52, 54, 56, 60, 62, 64; 76, 78, 80,
84, 86, 88; 124, 126, 128, 132, 134, 136; 220, 222, 224, 228,
230, 232; 244, 246, 248, 252, 254, 256; and 316, 318, 320,
324, 326, 328. In more specific embodiments, the CDR
sequences comprise SEQ ID NO: 76, 78, 80, 84, 86, 88; or
220, 222, 224, 228, 230, 232.
In a related embodiment, the invention comprises an
antibody or antigen-binding fragment of an antibody which
specifically binds hPCSK9, wherein the antibody or frag-
ment comprises heavy and light chain CDR domains con-
tained within heavy and light chain sequence pairs selected
from the group consisting of SEQ ID NO: 2/10, 18/20,
22/24, 26/34, 42/44, 46/48, 50/58, 66/68, 70/72, 74/82,
90/92, 94/96, 98/106, 114/116, 118/120, 122/130, 138/140,
142/144, 146/154, 162/164, 166/168, 170/178, 186/188,
190/192, 194/202, 210/212, 214/216, 218/226, 234/236,
238/240, 242/250, 258/260, 262/264, 266/274, 282/284,
286/288, 290/298, 306/308, 310/312, 314/322, 330/332,
334/336, 338/346, 354/356, 358/360, 362/370, 378/380,
382/384, 386/394, 402/404, 406/408, 410/418, 426/428,
430/432, 434/442, 450/452, 454/456, 458/466, 474/476,
478/480, 482/490, 498/500, 502/504, 506/514, 522/524,
526/528, 530/538, 546/548, 550/552, 554/562, 570/572,
574/576, 578/586, 594/596, 598/600, 602/610, 618/620,
622/624, 626/634, 642/644, 646/648, 650/658, 666/668,
670/672, 674/682, 690/692, 694/696, 698/706, 714/716,
718/720, 722/730, 738/740 and 742/744. In one embodi-
US 9,550,837 B2
ment, the CDR sequences are contained within HCVR and
LCVR selected from the amino acid sequence pairs of SEQ
ID NO: 50/58, 66/68, 70/72, 74/82, 90/92, 94/96, 122/130,
138/140, 142/144, 218/226, 234/236, 238/240, 242/250,
258/260, 262/264, 314/322, 330/332 and 334/336. In more
specific embodiments, the CDR sequences are comprised
within HCVR/LCVR sequences selected from SEQ ID NO:
90/92 or 218/226.
In one embodiment, the invention provides fully human
monoclonal antibody or antigen-binding fragment thereof
that specifically bind hPCSK9 and neutralize PCSK9 activ-
ity, wherein the antibody or fragment thereof exhibits one or
more of the following characteristics: (i) capable of reducing
serum total cholesterol at least about 25-35% and sustaining
the reduction over at least a 24 day period relative to a
predose level, preferably the reduction in serum total cho-
lesterol is at least about 30-40%; (ii) capable of reducing
serum LDL cholesterol at least about 65-80% and sustaining
the reduction over at least a 24 day period relative to a
predose level; (iii) capable of reducing serum triglyceride at
least about 25-40% relative to predose level; (iv) does not
reduce serum HDL cholesterol or reduces serum HDL
cholesterol no more than 5% relative to predose level; (v)
binds an epitope comprising amino acid residue 238 of
hPCSK9 (SEQ ID NO:755); (vi) exhibits an enhanced
binding affinity (K~) for hPCSK9 at pH 5.5 relative to the
K~ at pH 7.4, as measured by plasmon surface resonance,
wherein the enhanced affinity is at least about a 20- to
50-fold increase in affinity; (vii) binds human, human GOF
mutation D374Y, cynomolgus monkey, rhesus monkey,
mouse, rat and hamster PCSK9; (viii) comprises heavy and
light chain CDR3 sequences comprising SEQ ID NO:80 and
88; and (ix) comprises CDR sequences from SEQ ID NO:90
and 92.
In one embodiment, the invention provides fully human
monoclonal antibody or antigen-binding fragment thereof
that specifically bind human PCSK9 (hPCSK9) and neutral-
ize PCSK9 activity, wherein the antibody or fragment
thereof exhibits one or more of the following characteristics:
(i) capable of reducing serum LDL cholesterol at least about
40-70% and sustaining the reduction over at least a 60 or 90
day period relative to a predose level; (ii) capable of
reducing serum triglyceride at least about 25-40% relative to
predose level; (iii) does not reduce serum HDL cholesterol
or reduces serum HDL cholesterol no more than 5% relative
to predose level; (iv) binds an epitope comprising amino
acid residue 366 ofhPCSK9 (SEQ ID NO:755); (v) does not
exhibit an enhanced binding affinity for PCSK9 at an acidic
pH relative to a neutral pH, as measured by surface plasmon
resonance; (vi) binds human and monkey PCSK9, but does
not bind mouse, rat or hamster PCSK9; (vii) comprises
heavy and light chain CDR3 sequences comprising SEQ ID
NO:224 and 232; and (viii) comprises CDR sequences from
SEQ ID NO:218 and 226.
In a third aspect, the invention provides nucleic acid
molecules encoding anti-PCSK9 antibodies or fragments
thereof. Recombinant expression vectors carrying the
nucleic acids of the invention, and host cells into which such
vectors have been introduced, are also encompassed by the
invention, as are methods of producing the antibodies by
culturing the host cells under conditions permitting produc-
tion of the antibodies, and recovering the antibodies pro-
duced.
In one embodiment, the invention provides an antibody or
fragment thereof comprising a HCVR encoded by a nucleic
acid sequence selected from the group consisting of SEQ ID
NO: I, 17, 21, 25, 41, 45, 49, 65, 69, 73, 89, 93, 97, 113, 117,
6
10
16
20
26
30
36
40
46
60
66
60
66
121, 137, 141, 145, 161, 165, 169, 185, 189, 193, 209, 213,
217, 233, 237, 241, 257, 261, 265, 281, 285, 289, 305, 309,
313, 329, 333, 337, 353, 357, 361, 377, 381, 385, 401, 405,
409, 425, 429, 433, 449, 453, 457, 473, 477, 481, 497, 501,
505, 521, 525, 529, 545, 549, 553, 569, 573, 577, 593, 597,
601, 617, 621, 625, 641, 645, 649, 665, 669, 673, 689, 693,
697, 713, 717, 721, 737 and 741, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or
at least 99% homology thereof. In one embodiment, the
HCVR is encoded by a nucleic acid sequence selected from
the group consisting of SEQ ID NO: 49, 65, 69, 73, 89, 93,
121, 137, 141, 217, 233, 237, 241, 257, 261, 313, 329 and
333. In more specific embodiments, the HCVR is encoded
by a nucleic acid sequence selected from the group consist-
ing of SEQ ID NO: 89 and 217.
In one embodiment, the antibody or fragment thereof
further comprises a LCVR encoded by a nucleic acid
sequence selected from the group consisting of SEQ ID NO:
9, 19, 23, 33, 43, 47, 57, 67, 71, 81, 91, 95, 105, 115, 119,
129, 139, 143, 153, 163, 167, 177, 187, 191, 201, 211, 215,
225, 235, 239, 249, 259, 263, 273, 283, 287, 297, 307, 311,
321, 331, 335, 345, 355, 359, 369, 379, 383, 393, 403, 407,
417, 427, 431, 441, 451, 455, 465, 475, 479, 489, 499, 503,
513, 523, 527, 537, 547, 551, 561, 571, 575, 585, 595, 599,
609, 619, 623, 633, 643, 647, 657, 667, 671, 681, 691, 695,
705, 715, 719, 729, 739 and 743, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or
at least 99% homology thereof. In one embodiment, the
LCVR is encoded by a nucleic acid sequence selected from
the group consisting of SEQ ID NO: 57, 67, 71, 81, 91, 95,
129, 139, 143, 225, 235, 239, 249, 259, 263, 321, 331 and
335. In more specific embodiments, the LCVR is encoded
by a nucleic acid sequence selected from the group consist-
ing of SEQ ID NO: 91 and 225.
In one embodiment, the invention features an antibody or
antigen-binding fragment of an antibody comprising a
HCDR3 domain encoded by a nucleotide sequence selected
from the group consisting of SEQ ID NO:7, 31, 55, 79, 103,
127, 151, 175, 199, 223, 247, 271, 295, 319, 343, 367, 391,
415, 439, 463, 487, 511, 535, 559, 583, 607, 631, 655, 679,
703 and 727, or a substantially identical sequence having at
least 90%, at least 95%, at least 98%, or at least 99%
homology thereof; and a LCDR3 domain encoded by a
nucleotide sequence selected from the group consisting of
SEQ ID NO: 15, 39, 63, 87, 111, 135, 159, 183, 207, 231,
255, 279, 303, 327, 351, 375, 399, 423, 447, 471, 495, 519,
543, 567, 591, 615, 639, 663, 687, 711 and 735, or a
substantially identical sequence having at least 90%, at least
95%, at least 98%, or at least 99% homology thereof. In one
embodiment, the HCDR3 and LCDR3 comprise a sequence
pair encoded by the nucleic acid sequence of SEQ ID NO:
55/63, 79/87, 127/135, 223/231, 247/255 and 319/327,
respectively. In more specific embodiments, the HCDR3 and
LCDR3 comprise a sequence pair encoded by the nucleic
acid sequence of SEQ ID NO: 79/87 and 223/231.
In a further embodiment, the antibody or fragment thereof
further comprises, a HCDRI domain encoded by a nucleo-
tide sequence selected from the group consisting of SEQ ID
NO: 3, 27, 51, 75, 99, 123, 147, 171, 195, 219, 243, 267,
291, 315, 339, 363, 387, 411, 435, 459, 483, 507, 531, 555,
579, 603, 627, 651, 675, 699 and 723, or a substantially
identical sequence having at least 90%, at least 95%, at least
98%, or at least 99% homology thereof; a HCDR2 domain
encoded by a nucleotide sequence selected from the group
consisting of SEQ ID NO:5, 29, 53, 77, 101, 125, 149, 173,
197, 221, 245, 269, 293, 317, 341, 365, 389, 413, 437, 461,
485, 509, 533, 557, 581, 605, 629, 653, 677, 701 and 725,
US 9,550,837 B2
or a substantially identical sequence having at least 90%, at
least 95%, at least 98%, or at least 99% homology thereof;
a LCDRI domain encoded by a nucleotide sequence
selected from the group consisting of SEQ ID NO: 11, 35,
59, 83, 107, 131, 155, 179, 203, 227, 251, 275, 299, 323,
347, 371, 395, 419, 443, 467, 491, 515, 539, 563, 587, 611,
635, 659, 683, 707 and 731, or a substantially identical
sequence having at least 90%, at least 95%, at least 98%, or
at least 99% homology thereof; and a LCDR2 domain
encoded by a nucleotide sequence selected from the group
consisting of SEQ ID NO: 13, 37, 61, 85, 109, 133, 157, 181,
205, 229, 253, 277, 301, 325, 349, 373, 397, 421, 445, 469,
493, 517, 541, 565, 589, 613, 637, 661, 685, 709 and 733,
or a substantially identical sequence having at least 90%, at
least 95%, at least 98%, or at least 99% homology thereof.
In one embodiment, the heavy and light chain CDR
sequences are encoded by the nucleic acid sequences of SEQ
ID NO: 51, 53, 55, 59, 61, 63; 75, 77, 79, 83, 85, 87; 123,
125, 127, 131, 133, 135; 219, 221, 223, 227, 229, 231; 243,
245, 247, 251, 253, 255; and 315, 317, 319, 323, 325, 327.
In more specific embodiments, the heavy and light chain
CDR sequences are encoded by the nucleic acid sequences
of SEQ ID NO: 75, 77, 79, 83, 85, 87; and 219, 221, 223,
227, 229, 231.
In a fourth aspect, the invention features an isolated
antibody or antigen-binding fragment thereof that specifi-
cally binds hPCSK9, comprising a HCDR3 and a LCDR3,
wherein HCDR3 comprises an amino acid sequence of the
formula X -X -X -X -X -X -X -X -X -X -X -X -X
X' -X' -X' -X' -X' -X' -X (SEQ ID NO:747), wherein
X' is Ala, X is Arg or Lys, X isAsp, X is Ser orIle, X
is Asnor Val, X' is Leu or Trp, X is Gly or Met, X' is Asn
or Val, X is Phe or Tyr, X' is Asp, X" is Leu or Met, X'
is Asp or absent, X' is Tyr or absent, X' is Tyr or absent,
X' is Tyr or absent, X' is Tyr or absent, X' is Gly or
absent, X' is Met or absent, X' is Asp or absent, and X
is Val or absent; and LCDR3 comprises an amino acid
sequence of the formula X'-X -X -X -X -X -X -X -X
(SEQ ID NO:750), wherein X' is Gln or Met, X is Gln, X
is Tyror Thr, X is TyrorLeu, X is ThrorGln, X is Thr,
X is Pro, X is Tyr or Leu, and X is Thr.
In a further embodiment, the antibody or fragment thereof
further comprise a HCDRI sequence of the formula X'-X-
X -X -X -X -X X (SEQ ID NO:745), wherein X' is Gly,
X is Phe, X is Thr, X is Phe, X is SerorAsn, X is Ser
or Asn, X is Tyr or His, and X is Ala or Trp; a HCDR2
sequence of the formula X'-X -X -X -X -X -X -X (SEQ
ID NO:746), wherein X' is Ile, X is Ser or Asn, X is Gly
or Gln, X is Asp or Ser, X is Gly, X is Ser or Gly, X is
Thr or Glu, and X is Thr or Lys; a LCDRI sequence of the
formula X'-X -X -X -X -X -X -X -X -X' -X"-X' (SEQ
ID NO:748) wherein X' is Gln, X is Ser, X is Val or Leu,
X is Leu, X is His or Tyr, X is Arg or Ser, X is Ser orAsn,
X is Asn or Gly, X is Asn, X' is Arg or Asn, X" is Asn
or Tyr, and X' is Phe or absent; a LCDR2 sequence of the
formula X'-X -X (SEQ ID NO:749) wherein X' is Trp or
Leu, X is Ala or Gly, and X is Ser. FIG. 1 shows the
sequence alignment of heavy and light chain variable
regions for 316P and 300N mAbs.
In a fifth aspect, the invention features a human anti-
PCSK9 antibody or antigen-binding fragment of an antibody
comprising a heavy chain variable region (HCVR) encoded
by nucleotide sequence segments derived from V~, D~ and
J~ germline sequences, and a light chain variable region
(LCVR) encoded by nucleotide sequence segments derived
from V~ and J~ germline sequences, wherein the germline
sequences are (a) V~ gene segment 3-23, D~ gene segment
5
10
15
20
25
30
35
40
45
50
55
60
65
7-27, J~ gene segment 2, V~ gene segment 4-1 and J~ gene
segment 2; or (b) V~ gene segment 3-7, D~ gene segment
2-8, J~ gene segment 6, V~ gene segment 2-28 and J~ gene
segment 4.
In a sixth aspect, the invention features an antibody or
antigen-binding fragment thereof that binds to a PCSK9
protein of SEQ ID NO:755, wherein the binding of the
antibody or fragment thereof to a variant PCSK9 protein is
less than 50% of the binding between the antibody or
fragment thereof and the PCSK9 protein of SEQ ID NO:755.
In specific embodiment, the antibody or fragment thereof
binds to the variant PCSK9 protein with a binding affinity
(K~) which is less than about 50%, less than about 60%, less
than about 70%, less than about 80%, less than about 90%
or less than about 95% compared to the binding to PCSK9
(SEQ ID NO:755).
In one embodiment, the variant PCSK9 protein comprises
at least one mutation at position 238 of SEQ ID NO:755. In
a more specific embodiment, the mutation is D238R. In one
embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 90% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at residue 238. In
one embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 80% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at one or more of
residue 153, 159, 238 and 343. In a more specific embodi-
ment, the mutation is one of S153R, E159R, D238R and
D343R.
In one embodiment, the variant PCSK9 protein comprises
at least one mutation at position 366 of SEQ ID NO:755. In
a more specific embodiment, the mutation is E366K. In one
embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 95% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at residue 366. In
one embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 90% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at one or more of
residue 147, 366 and 380. In a more specific embodiment,
the mutation is one of S147F, E366K and V380M. In one
embodiment, the antibody or antibody fragment binding
affinity for the variant PCSK9 protein is at least 80% less
relative to the wildtype protein of SEQ ID NO:755, wherein
the variant protein comprises a mutation at one or more of
residue 147, 366 and 380. In a more specific embodiment,
the mutation is one of S147F, E366K and V380M.
The invention encompasses anti-PCSK9 antibodies hav-
ing a modified glycosylation pattern. In some applications,
modification to remove undesirable glycosylation sites may
be useful, or e.g. , removal of a fucose moiety to increase
antibody dependent cellular cytotoxicity (ADCC) function
(see Shield et al. (2002) JBC 277:26733). In other applica-
tions, modification of galactosylation can be made in order
to modify complement dependent cytotoxicity (CDC).
In a seventh aspect, the invention features a pharmaceu-
tical composition comprising a recombinant human anti-
body or fragment thereof which specifically binds hPCSK9
and a pharmaceutically acceptable carrier. In one embodi-
ment, the invention features a composition which is a
combination of an antibody or antigen-binding fragment of
an antibody of the invention, and a second therapeutic agent.
The second therapeutic agent may be any agent that is
advantageously combined with the antibody or fragment
thereof of the invention, for example, an agent capable of
US 9,550,837 B2
10
inducing a cellular depletion of cholesterol synthesis by
inhibiting 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A
(CoA) reductase, such as, for example, cerovastatin, atorv-
astatin, simvastatin, pitavastin, rosuvastatin, fluvastatin, lov-
astatin, pravastatin, etc. ; capable of inhibiting cholesterol
uptake and or bile acid re-absorption; capable of increasing
lipoprotein catabolism (such as niacin); and/or activators of
the LXR transcription factor that plays a role in cholesterol
elimination such as 22-hydroxycholesterol.
In an eighth aspect, the invention features methods for
inhibiting hPCSK9 activity using the anti-PCSK9 antibody
or antigen-binding portion of the antibody of the invention,
wherein the therapeutic methods comprise administering a
therapeutically eflective amount of a pharmaceutical com-
position comprising an antibody or antigen-binding frag-
ment of an antibody of the invention. The disorder treated is
any disease or condition which is improved, ameliorated,
inhibited or prevented by removal, inhibition or reduction of
PCSK9 activity. Specific populations treatable by the thera-
peutic methods of the invention include subjects indicated
for LDL apheresis, subjects with PCSK9-activating muta-
tions (gain of function mutations, "GOF"), subjects with
heterozygous Familial Hypercholesterolemia (heFH); sub-
jects with primary hypercholesterolemia who are statin
intolerant or statin uncontrolled; and subjects at risk for
developing hypercholesterolemia who may be preventably
treated. Other indications include dyslipidemia associated
with secondary causes such as Type 2 diabetes mellitus,
cholestatic liver diseases (primary biliary cirrhosis), neph-
rotic syndrome, hypothyroidism, obesity; and the prevention
and treatment of atherosclerosis and cardiovascular diseases.
In specific embodiments of the method of the invention,
the anti-hPCSK9 antibody or antibody fragment of the
invention is useful to reduce elevated total cholesterol,
non-HDL cholesterol, LDL cholesterol, and/or apolipopro-
tein B (apolipoprotein B100).
The antibody or antigen-binding fragment of the inven-
tion may be used alone or in combination with a second
agent, for example, an HMG-CoA reductase inhibitor and/or
other lipid lowering drugs.
Other embodiments will become apparent from a review
of the ensuing detailed description.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. Sequence comparison tables of heavy chain (A)
and light chain (B) variable regions and CDRs of antibodies
HI H316P and HI M300N.
FIG. 2. Antibody concentrations in serum over time. 316P
5 mg/kg ( ); 300N 5 mg/kg (0); 316P 15 mg/kg (8); 300N
15 mg/kg (~).
FIG. 3. Serum total cholesterol level as a percentage of
change over bufler control. Bufl'er control (*);316P 5 mg/kg
(8); 300N 5 mg/kg (4); 316P 15 mg/kg ( ); 300N 15
mg/kg (A).
FIG. 4. Serum LDL cholesterol level as a percentage of
change over bufler control: Bufler Control (*); 316P 5
mg/kg (8); 300N 5 mg/kg (4); 316P 15 mg/kg ( ); 300N
15 mg/kg (A).
FIG. 5. Serum LDL cholesterol level normalized to bufler
control. Bufler control (*);316P 5 mg/kg (8); 300N 5 mg/kg
(4); 316P 15 mg/kg ( ); 300N 15 mg/kg (A).
FIG. 6. Serum HDL cholesterol level as a percentage of
change over bufler control. Bufl'er control (*);316P 5 mg/kg
(8); 300N 5 mg/kg (4); 316P 15 mg/kg ( ); 300N 15
mg/kg (A).
6
10
16
20
26
30
36
40
46
60
66
60
66
FIG. 7. Serum triglyceride level expressed as a percentage
of change over bufler control. Bufler control (*); 316P 5
mg/kg (8); 300N 5 mg/kg (4); 316P 15 mg/kg ( ); 300N
15 mg/kg (A).
FIG. S. Serum LDL cholesterol level expressed as a
percentage of change over baseline following a single dose
subcutaneous administration. 316P 5 mg/kg (8); 300N 5
mg/kg (0).
FIG. 9. Antibody concentrations in serum over time
following a single dose subcutaneous administration. 316P
5 mg/kg (~); 300N 5 mg/kg (4).
FIG. 10. Western blot for mouse LDL receptor of total
liver homogenates. Samples were taken 24 hours after PBS
(lanes 1-3), 5 mg/kg 316P (lanes 4-6), or 5 mg/kg of
non-hPCSK9 specific mAb (lanes 7-8) administration and 4
hours after 1.2 mg/kg hPCSK9-mmh (all lanes).
FIG. 11.Eflects of 316P on serum LDL cholesterol level
in PCSK9 "' " mice. Bufl'er a control 316P I mg/kg (~ );
316P 5 mg/kg (1I1 ) 316P 10 mg/kg (I ).
FIG. 12.Anti-hPCSK9 mAb serum pharmacokinetic pro-
file in C57BL/6 mice. Single dose of Control I mAb (~) at
10 mg/kg; 316P (4) at 10 mg/kg and 300N (8) at 10 mg/kg.
FIG. 13.Anti-hPCSK9 mAb serum pharmacokinetic pro-
file in hPCSK9 heterozygous mice. Single dose of Control
I mAb (0) at 10mg/kg; 316P (4) at 10 mg/kg and 300N (8)
at 10 mg/kg.
FIG. 14. Efl'ect of 316P on serum LDL cholesterol levels
in Syrian Hamster fed a normal diet. Bufler control (0);
316P I mg/kg (8); 316P 3 mg/kg (4); 316P 5 mg/kg (T).
DETAILED DESCRIPTION
Before the present methods are described, it is to be
understood that this invention is not limited to particular
methods, and experimental conditions described, as such
methods and conditions may vary. It is also to be understood
that the terminology used herein is for the purpose of
describing particular embodiments only, and is not intended
to be limiting, since the scope of the present invention will
be limited only by the appended claims.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which this
invention belongs. Although any methods and materials
similar or equivalent to those described herein can be used
in the practice or testing of the present invention, preferred
methods and materials are now described. All publications
mentioned herein are incorporated herein by reference in
their entirety.
DEFINITIONS
The term "human proprotein convertase subtilisin/kexin
type 9" or "hPCSK9", as used herein, refers to hPCSK9
having the nucleic acid sequence shown in SEQ ID NO:754
and the amino acid sequence of SEQ ID NO:755, or a
biologically active fragment thereof.
The term "antibody", as used herein, is intended to refer
to immunoglobulin molecules comprised of four polypep-
tide chains, two heavy (H) chains and two light (L) chains
inter-connected by disulfide bonds. Each heavy chain is
comprised of a heavy chain variable region ("HCVR" or
"VH") and a heavy chain constant region (comprised of
domains CHI, CH2 and CH3). Each light chain is comprised
of a light chain variable region ("LCVR or "VL")and a light
chain constant region (CL). The VH and VL regions can be
further subdivided into regions of hypervariability, termed
US 9,550,837 B2
12
complementarity determining regions (CDR), interspersed
with regions that are more conserved, termed framework
regions (FR). Each VH and VL is composed of three CDRs
and four FRs, arranged from amino-terminus to carboxy-
terminus in the following order: FRI, CDRI, FR2, CDR2,
FR3, CDR3, FR4.
Substitution of one or more CDR residues or omission of
one or more CDRs is also possible. Antibodies have been
described in the scientific literature in which one or two
CDRs can be dispensed with for binding. Padlan et al. (1995
FASEB J. 9:133-139)analyzed the contact regions between
antibodies and their antigens, based on published crystal
structures, and concluded that only about one fifth to one
third of CDR residues actually contact the antigen. Padlan
also found many antibodies in which one or two CDRs had
no amino acids in contact with an antigen (see also, Vajdos
et al. 2002 J Mol Biol 320:415-428).
CDR residues not contacting antigen can be identified
based on previous studies (for example residues H60-H65 in
CDRH2 are often not required), from regions of Kabat
CDRs lying outside Chothia CDRs, by molecular modeling
and/or empirically. If a CDR or residue(s) thereof is omitted,
it is usually substituted with an amino acid occupying the
corresponding position in another human antibody sequence
or a consensus of such sequences. Positions for substitution
within CDRs and amino acids to substitute can also be
selected empirically. Empirical substitutions can be conser-
vative or non-conservative substitutions.
The term "human antibody", as used herein, is intended to
include antibodies having variable and constant regions
derived from human germline immunoglobulin sequences.
The human mAbs of the invention may include amino acid
residues not encoded by human germline immunoglobulin
sequences (e.g. , mutations introduced by random or site-
specific mutagenesis in vitro or by somatic mutation in
vivo), for example in the CDRs and in particular CDR3.
However, the term "human antibody", as used herein, is not
intended to include mAbs in which CDR sequences derived
from the germline of another mammalian species (e.g. ,
mouse), have been grafted onto human FR sequences.
The term "specifically binds, " or the like, means that an
antibody or antigen-binding fragment thereof forms a com-
plex with an antigen that is relatively stable under physi-
ologic conditions. Specific binding can be characterized by
an equilibrium dissociation constant of at least about I x10
M or less (e.g. , a smaller K~ denotes a tighter binding).
Methods for determining whether two molecules specifi-
cally bind are well known in the art and include, for
example, equilibrium dialysis, surface plasmon resonance,
and the like. An isolated antibody that specifically binds
hPCSK9 may, however, exhibit cross-reactivity to other
antigens such as PCSK9 molecules from other species.
Moreover, multi-specific antibodies (e.g. , bispecifics) that
bind to hPCSK9 and one or more additional antigens are
nonetheless considered antibodies that "specifically bind"
hPCSK9, as used herein.
The term "high affinity" antibody refers to those mAbs
having a binding affinity to hPCSK9 of at least 10 ' M;
preferably 10 "
M; even more preferably 10 '
M, as
measured by surface plasmon resonance, e.g. , BIACORE™
or solution-affinity ELISA.
By the term "slow ofi' rate", "Kofi" or "kd" is meant an
antibody that dissociates from hPCSK9 with a rate constant
of lx10 s
' or less, preferably lx10 s
' or less, as
determined by surface plasmon resonance, e.g. , BIA-
CORE™
5
10
15
20
25
30
35
40
45
50
55
60
65
The term "antigen-binding portion" of an antibody (or
simply "antibody fragment"), as used herein, refers to one or
more fragments of an antibody that retain the ability to
specifically bind to hPCSK9. An antibody fragment may
include a Fab fragment, a F(ab')~ fragment, a Fv fragment,
a dAb fragment, a fragment containing a CDR, or an isolated
CDR.
The specific embodiments, antibody or antibody frag-
ments of the invention may be conjugated to a therapeutic
moiety ("immunoconjugate"), such as a cytotoxin, a che-
motherapeutic drug, an immunosuppressant or a radioiso-
tope.
An "isolated antibody", as used herein, is intended to refer
to an antibody that is substantially free of other mAbs having
difi'erent antigenic specificities (e.g. , an isolated antibody
that specifically binds hPCSK9 is substantially free of mAbs
that specifically bind antigens other than hPCSK9). An
isolated antibody that specifically binds hPCSK9 may, how-
ever, have cross-reactivity to other antigens, such as PCSK9
molecules from other species.
A "neutralizing antibody", as used herein (or an "antibody
that neutralizes PCSK9 activity"), is intended to refer to an
antibody whose binding to hPCSK9 results in inhibition of
at least one biological activity of PCSK9. This inhibition of
the biological activity of PCSK9 can be assessed by mea-
suring one or more indicators of PCSK9 biological activity
by one or more of several standard in vitro or in vivo assays
known in the art (see examples below).
The term "surface plasmon resonance", as used herein,
refers to an optical phenomenon that allows for the analysis
of real-time biospecific interactions by detection of altera-
tions in protein concentrations within a biosensor matrix, for
example using the BIACORE™system (Pharmacia Biosen-
sor AB, Uppsala, Sweden and Piscataway, N.J.).
The term "K~",as used herein, is intended to refer to the
equilibrium dissociation constant of a particular antibody-
antigen interaction.
The term "epitope" is a region of an antigen that is bound
by an antibody. Epitopes may be defined as structural or
functional. Functional epitopes are generally a subset of the
structural epitopes and have those residues that directly
contribute to the affinity of the interaction. Epitopes may
also be conformational, that is, composed of non-linear
amino acids. In certain embodiments, epitopes may include
determinants that are chemically active surface groupings of
molecules such as amino acids, sugar side chains, phospho-
ryl groups, or sulfonyl groups, and, in certain embodiments,
may have specific three-dimensional structural characteris-
tics, and/or specific charge characteristics.
The term "substantial identity" or "substantially identi-
cal," when referring to a nucleic acid or fragment thereof,
indicates that, when optimally aligned with appropriate
nucleotide insertions or deletions with another nucleic acid
(or its complementary strand), there is nucleotide sequence
identity in at least about 90%, and more preferably at least
about 95%, 96%, 97%, 98% or 99% of the nucleotide bases,
as measured by any well-known algorithm of sequence
identity, such as FASTA, BLAST or GAP, as discussed
below.
As applied to polypeptides, the term "substantial similar-
ity" or "substantially similar" means that two peptide
sequences, when optimally aligned, such as by the programs
GAP or BESTFIT using default gap weights, share at least
90% sequence identity, even more preferably at least 95%,
98% or 99% sequence identity. Preferably, residue positions
which are not identical difier by conservative amino acid
substitutions. A "conservative amino acid substitution" is
13
US 9,550,837 B2
14
one in which an amino acid residue is substituted by another
amino acid residue having a side chain (R group) with
similar chemical properties (e.g. , charge or hydrophobicity).
In general, a conservative amino acid substitution will not
substantially change the functional properties of a protein. In
cases where two or more amino acid sequences differ from
each other by conservative substitutions, the percent or
degree of similarity may be adjusted upwards to correct for
the conservative nature of the substitution. Means for mak-
ing this adjustment are well known to those of skill in the art.
See, e.g. , Pearson (1994) Methods Mol. Biol. 24: 307-331,
which is herein incorporated by reference. Examples of
groups of amino acids that have side chains with similar
chemical properties include I) aliphatic side chains: glycine,
alanine, valine, leucine and isoleucine; 2) aliphatic-hydroxyl
side chains: serine and threonine; 3) amide-containing side
chains: asparagine and glutamine; 4) aromatic side chains:
phenylalanine, tyrosine, and tryptophan; 5) basic side
chains: lysine, arginine, and histidine; 6) acidic side chains:
aspartate and glutamate, and 7) sulfur-containing side
chains: cysteine and methionine. Preferred conservative
amino acids substitution groups are: valine-leucine-isoleu-
cine, phenylalanine-tyro sine, lysine-arginine, alanine-va-
line, glutamate-aspartate, and asparagine-glutamine. Alter-
natively, a conservative replacement is any change having a
positive value in the PAM250 log-likelihood matrix dis-
closed in Gonnet et al. (1992) Science 256: 1443 45, herein
incorporated by reference. A "moderately conservative"
replacement is any change having a nonnegative value in the
PAM250 log-likelihood matrix.
Sequence similarity for polypeptides is typically mea-
sured using sequence analysis software. Protein analysis
software matches similar sequences using measures of simi-
larity assigned to various substitutions, deletions and other
modifications, including conservative amino acid substitu-
tions. For instance, GCG software contains programs such
as GAP and BESTFIT which can be used with default
parameters to determine sequence homology or sequence
identity between closely related polypeptides, such as
homologous polypeptides from different species of organ-
isms or between a wild type protein and a mutein thereof.
See, e.g. , GCG Version 6.1. Polypeptide sequences also can
be compared using FASTA with default or recommended
parameters; a program in GCG Version 6.1. FASTA (e.g. ,
FASTA2 and FASTA3) provides alignments and percent
sequence identity of the regions of the best overlap between
the query and search sequences (Pearson (2000) supra).
Another preferred algorithm when comparing a sequence of
the invention to a database containing a large number of
sequences from different organisms is the computer program
BLAST, especially BLASTP or TBLASTN, using default
parameters. See, e.g. , Altschul et al. (1990) J. Mol. Biol.
215: 403 410 and (1997) Nucleic Acids Res. 25:3389 402,
each of which is herein incorporated by reference.
In specific embodiments, the antibody or antibody frag-
ment for use in the method of the invention may be mono-
specific, bispecific, or multispecific. Multispecific antibod-
ies may be specific for different epitopes of one target
polypeptide or may contain antigen-binding domains spe-
cific for epitopes of more than one target polypeptide. An
exemplary bi-specific antibody format that can be used in
the context of the present invention involves the use of a first
immunoglobulin (Ig) CH3 domain and a second Ig CH3
domain, wherein the first and second Ig CH3 domains differ
from one another by at least one amino acid, and wherein at
least one amino acid difference reduces binding of the
bispecific antibody to Protein A as compared to a bi-specific
5
10
15
20
25
30
35
40
45
50
55
60
65
antibody lacking the amino acid difference. In one embodi-
ment, the first Ig CH3 domain binds Protein A and the
second Ig CH3 domain contains a mutation that reduces or
abolishes Protein A binding such as an H95R modification
(by IMGT exon numbering; H435R by EU numbering). The
second CH3 may further comprise an Y96F modification (by
IMGT; Y436F by EU). Further modifications that may be
found within the second CH3 include: D16E, L18M, N44S,
K52N, V57M, and V82I (by IMGT; D356E, L358M,
N384S, K392N, V397M, and V422I by EU) in the case of
IgGI mAbs; N44S, K52N, and V82I (IMGT; N384S,
K392N, and V422I by EU) in the case of IgG2 mAbs; and
Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (by
IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q,
and V422I by EU) in the case of IgG4 mAbs. Variations on
the bi-specific antibody format described above are contem-
plated within the scope of the present invention.
By the phrase "therapeutically effective amount" is meant
an amount that produces the desired effect for which it is
administered. The exact amount will depend on the purpose
of the treatment, and will be ascertainable by one skilled in
the art using known techniques (see, for example, Lloyd
(1999)The Art, Science and Technology of Pharmaceutical
Compounding).
Preparation of Human Antibodies
Methods for generating human antibodies in transgenic
mice are known (see for example, U.S. Pat. No. 6,596,541,
Regeneron Pharmaceuticals, VELOCIMMUNE™). The
VELOCIMMUNE™ technology involves generation of a
transgenic mouse having a genome comprising human
heavy and light chain variable regions operably linked to
endogenous mouse constant region loci such that the mouse
produces an antibody comprising a human variable region
and a mouse constant region in response to antigenic stimu-
lation. The DNA encoding the variable regions of the heavy
and light chains of the antibody are isolated and operably
linked to DNA encoding the human heavy and light chain
constant regions. The DNA is then expressed in a cell
capable of expressing the fully human antibody. In specific
embodiment, the cell is a CHO cell.
Antibodies may be therapeutically useful in blocking a
ligand-receptor interaction or inhibiting receptor component
interaction, rather than by killing cells through fixation of
complement and participation in complement-dependent
cytotoxicity (CDC), or killing cells through antibody-depen-
dent cell-mediated cytotoxicity (ADCC). The constant
region of an antibody is thus important in the ability of an
antibody to fix complement and mediate cell-dependent
cytotoxicity. Thus, the isotype of an antibody may be
selected on the basis of whether it is desirable for the
antibody to mediate cytotoxicity.
Human antibodies can exist in two forms that are asso-
ciated with hinge heterogeneity. In one form, an antibody
molecule comprises a stable four-chain construct of approxi-
mately 150-160 kDa in which the dimers are held together
by an interchain heavy chain disulfide bond. In a second
form, the dimers are not linked via inter-chain disulfide
bonds and a molecule of about 75-80 kDa is formed com-
posed of a covalently coupled light and heavy chain (half-
antibody). These forms have been extremely difficult to
separate, even after affinity purification.
The frequency of appearance of the second form in
various intact IgG isotypes is due to, but not limited to,
structural differences associated with the hinge region iso-
type of the antibody. A single amino acid substitution in the
hinge region of the human IgG4 hinge can significantly
reduce the appearance of the second form (Angal et al.
15
US 9,550,837 B2
16
(1993) Molecular Immunology 30:105) to levels typically
observed using a human IgGI hinge. The instant invention
encompasses antibodies having one or more mutations in the
hinge, CH2 or CH3 region which may be desirable, for
example, in production, to improve the yield of the desired
antibody form.
Generally, a VELOCIMMUNE™ mouse is challenged
with the antigen of interest, and lymphatic cells (such as
B-cells) are recovered from the mice that express antibodies.
The lymphatic cells may be fused with a myeloma cell line
to prepare immortal hybridoma cell lines, and such
hybridoma cell lines are screened and selected to identify
hybridoma cell lines that produce antibodies specific to the
antigen of interest. DNA encoding the variable regions of the
heavy chain and light chain may be isolated and linked to
desirable isotypic constant regions of the heavy chain and
light chain. Such an antibody protein may be produced in a
cell, such as a CHO cell. Alternatively, DNA encoding the
antigen-specific chimeric antibodies or the variable domains
of the light and heavy chains may be isolated directly from
antigen-specific lymphocytes.
Initially, high affinity chimeric antibodies are isolated
having a human variable region and a mouse constant
region. As described below, the antibodies are characterized
and selected for desirable characteristics, including affinity,
selectivity, epitope, etc. The mouse constant regions are
replaced with a desired human constant region to generate
the fully human antibody of the invention, for example
wild-type or modified IgGI or IgG4 (for example, SEQ ID
NO:751, 752, 753). While the constant region selected may
vary according to specific use, high affinity antigen-binding
and target specificity characteristics reside in the variable
region.
Epitope Mapping and Related Technologies
To screen for antibodies that bind to a particular epitope
(e.g. , those which block binding of IgE to its high aflinity
receptor), a routine cross-blocking assay such as that
described Antibodies, Harlow and Lane (Cold Spring Harbor
Press, Cold Spring Harb. , N.Y) can be performed. Other
methods include alanine scanning mutants, peptide blots
(Reineke (2004) Methods Mol Biol 248:443-63) (herein
specifically incorporated by reference in its entirety), or
peptide cleavage analysis. In addition, methods such as
epitope excision, epitope extraction and chemical modifica-
tion of antigens can be employed (Tomer (2000) Protein
Science 9: 487-496) (herein specifically incorporated by
reference in its entirety).
The term "epitope" refers to a site on an antigen to which
B and/or T cells respond. B-cell epitopes can be formed both
from contiguous amino acids or noncontiguous amino acids
juxtaposed by tertiary folding of a protein. Epitopes formed
from contiguous amino acids are typically retained on
exposure to denaturing solvents, whereas epitopes formed
by tertiary folding are typically lost on treatment with
denaturing solvents. An epitope typically includes at least 3,
and more usually, at least 5 or 8-10 amino acids in a unique
spatial conformation.
Modification-Assisted Profiling (MAP), also known as
Antigen Structure-based Antibody Profiling (ASAP) is a
method that categorizes large numbers of monoclonal anti-
bodies (mAbs) directed against the same antigen according
to the similarities of the binding profile of each antibody to
chemically or enzymatically modified antigen surfaces (US
2004/0101920, herein specifically incorporated by reference
in its entirety). Each category may reflect a unique epitope
either distinctly diflerent from or partially overlapping with
epitope represented by another category. This technology
6
10
16
20
26
30
36
40
46
60
66
60
66
allows rapid filtering of genetically identical mAbs, such
that characterization can be focused on genetically distinct
mAbs. When applied to hybridoma screening, MAP may
facilitate identification of rare hybridoma clones that pro-
duce mAbs having the desired characteristics. MAP may be
used to sort the anti-PCSK9 mAbs of the invention into
groups of mAbs binding diflerent epitopes.
In various embodiments, the anti-hPCSK9 antibody or
antigen-binding fragment of an antibody binds an epitope
within the catalytic domain, which is about 153 to 425 of
SEQ ID NO:755); more specifically, an epitope from about
153 to about 250 or from about 250 to about 425; more
specifically, the antibody or antibody fragment of the inven-
tion binds an epitope within the fragment from about 153 to
about 208, from about 200 to about 260, from about 250 to
about 300, from about 275 to about 325, from about 300 to
about 360, from about 350 to about 400, and/or from about
375 to about 425.
In various embodiments, the anti-hPCSK9 antibody or
antigen-binding fragment of an antibody binds an epitope
within the propeptide domain (residues 31 to 152 of SEQ ID
NO:755); more specifically, an epitope from about residue
31 to about residue 90 or from about residue 90 to about
residue 152; more specifically, the antibody or antibody
fragment of the invention binds an epitope within the
fragment from about residue 31 to about residue 60, from
about residue 60 to about residue 90, from about residue 85
to about residue 110, from about residue 100 to about
residue 130, from about residue 125 to about residue 150,
from about residue 135 to about residue 152, and/or from
about residue 140 to about residue 152.
In some embodiments, the anti-hPCSK9 antibody or
antigen-binding fragment of an antibody binds an epitope
within the C-terminal domain, (residues 426 to 692 of SEQ
ID NO:755); more specifically, an epitope from about resi-
due 426 to about residue 570 or from about residue 570 to
about residue 692; more specifically, the antibody or anti-
body fragment of the invention binds an epitope within the
fragment from about residue 450 to about residue 500, from
about residue 500 to about residue 550, from about residue
550 to about residue 600, and/or from about residue 600 to
about residue 692.
In some embodiments, the antibody or antibody fragment
binds an epitope which includes more than one of the
enumerated epitopes within the catalytic, propeptide or
C-terminal domain, and/or within two or three diflerent
domains (for example, epitopes within the catalytic and
C-terminal domains, or within the propeptide and catalytic
domains, or within the propeptide, catalytic and C-terminal
domains.
In some embodiments, the antibody or antigen-binding
fragment binds an epitope on hPCSK9 comprising amino
acid residue 238 of hPCSK9 (SEQ ID NO:755). Experimen-
tal results (Table 27) show that when D238 was mutated, the
K~ of mAb 316P exhibited &400-fold reduction in binding
affinity (-Ix10 M to -410x10 M) and T„~decreased
&30-fold (from -37 to -I min). In a specific embodiment,
the mutation was D238R. In specific embodiments, the
antibody or antigen-binding fragment of the invention binds
an epitope of hPCSK9 comprising two or more of amino
acid residues at positions 153, 159, 238 and 343.
As shown below, a mutation in amino acid residue 153,
159 or 343 resulted in about a 5- to 10-fold decrease in
affinity or similar shortening in T„~.In specific embodi-
ments, the mutation was S153R, E159R and/or D343R.
In some embodiments, the antibody or antigen-binding
fragment binds an epitope on hPCSK9 comprising amino
17
US 9,550,837 B2
18
acid residue 366 of hPCSK9 (SEQ ID NO:755). Experimen-
tal results (Table 27) show that when E366 was mutated, the
affinity of mAb 300N exhibited about 50-fold decrease
(-0.7x10 M to -36x10 M) and a similar shortening in
Tying (from -120 to -2 min). In a specific embodiment, the
mutation is E366K.
The present invention includes anti-PCSK9 antibodies
that bind to the same epitope as any of the specific exem-
plary antibodies described herein. Likewise, the present
invention also includes anti-PCSK9 antibodies that compete
for binding to PCSK9 or a PCSK9 fragment with any of the
specific exemplary antibodies described herein.
One can easily determine whether an antibody binds to
the same epitope as, or competes for binding with, a refer-
ence anti-PCSK9 antibody by using routine methods known
in the art. For example, to determine if a test antibody binds
to the same epitope as a reference anti-PCSK9 antibody of
the invention, the reference antibody is allowed to bind to a
PCSK9 protein or peptide under saturating conditions. Next,
the ability of a test antibody to bind to the PCSK9 molecule
is assessed. If the test antibody is able to bind to PCSK9
following saturation binding with the reference anti-PCSK9
antibody, it can be concluded that the test antibody binds to
a diflerent epitope than the reference anti-PCSK9 antibody.
On the other hand, if the test antibody is not able to bind to
the PCSK9 molecule following saturation binding with the
reference anti-PCSK9 antibody, then the test antibody may
bind to the same epitope as the epitope bound by the
reference anti-PCSK9 antibody of the invention.
To determine if an antibody competes for binding with a
reference anti-PCSK9 antibody, the above-described bind-
ing methodology is performed in two orientations: In a first
orientation, the reference antibody is allowed to bind to a
PCSK9 molecule under saturating conditions followed by
assessment of binding of the test antibody to the PCSK9
molecule. In a second orientation, the test antibody is
allowed to bind to a PCSK9 molecule under saturating
conditions followed by assessment of binding of the refer-
ence antibody to the PCSK9 molecule. If, in both orienta-
tions, only the first (saturating) antibody is capable of
binding to the PCSK9 molecule, then it is concluded that the
test antibody and the reference antibody compete for binding
to PCSK9. As will be appreciated by a person of ordinary
skill in the art, an antibody that competes for binding with
a reference antibody may not necessarily bind to the iden-
tical epitope as the reference antibody, but may sterically
block binding of the reference antibody by binding an
overlapping or adjacent epitope.
Two antibodies bind to the same or overlapping epitope if
each competitively inhibits (blocks) binding of the other to
the antigen. That is, a I-, 5-, 10-, 20- or 100-fold excess of
one antibody inhibits binding of the other by at least 50'ro but
preferably 75'ro, 90'ro or even 99'ro as measured in a com-
petitive binding assay (see, e.g. , Junghans et al. , Cancer Res.
1990 50:1495-1502).Alternatively, two antibodies have the
same epitope if essentially all amino acid mutations in the
antigen that reduce or eliminate binding of one antibody
reduce or eliminate binding of the other. Two antibodies
have overlapping epitopes if some amino acid mutations that
reduce or eliminate binding of one antibody reduce or
eliminate binding of the other.
Additional routine experimentation (e.g. , peptide muta-
tion and binding analyses) can then be carried out to confirm
whether the observed lack of binding of the test antibody is
in fact due to binding to the same epitope as the reference
antibody or if steric blocking (or another phenomenon) is
responsible for the lack of observed binding. Experiments of
5
10
15
20
25
30
35
40
45
50
55
60
65
this sort can be performed using ELISA, RIA, surface
plasmon resonance, flow cytometry or any other quantitative
or qualitative antibody-binding assay available in the art.
In a specific embodiment, the invention comprises an
anti-PCSK9 antibody or antigen binding fragment of an
antibody that binds an PCSK9 protein of SEQ ID NO:755,
wherein the binding between the antibody or fragment
thereof to PCSK9 and a variant PCSK9 protein is less than
50'ro of the binding between the antibody or fragment and
the PCSK9 protein of SEQ ID NO:755. In one specific
embodiment, the variant PCSK9 protein comprises at least
one mutation of a residue at a position selected from the
group consisting of 153, 159, 238 and 343. In a more specific
embodiment, the at least one mutation is S153R, E159R,
D238R, and/or D343R. In another specific embodiment, the
variant PCSK9 protein comprises at least one mutation of a
residue at a position selected from the group consisting of
366. In one specific embodiment, the variant PCSK9 protein
comprises at least one mutation of a residue at a position
selected from the group consisting of 147, 366 and 380. In
a more specific embodiment, the mutation is S147F, E366K
and V380M.
Immunoconjugates
The invention encompasses a human anti-PCSK9 mono-
clonal antibody conjugated to a therapeutic moiety ("immu-
noconjugate"), such as a cytotoxin, a chemotherapeutic
drug, an immunosuppressant or a radioisotope. Cytotoxin
agents include any agent that is detrimental to cells.
Examples of suitable cytotoxin agents and chemotherapeutic
agents for forming immunoconjugates are known in the art,
see for example, WO 05/103081.
Bispecifics
The antibodies of the present invention may be mono-
specific, bispecific, or multispecific. Multispecific mAbs
may be specific for difl'erent epitopes of one target polypep-
tide or may contain antigen-binding domains specific for
more than one target polypeptide. See, e.g. , Tutt et al. (1991)
J. Immunol. 147:60-69.The human anti-PCSK9 mAbs can
be linked to or co-expressed with another functional mol-
ecule, e.g. , another peptide or protein. For example, an
antibody or fragment thereof can be functionally linked
(e.g. , by chemical coupling, genetic fusion, noncovalent
association or otherwise) to one or more other molecular
entities, such as another antibody or antibody fragment, to
produce a bispecific or a multispecific antibody with a
second binding specificity.
An exemplary bi-specific antibody format that can be
used in the context of the present invention involves the use
of a first immunoglobulin (Ig) CH3 domain and a second Ig
CH3 domain, wherein the first and second Ig CH3 domains
difl'er from one another by at least one amino acid, and
wherein at least one amino acid diflerence reduces binding
of the bispecific antibody to Protein A as compared to a
bi-specific antibody lacking the amino acid diflerence. In
one embodiment, the first Ig CH3 domain binds Protein A
and the second Ig CH3 domain contains a mutation that
reduces or abolishes Protein A binding such as an H95R
modification (by IMGT exon numbering; H435R by EU
numbering). The second CH3 may further comprise a Y96F
modification (by IMGT; Y436F by EU). Further modifica-
tions that may be found within the second CH3 include:
D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT;
D356E, L358M, N384S, K392N, V397M, and V422I by
EU) in the case of IgGI antibodies; N44S, K52N, and V82I
(IMGT; N384S, K392N, and V422I by EU) in the case of
IgG2 antibodies; and Q15R, N44S, K52N, V57M, R69K,
E79Q, and V82I (by IMGT; Q355R, N384S, K392N,
19
US 9,550,837 B2
20
V397M, R409K, E419Q, and V422I by EU) in the case of
IgG4 antibodies. Variations on the bi-specific antibody for-
mat described above are contemplated within the scope of
the present invention.
Bioequivalents
The anti-PCSK9 antibodies and antibody fragments of the
present invention encompass proteins having amino acid
sequences that vary from those of the described mAbs, but
that retain the ability to bind human PCSK9. Such variant
mAbs and antibody fragments comprise one or more addi-
tions, deletions, or substitutions of amino acids when com-
pared to parent sequence, but exhibit biological activity that
is essentially equivalent to that of the described mAbs.
Likewise, the anti-PCSK9 antibody-encoding DNA
sequences of the present invention encompass sequences
that comprise one or more additions, deletions, or substitu-
tions of nucleotides when compared to the disclosed
sequence, but that encode an anti-PCSK9 antibody or anti-
body fragment that is essentially bioequivalent to an anti-
PCSK9 antibody or antibody fragment of the invention.
Examples of such variant amino acid and DNA sequences
are discussed above.
Two antigen-binding proteins, or antibodies, are consid-
ered bioequivalent if, for example, they are pharmaceutical
equivalents or pharmaceutical alternatives whose rate and
extent of absorption do not show a significant difl'erence
when administered at the same molar dose under similar
experimental conditions, either single does or multiple dose.
Some antibodies will be considered equivalents or pharma-
ceutical alternatives if they are equivalent in the extent of
their absorption but not in their rate of absorption and yet
may be considered bioequivalent because such diflerences in
the rate of absorption are intentional and are reflected in the
labeling, are not essential to the attainment of eflective body
drug concentrations on, e.g. , chronic use, and are considered
medically insignificant for the particular drug product stud-
ied. In one embodiment, two antigen-binding proteins are
bioequivalent if there are no clinically meaningful difl'er-
ences in their safety, purity, and potency.
In one embodiment, two antigen-binding proteins are
bioequivalent if a patient can be switched one or more times
between the reference product and the biological product
without an expected increase in the risk of adverse efl'ects,
including a clinically significant change in immunogenicity,
or diminished eflectiveness, as compared to continued
therapy without such switching.
In one embodiment, two antigen-binding proteins are
bioequivalent if they both act by a common mechanism or
mechanisms of action for the condition or conditions of use,
to the extent that such mechanisms are known.
Bioequivalence may be demonstrated by in vivo and in
vitro methods. Bioequivalence measures include, e.g. , (a) an
in vivo test in humans or other mammals, in which the
concentration of the antibody or its metabolites is measured
in blood, plasma, serum, or other biological fluid as a
function of time; (b) an in vitro test that has been correlated
with and is reasonably predictive of human in vivo bioavail-
ability data; (c) an in vivo test in humans or other mammals
in which the appropriate acute pharmacological eflect of the
antibody (or its target) is measured as a function of time; and
(d) in a well-controlled clinical trial that establishes safety,
efficacy, or bioavailability or bioequivalence of an antibody.
Bioequivalent variants of anti-PCSK9 antibodies of the
invention may be constructed by, for example, making
various substitutions of residues or sequences or deleting
terminal or internal residues or sequences not needed for
biological activity. For example, cysteine residues not essen-
5
10
15
20
25
30
35
40
45
50
55
60
65
tial for biological activity can be deleted or replaced with
other amino acids to prevent formation of unnecessary or
incorrect intramolecular disulfide bridges upon renaturation.
Treatment Population
The invention provides therapeutic methods for treating a
human patient in need of a composition of the invention.
While modifications in lifestyle and conventional drug treat-
ment are often successful in reducing cholesterol levels, not
all patients are able to achieve the recommended target
cholesterol levels with such approaches. Various conditions,
such as familial hypercholesterolemia (FH), appear to be
resistant to lowering of LDL-C levels in spite of aggressive
use of conventional therapy. Homozygous and heterozygous
familial hypercholesterolemia (hoFH, heFH) is a condition
associated with premature atherosclerotic vascular disease.
However, patients diagnosed with hoFH are largely unre-
sponsive to conventional drug therapy and have limited
treatment options. Specifically, treatment with statins, which
reduce LDL-C by inhibiting cholesterol synthesis and
upregulating the hepatic LDL receptor, may have little efl'ect
in patients whose LDL receptors are non-existent or defec-
tive. A mean LDL-C reduction of only less than about 20%
has been recently reported in patients with genotype-con-
firmed hoFH treated with the maximal dose of statins. The
addition of ezetimibe 10 mg/day to this regimen resulted in
a total reduction of LDL-C levels of 27%, which is still far
from optimal. Likewise, many patients are statin non-re-
sponsive, poorly controlled with statin therapy, or cannot
tolerate statin therapy; in general, these patients are unable
to achieve cholesterol control with alternative treatments.
There is a large unmet medical need for new treatments that
can address the short-comings of current treatment options.
Specific populations treatable by the therapeutic methods
of the invention include patients indicated for LDL aphere-
sis, subjects with PCSK9-activating (GOF) mutations, het-
erozygous Familial Hypercholesterolemia (heFH); subjects
with primary hypercholesterolemia who are statin intolerant
or statin uncontrolled; and subjects at risk for developing
hypercholesterolemia who may be preventably treated.
Therapeutic Administration and Formulations
The invention provides therapeutic compositions com-
prising the anti-PCSK9 antibodies or antigen-binding frag-
ments thereof of the present invention. The administration of
therapeutic compositions in accordance with the invention
will be administered with suitable carriers, excipients, and
other agents that are incorporated into formulations to
provide improved transfer, delivery, tolerance, and the like.
A multitude of appropriate formulations can be found in the
formulary known to all pharmaceutical chemists: Reming-
ton's Pharmaceutical Sciences, Mack Publishing Company,
Easton, Pa. These formulations include, for example, pow-
ders, pastes, ointments, jellies, waxes, oils, lipids, lipid
(cationic or anionic) containing vesicles (such as LIPOFEC-
TIN ), DNA conjugates, anhydrous absorption pastes, oil-
in-water and water-in-oil emulsions, emulsions carbowax
(polyethylene glycols of various molecular weights), semi-
solid gels, and semi-solid mixtures containing carbowax.
See also Powell et al. "Compendium of excipients for
parenteral formulations" PDA (1998) I Pharm Sci Technol
52:238-311.
The dose may vary depending upon the age and the size
of a subject to be administered, target disease, conditions,
route of administration, and the like. When the antibody of
the present invention is used for treating various conditions
and diseases associated with PCSK9, including hypercho-
lesterolemia, disorders associated with LDL and apolipo-
protein B, and lipid metabolism disorders, and the like, in an
21
US 9,550,837 B2
22
adult patient, it is advantageous to intravenously administer
the antibody of the present invention normally at a single
dose of about 0.01 to about 20 mg/kg body weight, more
preferably about 0.02 to about 7, about 0.03 to about 5, or
about 0.05 to about 3 mg/kg body weight. Depending on the
severity of the condition, the frequency and the duration of
the treatment can be adjusted.
Various delivery systems are known and can be used to
administer the pharmaceutical composition of the invention,
e.g. , encapsulation in liposomes, microparticles, microcap-
sules, recombinant cells capable of expressing the mutant
viruses, receptor mediated endocytosis (see, e.g. , Wu et al.
(1987) J. Biol. Chem. 262:4429-4432). Methods of intro-
duction include, but are not limited to, intradermal, intra-
muscular, intraperitoneal, intravenous, subcutaneous, intra-
nasal, epidural, and oral routes. The composition may be
administered by any convenient route, for example by
infusion or bolus injection, by absorption through epithelial
or mucocutaneous linings (e.g. , oral mucosa, rectal and
intestinal mucosa, etc.) and may be administered together
with other biologically active agents. Administration can be
systemic or local.
The pharmaceutical composition can be also delivered in
a vesicle, in particular a liposome (see Langer (1990)
Science 249:1527-1533;Treat et al. (1989) in Liposomes in
the Therapy of Infectious Disease and Cancer, Lopez Ber-
estein and Fidler (eds. ), Liss, New York, pp. 353-365;
Lopez-Berestein, ibid. , pp. 317-327; see generally ibid. ).
In certain situations, the pharmaceutical composition can
be delivered in a controlled release system. In one embodi-
ment, a pump may be used (see Langer, supra; Sefton (1987)
CRC Crit. Ref. Biomed. Eng. 14:201).In another embodi-
ment, polymeric materials can be used; see, Medical Appli-
cations of Controlled Release, Langer and Wise (eds. ), CRC
Pres. , Boca Raton, Fla. (1974). In yet another embodiment,
a controlled release system can be placed in proximity of the
composition's target, thus requiring only a fraction of the
systemic dose (see, e.g. , Goodson, in Medical Applications
of Controlled Release, supra, vol. 2, pp. 115-138, 1984).
The injectable preparations may include dosage forms for
intravenous, subcutaneous, intracutaneous and intramuscu-
lar injections, drip infusions, etc. These injectable prepara-
tions may be prepared by methods publicly known. For
example, the injectable preparations may be prepared, e.g. ,
by dissolving, suspending or emulsifying the antibody or its
salt described above in a sterile aqueous medium or an oily
medium conventionally used for injections. As the aqueous
medium for injections, there are, for example, physiological
saline, an isotonic solution containing glucose and other
auxiliary agents, etc. , which may be used in combination
with an appropriate solubilizing agent such as an alcohol
(e.g. , ethanol), a polyalcohol (e.g. , propylene glycol, poly-
ethylene glycol), a nonionic surfactant [e.g. , polysorbate 80,
HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated
castor oil)], etc. As the oily medium, there are employed,
e.g. , sesame oil, soybean oil, etc. , which may be used in
combination with a solubilizing agent such as benzyl ben-
zoate, benzyl alcohol, etc. The injection thus prepared is
preferably filled in an appropriate ampoule. A pharmaceu-
tical composition of the present invention can be delivered
subcutaneously or intravenously with a standard needle and
syringe. In addition, with respect to subcutaneous delivery,
a pen delivery device readily has applications in delivering
a pharmaceutical composition of the present invention. Such
a pen delivery device can be reusable or disposable. A
reusable pen delivery device generally utilizes a replaceable
cartridge that contains a pharmaceutical composition. Once
5
10
15
20
25
30
35
40
45
50
55
60
65
all of the pharmaceutical composition within the cartridge
has been administered and the cartridge is empty, the empty
cartridge can readily be discarded and replaced with a new
cartridge that contains the pharmaceutical composition. The
pen delivery device can then be reused. In a disposable pen
delivery device, there is no replaceable cartridge. Rather, the
disposable pen delivery device comes prefilled with the
pharmaceutical composition held in a reservoir within the
device. Once the reservoir is emptied of the pharmaceutical
composition, the entire device is discarded.
Numerous reusable pen and autoinjector delivery devices
have applications in the subcutaneous delivery of a phar-
maceutical composition of the present invention. Examples
include, but certainly are not limited to AUTOPEN (Owen
Mumford, Inc. , Woodstock, UK), DISETRONIC™ pen
(Disetronic Medical Systems, Burghdorf, Switzerland),
HUMALOG MIX 75/25™ pen, HUMALOG™ pen,
HUMALIN 70/30™pen (Eli Lilly and Co., Indianapolis,
Ind. ), NOVOPEN I, II and III (Novo Nordisk, Copenha-
gen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk,
Copenhagen, Denmark), BD™pen (Becton Dickinson,
Franklin Lakes, N.J.), OPTIPEN, OPTIPEN PRO™,
OPTIPEN STARLET™,and OPTICLIK™(sanofi-aventis,
Frankfurt, Germany), to name only a few. Examples of
disposable pen delivery devices having applications in sub-
cutaneous delivery of a pharmaceutical composition of the
present invention include, but certainly are not limited to the
SOLOSTAR™ pen (sanofi-aventis), the FLEXPEN
(Novo Nordisk), and the KWIKPEN (Eli Lilly).
Advantageously, the pharmaceutical compositions for
oral or parenteral use described above are prepared into
dosage forms in a unit dose suited to fit a dose of the active
ingredients. Such dosage forms in a unit dose include, for
example, tablets, pills, capsules, injections (ampoules), sup-
positories, etc. The amount of the aforesaid antibody con-
tained is generally about 5 to about 500 mg per dosage form
in a unit dose; especially in the form of injection, it is
preferred that the aforesaid antibody is contained in about 5
to about 100 mg and in about 10 to about 250 mg for the
other dosage forms.
The invention provides therapeutic methods in which the
antibody or antibody fragment of the invention is useful to
treat hypercholesterolemia associated with a variety of con-
ditions involving hPCSK9. The anti-PCSK9 antibodies or
antibody fragments of the invention are particularly useful
for the treatment of hypercholesterolemia and the like.
Combination therapies may include the anti-PCSK9 anti-
body of the invention with, for example, one or more of any
agent that (I) induces a cellular depletion of cholesterol
synthesis by inhibiting 3-hydroxy-3-methylglutaryl (HMG)-
coenzyme A (CoA) reductase, such as cerivastatin, atorvas-
tatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lov-
astatin, pravastatin; (2) inhibits cholesterol uptake and or
bile acid re-absorption; (3) increase lipoprotein catabolism
(such as niacin); and activators of the LXR transcription
factor that plays a role in cholesterol elimination such as
22-hydroxycholesterol or fixed combinations such as
ezetimibe plus simvastatin; a statin with a bile resin (e.g. ,
cholestyramine, colestipol, colesevelam), a fixed combina-
tion of niacin plus a statin (e.g. , niacin with Iovastatin); or
with other lipid lowering agents such as omega-3-fatty acid
ethyl esters (for example, omacor).
EXAMPLES
The following examples are put forth so as to provide
those of ordinary skill in the art with a complete disclosure
23
US 9,550,837 B2
24
and description of how to make and use the methods and
compositions of the invention, and are not intended to limit
the scope of what the inventors regard as their invention.
Eflorts have been made to ensure accuracy with respect to
numbers used but some experimental errors and deviations
should be accounted for. Unless indicated otherwise,
molecular weight is average molecular weight, temperature
is in degrees Centigrade, and pressure is at or near atmo-
spheric.
10
Example I
Generation of Human Antibodies to Human PCSK9
VELOCIMMUNE™ mice were immunized with human
PCSK9, and the antibody immune response monitored by
antigen-specific immunoassay using serum obtained from
these mice. Anti-hPCSK9 expressing B cells were harvested
from the spleens of immunized mice shown to have elevated
anti-hPCSK9 antibody titers were fused with mouse
myeloma cells to form hybridomas. The hybridomas were
screened and selected to identify cell lines expressing
hPCSK9-specific antibodies using assays as described
below. The assays identified several cell lines that produced
chimeric anti-hPCSK9 antibodies designated as HIM300,
HI M504, H IM505, HI M500, HI M497, H IM498,
HI M494, H IM309, HI M312, HI M499, H IM493,
HI M496, H IM503, HI M502, HI M508, HI M495 and
Hl M492.
Human PCSK9-specific antibodies were also isolated
directly from antigen-immunized B cells without fusion to
myeloma cells, as described in U.S. 2007/0280945AI,
hereby incorporated by reference in its entirety. Heavy and
light chain variable regions were cloned to generate fully
human anti-hPCSK9 antibodies designated as HIH313,
HIH314, HIH315, HIH316, HIH317, HIH318, HIH320,
HIH321 and HIH334. Stable recombinant antibody-ex-
pressing CHO cell lines expressing these antibodies were
established.
40
TABLE I-continued
Hea Chain Variable Re ion
Light Chain
VVbt R l
Antibody
HJM504
HJM505
HJM500
H1M497
H1M498
H1M494
H1M309
H1M312
H1M499
H1M493
H1M496
HJM503
HJM502
HJM508
HJM495
H1M492
VH
3-30
3-30
2-5
1-18
3-21
3-11
3-21
3-21
3-21
3-21
3-13
1-18
3-13
3-13
3-9
3-23
2-8
2-8
5-5
2-2
2-2
5-12
6-13
6-13
6-13
6-13
6-19
2-2
6-13
6-13
4-17
3-3
JH VK JK
2-28
2-28
2-28
2-30
1-5
3-20
1-5
1-5
1-5
1-5
3-15
2-28
3-15
3-15
1-9
3-20
Example 3
Antigen Binding Affinity Determination
TABLE 2
Equilibrium dissociation constants (K~) for hPCSK9
binding to mAbs generated by hybridoma cell lines
described above were determined by surface kinetics in a
real-time biosensor surface plasmon resonance assay (BIA-
CORE™T100). Each antibody was captured at a flow rate
of 4 iJI/min for 90 sec on a goat anti-mouse IgG polyclonal
antibody surface created through direct chemical coupling to
a BIACORE™chip to form a captured antibody surface.
Human PCSK9-myc-myc-his (hPCSK9-mmh) at a concen-
tration of 50 nM or 12.5 nM was injected over the captured
antibody surfaces at a flowrate of 50 iJI/min for 300 sec, and
antigen-antibody dissociation was monitored for 15 min at
either 25' C. or 37' C. (K~c PM; TI/2=min).
Example 2
Gene Utilization Analysis Antibody
25' C. 37' C.
KD T I/2 KD T I/2
TABLE I
Light Chain
H Cbl V lbl R l ~Vibl R
Antibody VH JH VK JK
To analyze the structure of the mAbs produced, the 4~
nucleic acids encoding antibody variable regions were
cloned and sequenced. The predicted amino acid sequences
of the variable regions were confirmed by ¹erminal amino
acid sequencing. From the nucleic acid sequence and pre-
dicted amino acid sequence of the mAbs, gene usage was
identified for each antibody chain.
H1M300
H1M309
H1M312
H1M493
H1M494
HJM495
H1M496
H1M497
H1M498
H1M499
H1M500
H1M502
H1M503
H1M504
H1M505
HJM508
H1M510
399
29.9
0.225
46.5
870
440
254
20. 1
6400
106
1400
78.3
510
3470
2740
138
1070
170
7461
15568
4921
114
222
257
5801
30
2253
91
958
118
35
42
572
68
1510
537
432
522
2350
7500
421
480
7500
582
6010
411
1880
11200
9200
442
3960
32
326
392
341
30
19
118
290
14
316
15
151
30
6
6
139
10
H1H313
H1H314
H1H315
H1H316
H1H317
H1H318
H1H320
H1H321
H1H334
H1M300
3-13
3-33
3-33
3-23
3-13
4-59
1-18
2-5
2-5
3-7
1-26
3-3
3-3
7-27
1-26
3-10
2-2
1-7
6-6
2-8
3-15
1-5
4-1
4-1
1-6
1-9
2-30
2-28
2-28
2-28
3
60
1
2
1
1
1
4
65
4
Equilibrium dissociation constants (K~) for hPCSK9
binding to mAbs generated via direct isolation of spleno-
cytes were determined by surface kinetics in a real-time
biosensor surface plasmon resonance assay (BIACORE™
T100). Each selected antibody was captured at a flowrate of
2 iJI/min for 6 min on a goat anti-human IgG polyclonal
antibody surface created through direct chemical coupling to
a BIACORE™chip to form a captured antibody surface.
25
US 9,550,837 B2
Human PCSK9-mmh at a concentration of 50 nM or 12.5
nM was injected over the captured antibody surface at a
flowrate of 70 pl/min for 5 min, and antigen-antibody
dissociation was monitored for 15 min at either 25' C. or 37'
C (K22:pM' Tt/2™).
26
TABLE 5
High hPCSK9
Densi Surface
Low hPCSK9
Densi Surface
~H7.4 ~H4. 4 ~H7.4 ~H4. 4
TABLE 3 Antibody KD T„2 KD T„2 KD T„2 KD Tt/2
26' C. 37' C.
316P 191 74 144 83 339 46 188 68
300N 66 607 1180 26 310 119 1380 13
Control I 20000 29 ND ND ND ND ND ND
Antibody KD T I/2 KD T I/2
HIH313P
HI H314P
HIH316P
HIH316P
HIH317P
HIH318P
HIH320P
HIH321P
HIH334P
244
3990
129
377
30400
972
771
866
3760
230
66
42
137
69
28
106
46
780
3660
413
1080
18600
1690
1930
3360
16900
60
43
36
70
28
23
TABLE 4
Antibody kd (I/si Tt/2 (mini
Dissociation rate (kd) of selected mAbs for tagged rhesus
monkey (Macaca mulata) PCSK9 (mmPCSK9; SEQ ID
NO:756) (mmPCSK9-mmh) at 25' C. was determined as
described above.
The antigen binding properties of 316P and 300N at pH
7.4 or pH 5.5 were determined by a modified BIACORE™
assay as described above. Briefly, mAbs were immobilized
onto BIACORE™CM5 sensor chips via amine coupling.
Varying concentrations of myc-myc-his tagged hPCSK9,
mouse PCSK9 (mPCSK9, SEQ ID NO:757), hPCSK9 with
a gain of function (GOF) point mutation of D374Y (hPCSK9
20 (D374Y), cynomolgus monkey (Macaca fascicuiaris)
PCSK9 (mfPCSK9, SEQ ID NO:761) (mfPCSK9), rat (Rat-
tus norvegicus) PCSK9 (rPCSK9, SEQ ID NO:763), and
his-tagged Syrian golden hamster (Mesocnicetus auratus)
PCSK9 (maPCSK9, SEQ ID NO:762) (maPCSK9), ranging
from 11 to 100 nM, were injected over the antibody surface
at the flow rate of 100 pl/ml for 1.5 min and antigen-
antibody dissociation was monitored in real time for 5 min
at either 25' C. (Table 6) or 37' C. (Table 7). Control II:
30 anti-hPCSK9 mAbs SEQ ID NO:67/12 (WO 2009/026558)
(NB: no binding was observed under the experimental
condition) (KD7 pM; Tt/2=min).
HIH313P
HIH318P
HIH334P
HIH316P
HIH316P
HIH320P
HIM300
HIM604
H IM497
HIM603
HIM496
2.92 x 10
3.69 x 10
8.06 x 10
2.29 x 10
2.29 x 10
3.17 x 10
1.62 x 10
6.04 x 10
6.60 x 10
8.73 x 10
4.46 x 10
Example 4
396
3
I
61
61
36
76
23
176
132
260
36
40
46
Antigen
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
TABLE 6
H Effect at 26' C.
H 7.4
1260
4460
2490
1420
8360
24100
36
10
16
42
8
2
300N
22 39
63 11
166 13
8 23
87 8
349 6
KD T 1/2 KD T t/2
316P
Eflect of pH on Antigen Binding Affinity
The eflects of pH on antigen binding affinity for CHO
cell-produced fully human anti-hPCSK9 mAbs was assessed
as described above. The mAbs tested are fully human
versions of HI H316P ("316P")(HCVR/LCVR SEQ ID NO:
90/92; CDR sequences SEQ ID NO: 76/78/80 and 84/86/88)
and HIM300N ("300N") (HCVR/LCVR SEQ ID NO: 218/
226; CDR sequences SEQ ID NO:220/222/224 and 228/
230/232). Human PCSK9-myc-myc-his (hPCSK9-mmh)
was captured on an anti-myc mAb surface either at a high
density (about 35 to 45 resonance units) (RU) or at a low
density (about 5 to 14 RU). Each antibody, at 50 nM in
HBST (pH 7.4 or pH 5.5) was injected over the captured
hPCSK9 surface at a flow rate of 100 pl/ml for 1.5 min at 25'
C. and antigen-antibody dissociation was monitored for 10
min. Control I: anti-hPCSK9 mAb SEQ ID NO:79/101 (WO
2008/063382) (K22:pM' Tt/2:min).
60
60
66
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
1100
NB
1310
2170
NB
NB
76 3100
NB NB
46 9030
31 38600
NB NB
NB NB
Control I
6
NB
3
0.4
NB
NB
33100
NB
71000
362000
NB
NB
14
NB
ll
0.2
NB
NB
Control
1740 31
NB NB
7320 30
67200 3
NB NB
NB NB
H
143 266 2 212
3600 11 33 12
191 166 49 66
102 262 12 63
6600 3 ND ND
22400 2 106 6
27
TABLE 7
H Effect at 37' C.
US 9,550,837 B2
28
H 5.5
Example 6
Binding Specificity of Anti-hPCSK9 mAbs
Antigen KD T„2 KD Tt/2
316P
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
4000
12200
6660
3770
21700
55100
9 142
3 13600
4 1560
ll 44
2 ND
2 399
300N
ll
3
5
5
ND
I
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
2470
NB
2610
4810
NB
NB
20 11900
NB NB
14 28000
8 65200
NB NB
NB NB
Control I
I
NB
I
0.1
NB
NB
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9
45900
NB
169000
500000
NB
NB
0.1 11300
NB NB
0.4 27000
0.6 5360
NB NB
NB NB
Control H
3
NB
3
0.3
NB
NB
hPCSK9-mmh
mPCSK9-mmh
hPCSK9(D347YFmmh
mfPCSK9-mmh
maPCSK9-h
rPCSK9p-mmh
284 87 20 44
8680 3 89 3
251 57 483 26
180 127 214 65
8830 0 5 ND ND
30200 I 233 I
Example 5
Anti-hPCSK9 mAbs Binding to hPCSK9 with
Point Mutation D374Y
316P, 300N, and Control I anti-hPCSK9 mAbs were
captured on an amine-coupled anti-hFc CM5 chip on BIA-
CORE™2000. Tagged (myc-myc-his) human PCS K9,
human PCSKI (hPCSKI) (SEQ ID NO:759), human
PCSK7 (hPCSK7) (SEQ ID NO:760), or mouse PCSK9
10
were injected (100 nM) over the captured mAb surface and
allowed to bind at 25' C. for 5 min. Changes in RU were
recorded. Results: 300N and Control I bound only to
hPCSK9, and 316P bound both hPCSK9 and mPCSK9.
The binding specificities of anti-hPCSK9 mAbs were
determined by ELISA. Briefly, anti-hPCSK9 antibody was
coated on a 96-well plate. Human PCSK9-mmh, mPCSK9-
mmh, maPCSK9-h, hPCSKl-mmh, or hPCSK7-mmh, at 1.2
nM, were added to antibody-coated plates and incubated at
RT for I hr. Plate-bound PCSK protein was then detected by
HRP-conjugated anti-His antibody. Results show that 316P
binds human, mouse, and hamster PCSK9, whereas 300N
and Control I only bound hPCSK9. None of the anti-
hPCSK9 mAbs exhibited significant binding to hPCSKI or
hPCSK7.
Example 7
Cross-Reactivity of Anti-hPCSK9 mAbs
30
Cross-reactivity of anti-hPCSK9 mAbs with mmPCSK9,
mfPCSK9, mPCSK9, maPCSK9, or rPCSK9 was deter-
mined using BIACORE™3000.Briefly, anti-hPCSK9 mAbs
were captured on an anti-hFc surface created through direct
35
chemical coupling to a BIACORE™chip. Purified tagged
hPCSK9, hPCSK9(D374Y), mmPCSK9, mfPCSK9,
mPCSK9, maPCSK9, or rPCSK9, each at 1.56 nM to 50
nM, was injected over the antibody surface at either 25' C.
or 37' C. Binding between 316P, 300N, Control I, Control
II, or Control III and the PCSK9 proteins was determined
(K~=pM; Tt/2=min) (ND=not determined).
The binding affinity of selected anti-hPCSK9 mAbs to
hPCSK9 with a gain of function (GOF) point mutation of
D374Y (hPCSK9(D374Y)-mmh) was determined as
described above. Each antibody was captured at a flowrate
of 40 pl/min for 8-30 sec on a goat anti-human IgG poly-
clonal antibody surface created through direct chemical
coupling to a BIACORE™chip to form a captured antibody
surface. hPCSK9(D374Y)-mmh at varying concentrations
of 1.78 nM to 100 nM was injected over the captured
antibody surface at a flowrate of 50 pl/min for 5 min, and the
dissociation of hPCSK9(D374Y)-mmh and antibody was
monitored for 15 min at 25' C. Control III: anti-hPCSK9
mAbs SEQ ID NO:49/23 (WO 2009/026558) (K~7 PM;
Tt/2 ).
TABLE 8
45
Antigen
hPCSK9-mmh
60 hPCSK9(D374YFmmh
mmPCSK9-mmh
mfPCSK9-mmh
mPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
TABLE 9
316P mAb
37' C. 25' C.
1800
4200
1800
1800
4700
19000
37500
9
4
21
ll
3
I
I
580
1690
550
520
2300
6810
14500
36
15
92
60
ll
5
2
TABLE 10
300N mAb
KD T I/2 KD T I/2
Antibody KD T I/2
60 37' C. 25' C.
316P
300N
Control I
Control H
Control HI
1780
1060
23600
66
1020
14
49
25
216
126
Antigen
hPCSK9-mmh
hPCSK9(D374YFmmh
mmPCSK9-mmh
mfPCSK9-mmh
KD T„2 KD Tt/2
2400 22 740 110
2200 14 900 65
1600 26 610 79
3800 11 1500 45
29
US 9,550,837 B2
30
Antigen
mPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
TABLE 10-continued
300N mAb
37' C. 25' C.
TABLE 11
Control I mAb
37' C. 25' C.
KD TI/r KD TI/r
NB NB NB NB
NB NB NB NB
NB NB NB NB
5
10
15
a CM5 chip to create a receptor or receptor fragment surface.
Selected anti-hPCSK9 mAbs, at 62.5 nM (2.5 fold excess
over antigen), were premixed with 25 nM of hPCSK9-mmh,
followed by 40 min incubation at 25' C. to allow antibody-
antigen binding to reach equilibrium to form equilibrated
solutions. The equilibrated solutions were injected over the
receptor or receptor fragment surfaces at 2 pl/min for 40 min
at 25' C. Changes in RU due to the binding of the anti-
hPCSK9 mAbs to hLDLR-ecto, EGF-A-hFc, or EGF-AB-
hFc were determined. Results show that HIH316P and
HI M300N blocked the binding of hPCSK9-mmh to
hLDLR-ecto, hLDLR EGF-A domain, and hLDLR EGF-AB
domains; HIH320P blocked the binding ofhPCSK9-mmh to
hLDLR-ecto and hLDLR EGF-A domain; and HIH321P
blocked the binding of hPCSK9-mmh to hLDLR EGF-A
domain.
Antigen
hPCSK9-mmh
hPCSK9(D374YFmmh
mmPCSK9-mmh
mfPCSK9-mmh
mPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
Antigen
hPCSK9-mmh
hPCSK9(D374YFmmh
mfPCSK9-mmh
mPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
TABLE 12
Control H mAb
37' C.
KD T I/2
91
93
33
4700
60800
14100
162
90
252
3
0.4
I
TABLE 13
Control HI mAb
37' C.
Kr/ TI/r
226000 2
ND ND
420000 3
14300 10
NB NB
NB NB
NB NB
Kr/ TI/r
27500 16
23600 25
291000 2
24900 14
NB NB
NB NB
NB NB
25' C.
KD TI/r
61 372
66 216
26 546
2300 11
25000 2
6900 3
25' C.
20
25
30
35
40
The ability of the mAbs to block hPCSK9 binding to
hLDLR-ecto, hLDLR EGF-A domain, or hLDLR EGF-AB
domains was also evaluated with an ELISA-based immu-
noassay. Briefly, hLDLR-ecto, hLDLR EGF-A-hFc or
hLDLR EGF-AB-hFc, each at 2 pg/ml, was coated on a
96-well plate in PBS bufler overnight at 4' C., and nonspe-
cific binding sites blocked with BSA. This plate was used to
measure free hPCSK9-mmh in a PCSK9-mmh solution
pre-equilibrated with varying concentrations of anti-
hPCSK9 mAbs. A constant amount of hPCSK9-mmh (500
pM) was pre-mixed with varied amounts of antibody, rang-
ing from 0 to -50 nM in serial dilutions, followed by I hr
incubation at room temperature (RT) to allow antibody-
antigen binding to reach equilibrium. The equilibrated
sample solutions were transferred to receptor or receptor
fragment coated plates. After I hour of binding, the plates
were washed and bound hPCSK9-mmh detected using HRP
conjugated anti-myc antibody. IC5o values (in pM) were
determined as the amount of antibody required to achieve
50% reduction of hPCSK9-mmh bound to the plate-coated
receptor or receptor fragment. The results show that specific
mAbs functionally block PCSK9 from binding the three
receptors at both neutral pH (7.2) and acidic pH (5.5).
TABLE 14
Antigen KD T I/2 KD T I/2
45
pH 7.2
Plate Coating Surface
pH 5.5
hPCSK9-mmh
hPCSK9(D374YFmmh
mfPCSK9-mmh
mPCSK9-mmh
maPCSK9-h
rPCSK9-mmh
380
130
110
33500
780
NB
378
660
750
I
107
NB
490
1000
340
10900
2100
33200
450
126
396
4
67
2
50
Ab
316P
300N
Control
hLDLR- hLDLR-
&125 &125 &125 &125
144 146 &125 1492
&100,000 &100,000
&125 &125
538 447
&100,000 &100,000
ecto EGF-A EGF-AB ecto EGF-A EGF-AB
Example 8
Inhibition of Binding Between hPCSK9 and
hLDLR Domains
I
Control
Control
HI
288
303
510 274 411
635 391 742
528 508
787 1073
The ability of selected anti-hPCSK9 mAbs to block
hPCSK9 binding to human LDLR full length extracellular
domain (hLDLR-ecto SEQ ID NO:758), hLDLR EGF-A
domain (amino acids 313-355 of SED ID NO:758), or
hLDLR EGF-AB domains (amino acids of 314-393 of SEQ
ID NO:758) (LDLR Genbank number NM 000527) was
evaluated using BIACORE™3000. Briefly, hLDLR-ecto,
EGF-A-hFc, or EGF-AB-hFc protein was amine-coupled on
60
65
The ability of the mAbs to block hPCSK9 GOF mutant
hPCSK9(D374Y)-mmh binding to hLDLR EGF-A domain
or hLDLR EGF-AB domain (IC5o values in pM) was also
evaluated with the ELISA-based immunoassay described
above using a constant amount of 0.05 nM hPCSK9
(D374Y)-mmh.
US 9,550,837 B2
31
TABLE 15
pH 7.2 pH 5.5
Plate Contin Surface
EGF-A EGF-AB EGF-A EGF-AB
32
10 pl/ml for 15 min at 25' C. Changes in RU due to the
binding between the free hPCSK9-mmh in the mixture to
either hLDLR or hLDLR-EGFA were recorded. The binding
of hPCSK9 to either hLDLR or hLDLR-EGFA was com-
pletely blocked by 316P and 300N but not by Control I mAb.
316P
300N
Control I
Control H
Control HI
203
135
&100,000
72
537
139
142
&100,000
57
427
1123
3463
&100,000
129
803
1139
3935
&100,000
118
692 10
Example 9
Epitope Mapping
The ability of the mAbs to block either mmPCSK9 or
mPCSK9 binding to hLDLR-ecto domain, hLDLR EGF-A
domain, or hLDLR EGF-AB domain (IC5o values in pM)
was evaluated at neutral pH (7.2) with the ELISA-based
immunoassay describe above using a constant amount of I
nM of mmh-tagged mmPCSK9 or I nM of mPCSK9.
TABLE 16
I nM mmPCSK9-mmh I nM mPCSK9-mmh
20
hLDLR-
ecto
EGF-
A
EGF-
AB
EGF-
A
EGF-
AB
316P &250 &250 &250 &250 &250
300N 255 256 290 &33000 &33000
25
TABLE 17
The ability of the mAbs to block hPCSK9, mmPCSK9,
rPCSK9, maPCSK9, mfPCSK9, or mPCSK9 binding to
hLDLR EGF-A domain (IC5o values in pM) was evaluated 30
at neutral pH (7.2) (Table 17) acidic pH (5.5, Table 18) with
the ELISA-based immunoassay described above using a
constant amount of 0.5 nM of hPCSK9-mmh, I nM of
mmPCSK9-mmh, I nM of rPCSK9-mmh, I nM of
maPCSK9-h, 0.3 nM of mfPCSK9-mmh, or I nM of 36
mPCSK9-mmh.
In order to determine epitope-binding specificity, three
chimeric PCSK9-mmh proteins were generated in which
specific human PCSK9 domains were substituted with
mouse PCSK9 domains. Chimeric protein ¹I consists of a
mouse PCSK9 pro-domain (amino acid residues 1-155 of
SEQ ID NO:757) followed by a human PCSK9 catalytic
domain (residues 153-425 of SEQ ID NO:755) and a mouse
PCSK9 C-terminal domain (residues 429-694 SEQ ID
NO:757) (mPro-hCat-mC-term-mmh). Chimeric protein ¹2
consists of a human PCSK9 pro-domain (residues 1-152 of
SEQ ID NO:755) followed by a mouse PCSK9 catalytic
domain (residues 156-428 of SEQ ID NO:757) and a mouse
PCSK9 C-terminal (hpro-mCat-mC-term-mmh). Chimeric
protein ¹3 consists of mouse PCSK9 pro-domain and a
mouse PCSK9 catalytic domain followed by a human
PCSK9 C-terminal domain (residues 426-692 of SEQ ID
NO:755) (mPro-mCat-hC-term-mmh). In addition, hPCSK9
with a point mutation of D374Y (hPCSK9 (D374Y)-mmh)
was generated.
Binding specificity of mAbs to test proteins hPCSK9-
mmh, mouse PCSK9-mmh, chimeric proteins ¹I, ¹2, and
¹3, and hPCSK9 (D374Y)-mmh were tested as follows: the
mAbs were coated on a 96-well plate overnight at 4' C., then
each test protein (1.2 nM) was added to the plate. After I hr
binding at RT, the plate was washed and bound test protein
detected using HRP-conjugated anti-myc polyclonal anti-
body (++=OD&1.0; +=OD 0.4—1.0; —=OD&0.4).
hPCSK9 mmPCSK9 rPCSK9 maPCSK9 mfPCSK9 mPCSK9
316P
300N
Control
I
Control
H
Control
HI
&125 &250 2662 349
182 460 &100000 &100000
&100000 &100000 &100000
146 83 2572 2038
249 293 &100000 245
75 305
473 &100000
&100000 &100000
361 855
572 &100000
TABLE 18
hPCSK9 mmPCSK9 rPCSK9 maPCSK9 mPCSK9
316P
300N
Control I
Control H
Control
HI
&125
223
&10000
154
390
&250
3704
&100000
&250
376
42880
&100000
&100000
11640
&100000
1299
&100000
&100000
8339
414
991
&100000
&100000
2826
&100000
The ability of 316P and Control I to block hPCSK9
binding to hLDLR was also determined. Briefly, either
recombinant hLDLR or hLDLR-EGFA-mFc was immobi-
lized onto BIACORE™CM5 chips via amine coupling. An
antigen-antibody mixture of 100 nM hPCSK9-mmh and
316P, Control I mAb, or a non-hPCSK9 specific mAb (each
at 250 nM) was incubated at RT for I hr, and then injected
over the hLDLR or hLDLR-EGFA surface at the flow rate of
40
45
50
60
65
TABLE 19
Chimeric Protein
Antibody hPCSK9 mPCSK9 ¹I ¹2 ¹3 hPCSK9(D374Yi
HI M300
HI M309
HI M312
HI M492
HI M493
HI M494
HI M495
HI M496
HI M497
HI M498
HI M499
HI M500
HI M502
HI M503
HI M504
HI M505
HI M508
HIH318P
HI H334P
HIH316P
HIH320P
Control I
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
Binding specificity of 316P, 300N and control anti-
hPCSK9 mAbs to hPCSK9-mmh, mPCSK9-mmh,
mmPCSK9-mmh, mfPCSK9-mmh, rPCSK9-mmh, chime-
ric proteins ¹I, ¹2, and ¹3, and hPCSK9 (D374Y)-mmh
33
US 9,550,837 B2
were tested as described above except that the protein
concentration is 1.7 nM (—=OD(0.7; +=OD 0.7—1.5;
++=OD&1.5).
34
TABLE 22
Second mAb
TABLE 20
First mAb
5
316P 300N Control I Control H Control HI
hPCSK9-mmh
mPCSK9-mmh
mmPCSK9-mmh
mfPCSK9-mmh
rPCSK9-mmh
Chimeric Protein ¹I
Chimeric Protein ¹2
Chimeric Protein ¹3
IIPCSK9 (D374Y1
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
316P 300N Control I Control H Control HI
316P
300N
Control I
Control H
Control HI
10
100 101 27 99 101
77 100 12 82 —2
6 12 100 6 9
91 102 -6 100 3
73 10 —12 I 100
Example 11
Increase of LDL Uptake by Anti-hPCSK9
Antibodies
TABLE 21
Chimeric Protein
Antibody hPCSK9 mPCSK9 ¹I ¹2 ¹3
316P
300N
Control I
500
320
65
505 529 451 467
13 243 76 10
7 4 3 69
Similar results for selected mAbs were obtained by BIA-
CORE™binding assay. Briefly, 316P, 300N, or Control I
mAb was captured on an amine-coupled anti-hFc CM5 chip
and 100 nM of each protein injected over the mAb-captured
surface. Changes in RU due to the binding of each protein
to the mAb surface was determined.
The ability of anti-hPCSK9 mAbs to increase LDL uptake
in vitro was determined using a human hepatocellular liver
carcinoma cell line (HepG2). HepG2 cells were seeded onto
20 96-well plates at 9x10 cells/well in DMEM complete media
and incubated at 37' C., 5% COn, for 6 hr to form HepG2
monolayers. Human PCSK9-mmh, at 50 nM in lipoprotein
deficient medium (LPDS), and a test mAb was added in
various concentrations from 500 nM to 0.98 nM in LPDS
25 medium. Data are expressed as ICso values for each experi-
ment (ICso=antibody concentration at which increases LDL
uptake by 50%). In addition, the experiment also showed
that both 316P and 300N were able to completely reverse the
inhibitory efl'ect of hPCSK9 on LDL uptake, while Control
30 I mAb or HIM508 anti-hPCSK9 mAb reversed the inhibi-
tory efl'ect by about 50%.
TABLE 23
To further assess the binding specificity of 316P, which
cross-reacts with mPCSK9-mmh, a cross-competition
ELISA assay was developed to determine binding domain
specificity. Briefly, mAbs specific for chimeric protein ¹I,
¹2, or ¹3, were first coated on a 96-well plate overnight at
I pg/ml. Human PCSK9-mmh (2 pg/ml) was then added to
each well followed by I hr incubation at RT. 316P (I pg/ml)
was added and incubated for another hour at RT. Plate-
bound 316P was detected using HRP-conjugated anti-hFc
polyclonal antibody. Although 316P binding to hPCSK9-
mmh was not afl'ected by the presence of mAbs specific for
either chimeric protein ¹2 or chimeric protein ¹3, 316P
binding to hPCSK9-mmh was greatly reduced by the pres-
ence of antibody specific for chimeric protein ¹1.
Example 10
BIACORE™-BasedAntigen Binding Profile
Assessment
35
40
Antibody
316P
300N
Control I
HIM' 08
ICso (nMl
21.30
22. 12
&250
&250
The ability of anti-hPCSK9 mAbs to reverse the inhibi-
tory efl'ect on LDL uptake by PCSK9 protein from diflerent
mammalian species was also tested in a HepG2 cell line as
described above. Briefly, HepG2 cells were incubated over-
45
night with serial dilutions of antibody in LPDS medium
(beginning with 500 nM) and 50 nM of hPCSK9-mmh,
mfPCSK9-mmh, mPCSK9-mmh, rPCSK9-mmh, or
maPCSK9-h. HepG2 cells were also incubated overnight
with serial dilutions of antibody in LPDS (beginning with 50
nM) and I nM hPCSK9(D374Y). As shown in Table 24,
while 316P was able to completely reverse the inhibitory
eflect on LDL by all PCSK9 proteins tested, 300N was only
able to reverse the inhibitory eflect on LDL uptake by
hPCSK9, hPCSK9 (D374Y), and mfPCSK9. Values are
expressed as nM ICso.
Antibody binding profiles were also established for 316P,
300N, Control I, II, and III mAbs using BIACORE™1000.
Briefly, hPCSK9-mmh was captured on an anti-myc surface.
A first anti-hPCSK9 mAb (50 pg/ml) was injected over the
PCSK9-bound surface for 10 min, at a flow rate of 10 pl/min
at 25' C. A second anti-hPCSK9 mAb (50 pg/ml) was then
injected over the first mAb-bound surface for 10 min, at a
flow rate of 10 pl/min at 25' C. Ability of the first mAb to
block binding of the second mAb was measured and is
expressed as percent inhibition.
60 hPCSK9-mmh
IIPCSK9(D374YF
mmh
mfPCSK9-mmh
mPCSK9-mmh
rPCSK9-mmh
maPCSK9-h
TABLE 24
14.1 12.6 &500
2.1 1.1 &50
13.4
0.7
12.4
0.6
14.7 13.4 &500
21.2 &500 &500
27.7 &500 &500
14.4 &500 &500
14.2
19
21.9
29.5
13.6
&500
&500
12.7
316P 300N Control I Control H Control HI
35
US 9,550,837 B2
36
Example 12
Neutralization of Biological Effect of hPCSK9 In
Vivo
To assess the biological eflect of neutralizing PCSK9,
hPCSK9 was over-expressed in C57BL/6 mice by hydro-
dynamic delivery (HDD) of DNA constructs encoding full-
length hPCSK9-mmh. 4 mice (C57BL/6) were injected with
empty vector/saline (control), and 16 mice were injected
with a 50 pg hPCSK9-mmh-DNA/saline mixture in the tail
vein equal to 10%of their body weight. At day 7 after HDD,
delivery of hPCSK9 resulted in a 1.6-fold elevation of total
cholesterol, 3.4-fold elevation in LDL-cholesterol (LDL-C)
and a 1.9-fold elevation in non-HDL cholesterol (relative to
control). Serum hPCSK9 levels on day 7 were all greater
than I pg/ml, as assessed by quantitative ELISA.
Administration of HIM300N on day 6 after HDD to 3
experimental groups (I, 5 or 10 mg/kg) (n=4 per group) via
intraperitoneal (Lp.) injection resulted in a significant attenu-
ation of serum cholesterol levels. At 18 hours after admin-
istration, total cholesterol was reduced by 9.8%, 263% and
26.8%, LDL-C was reduced by 5.1%, 523% and 56.7%, and
non-HDL cholesterol was reduced by 7.4%, 33.8% and
28.6% in the I, 5 or 10 mg/kg HIM300N treated groups,
respectively.
Example 13
Pharmacokinetic and Serum Chemistry Study in
Monkeys
A pharmacokinetic (PK) study was conducted in na'ive
male cynomolgus monkeys (Macaca fascicuiaris) with a
body weight range between 5-7 kg and aged between 3-5
years.
Group Assignments.
The monkeys were assigned into 5 treatment groups:
Treatment Group I (n=3) received control bufl'er (10 mM
sodium phosphate, pH 6, I ml/kg); Treatment Group 2 (n=3)
received I ml/kg of 316P (5 mg/ml); Treatment Group 3
(n=3) received I ml/kg 300N (5 mg/ml); Treatment Group 4
(n=3) received I ml/kg 316P (15 mg/ml); and Treatment
Group 5 (n=3) received I ml/kg 300N (15 mg/ml). All
treatments were administered by IV bolus followed by a I
ml saline flush. Total dose volume (ml) was calculated on the
most recent body weight (each animal was weighed twice
during acclimation and once weekly throughout the study).
A single dose of test mAb or bufl'er control was administered
on Day 1.
Animal Care.
Animals were housed in a temperature- and humidity-
monitored environment. The targeted range of temperature
and relative humidity was between 18-29' C. and 30-70%,
respectively. An automatic lighting system provided a
12-hour diurnal cycle. The dark cycle could be interrupted
for study- or facility-related activities. The animals were
individually housed in cages that comply with the Animal
Welfare Act and recommendations set forth in The Guide for
the Care and Use of Laboratory Animals (National Research
Council 1996).
Diet and Feeding.
Animals were fed twice per day according to SNBL USA
SOPs. Animals were fasted when required by specific pro-
cedures (e.g. , prior to blood draws for serum chemistry,
urine collection, or when procedures involving sedation are
performed). The diet was routinely analyzed for contami-
6
10
16
20
26
30
36
40
46
60
60
66
TABLE 25
316P 300N
PK Parameter 6 mg/kg 16 mg/kg 6 mg/kg 16 mg/kg
T
„„ ihi
C ittg/mli
Tua ihi
0.428
184
83
0.106
627
184
4.02 0.428
226 1223
216 366
Serum Chemistry.
Blood samples were collected at pre-dose, 12 hr, 48 hr,
and subsequently once every 48 hr, for clinical chemistry
analysis, in particular lipid profiles (i.e. cholesterol, LDL-C,
HDL-C, trlglycerides). With the exception of the 12 hr
post-dose sample, all animals were subject to an overnight
fast prior to sample collection. The sample volume was
approximately I ml. Chemistry parameters were determined
using an Olympus automated analyzer. Parameters measured
(Xybion code): Albumin (ALB); Alkaline Phosphatase
(ALP); Alanine Aminotransferase (ALT); Aspartate
nants and found to be within manufacturer's specifications.
No contaminants were expected to be present at levels that
would interfere with the outcome of the study.
Experimental Design.
An appropriate number of animals were selected from
SNBL USA stock. Animals were examined for health by
veterinary stafl; and had undergone serum chemistry, hema-
tology, and coagulation screening. Sixteen males, confirmed
healthy, were assigned to the study. Fifteen males were
assigned to specific study groups and the remaining animal
was available as a spare. A stratified randomization scheme
incorporating serum cholesterol level (based on the average
of two draws in acclimation) was used to assign animals to
study groups.
Acclimation Period.
Previously quarantined animals were acclimated to the
study room for a minimum of 14 days prior to initiation of
dosing. Acclimation phase data was collected from all
animals, including the spare. All animals were assessed for
behavioral abnormalities that could afl'ect performance on
study. The spare animal was returned to stock after day 1.
Blood Collection.
Blood was collected by venipuncture from a peripheral
vein from restrained, conscious animals. Whenever possible,
blood was collected via a single draw and then divided
appropriately.
PK Study.
Blood samples (1.5 ml) were collected at pre-dose, 2 min,
15, min, 30min, I hr, 2 br, 4 br, 8 br, 12hr, 24 br, and
subsequently once every 24 hr in serum separator tubes
(SST). Specimen storage serum is transferred to 2 vials and
stored at —60' C. or below.
Serum samples were analyzed using an optimized ELISA
(enzyme-linked immunosorbant assay) procedure. Briefly, a
microtiter plate was first coated with hPCSK9-mmh. Test
mAb 316P or 300N was then captured on the hPCSK9-mmh
plate. The captured 316P or 300N was detected using a
biotinylated mouse anti-hIgG4 followed by binding to Neu-
trAvidin-HRP. Varying concentrations of 316P or 300N,
ranging from 100 to 1.56 ng/ml, were used as standards. One
percent monkey serum (assay matrix) in the absence of 316P
or 300N was used as the zero (0 ng/ml) standard. The results,
shown in FIG. 2, indicate a dose-dependent increase in
serum 316P and 300N levels. PK parameters were analyzed
using WinNonlin software (Noncompartmental analysis,
Model 201-IV bolus administration).
37
US 9,550,837 B2
38
TABLE 26
PK Parameter 316P 300N
T (hi
C „„(ttg/mli
Tta (hi
60
46
64
84
63
286
Example 14
Attenuation of LDL Receptor Degradation by
Anti-hPCSK9 Antibodies
To assess the biological efi'ect of PCSK9 on hepatic LDL
receptor levels and subsequent efi'ects on serum LDL-C
Transaminase (AST); Total Bilirubin (TBIL); Calcium (Ca);
Total Cholesterol (TCho); Creatine Kinase (CK); Creatinine
(CRN); Gamma Glutamyltransaminase (GGT); Glucose
(GLU); Inorganic Phosphorus (IP); Total Protein (TP); Tri-
glyceride (TRIG); Blood Urea Nitrogen (BUN); Globulin
(GLOB); Albumin/Globulin Ratio (A/G); Chloride (CI);
Potassium (K); Sodium (Na); LDL and HDL cholesterol.
Residual serum was stored at —20' C. or below and disposed
of no sooner than one week after analysis.
Results from samples through Day 105 post-dose time
point are shown in FIGS. 3-7. There was a reduction in total
cholesterol and LDL-C in animals receiving 316P and 300N,
regardless of dose, within 24 hours of the first dose. Serum
total cholesterol reduced rapidly and robustly (-35'ro, FIG.
3). A robust decrease of -80'ro was seen in LDL-C (FIGS.
4-5) by day 6. In animals that received a 15 mg/kg dose of
300N, the reduction in both total cholesterol (-10-15'ro
reduction) and LDL-C (-40'ro reduction) continued to at
least day 80 of the study. In addition, HDL-C was elevated
in animals that received 316P at 15 mg/kg (FIG. 6).Animals
that received a higher dose (15 mg/kg) of either 316P or
300N also showed a reduction in triglycerides during the
course of study (FIG. 7). 316P exhibited maximal suppres-
sion of LDL-C levels of up to 80'ro relative to baseline. The
length of this suppression was dose-dependent with at least
60'ro suppression (relative to baseline LDL-C levels) lasting
approximately 18 days (5 mg/kg dose) and approximately 45
days (15 mg/kg dose). 300N exhibits a distinct pharmaco-
dynamic profile from 316P. LDL-C suppression by 300N
was sustained for a much longer period of time at compa-
rable doses (50'ro LDL-C suppression for 28 days following
a 5 mg/kg dose and 50're LDL-C suppression for approxi-
mately 90 days following a 15 mg/kg dose). There was little
or no measurable change in liver function as determined by
ALT and AST measurements. All animals receiving an
anti-PCSK9 antibody in the study exhibited a rapid suppres-
sion If LDL-C and total cholesterol.
A similar LDL-C lowering efi'ect of 316P and 300N was
also observed in cynomolgous monkeys that received a
single subcutaneous (SC) administration of either 5 mg/kg
316P or 5 mg/kg 300N (FIG. S). Both 316P and 300N
dramatically suppressed LDL-C levels and maintained an
LDL-C lowering efi'ect for approximately 15 and 30 days,
respectively (FIG. S). The pharmacodynamic efi'ect (ap-
proximately 40'ro LDL-C suppression) approximately cor-
relates with functional antibody levels in monkey serum
(FIG. 9). As antibody levels decrease below 10 pg/ml,
LDL-C suppression appeared to diminish as well. In addi-
tion, 300N demonstrated a substantially longer circulating
half-life than 316P and hence a longer observed LDL-C
suppression.
6
10
16
20
26
30
36
40
46
60
66
60
66
levels, hPCSK9 was administered to mice expressing
hPCSK9 but not mPCSK9 (PCSK9 "' " mice) by intrave-
nous injection. Specifically, PCSK9 "' "mice were injected
with PBS (control), or 1.2 mg/kg hPCSK9-mmh via the tail
vein. Six hours after delivery of hPCSK9, a 1.4-fold eleva-
tion (relative to baseline level) in total cholesterol and a
23-fold elevation in LDL-C) in serum were observed.
Analysis of hepatic LDL receptor levels in a separate cohort
(n=3) of animals 4 hours after hPCSK9 administration
revealed a significant reduction in detectable LDL receptor
in liver homogenates.
To assess the biological efiect of anti-hPCSK9 on hepatic
LDL receptor levels and subsequent efiects on serum LDL-C
levels, 316P and a non-hPCSK9 specific mAb were admin-
istered to PCSK9 "' "mice at equivalent dose (5 mg/kg i.p.)
20 hours prior to the hPCSK9-mmh protein injection
described above. Four hours after the hPCSK9 administra-
tion, mice were sacrificed and a total of eight tissues (liver,
brain, lung, kidney, heart, ileum, adrenal, and pancreas)
were collected and levels of LDL receptor were determined
by Western blot. Changes in LDL receptor levels were only
observed in liver. In comparison to PBS control dosing,
administration of 316P significantly blocked the PCSK9-
mediated increases in total cholesterol and LDL cholesterol
(LDL-C=2.49 mg/dl at baseline and 3.1 mg/dl 6 hours after
PCSK9; a 25'ro increase compared to 135'ro with vehicle).
Prior administration of the non-hPCSK9 specific mAb
blocked LDL-C increases by approximately 27'ro from PBS
alone (LDL-C=4. 1 mg/dl compared to PBS 5.6 mg/dl).
Analysis of LDL receptor levels in a separate cohort of mice
(n=3 per treatment group) revealed a significant reduction in
LDL receptor levels with PCSK9 administration, which was
blocked by 316P but not by the non-hPCSK9 specific mAb
(FIG. 10).
Efi'ect of difi'erent doses of 316P was also evaluated in
PCSK9 "' " mice with both elevated LDL-C and elevated
hPCSK9 levels. PCSK9 "' "mice were first placed on a high
carbohydrate diet for 8 weeks, resulting in a -2-fold eleva-
tion in both LDL-C and hPCSK9 levels. Either 316P or a
non-hPCSK9 specific mAb, each at I mg/kg, 5 mg/kg, or 10
mg/kg, were administered to the mice. Sera were collected
24 hours later and LDL-C levels were analyzed. 316P was
efiective in decreasing LDL-C levels in a dose-dependent
manner (FIG. 11). In addition, 316P administered at a dose
of 10 mg/kg, rapidly reduced LDL-C levels back to original
(pre-diet) values within 24 hours.
Example 15
Mouse PK Studies
A PK study was conducted in 6-week-old C57BL/6 mice
and 11-15 week old hPCSK9 heterozygous mice. A single
injection of Control I, 316P, or 300N, each at 10 mg/kg, was
administered SC. Serum bleeds were measured for hIgG
levels at 0 hr (pre-bleed), 6 hr, day I, 3, 6, 10, 14, 21, 28, 35,
42 and 56, for a total of 12 time points, using an anti-hFc
capture and anti-hFc detection sandwich ELISA (FIGS. 12
and 13).All mAbs achieved their T at approximately 3
days with corresponding C levels of approximately
47-115 pg/ml for C57BL/6 mice and 55-196 pg/ml for
hPCSK9 heterozygous mice. At Day 56, Control I mAb
levels were about 12 pg/ml and 300N levels were about 11
pg/ml whereas 316P levels were about less than 0.02 pg/ml
in C57BL/6 mice. At Day 56 in hPCSK9 heterozygous mice,
39
US 9,550,837 B2
40
Control I mAb levels were about 29 pg/ml, while both 300N
and 316P levels were below the quantifiable limit (BQL) of
0.02 pg/ml.
Example 16
Anti-hPCSK9 Antibody Binding to Mutant/Variant
hPCSK9
To further assess binding between hPCSK9 and anti-
hPCSK9 mAbs, 21 variant hPCSK9 proteins in which each
variant contained a single point mutation and two variant
hPCSK9 proteins each contained a double mutation were
generated. Each selected antibody was captured on a F(ab')2
anti-higG surface created through direct chemical coupling
to a BIACORE™chip to form a captured antibody surface.
Each mmh-tagged variant hPCSK9 at varying concentra-
tions from 100 nM to 25 nM was then injected over the
captured antibody surface at a flowrate of 60 pl/min for 240
sec, and the dissociation of variant hPCSK9 and antibody
was monitored in real time for 20 min at 25' C. nb: no
binding was observed under these experimental conditions
(K~=Mx10; T„2=min; WT~ildtype).
TABLE 27
E366 of hPCSK9 (SEQ ID NO:755). Additionally, the
BIACORE™assays show that 300N binding affinity and
Tt/2 were reduced between 2- to &10-fold when a residue at
147 or 380 was mutated. Specifically, K~ was reduced from
about 0.69x10 M to between about 2-9x10 M when any
of S147 or V380 were mutated; while T„2was shortened
from about 120 min to between about 24-66 min. Compared
to 316P, 300N binding to hPCSK9 was not reduced by a
mutation at residue 238.
In contrast, Control I antibody did not exhibit an altered
binding affinity or T„2in response to any of the positional
mutations tested; Control II antibody exhibited a 40-fold
decreased aflinity when residue 215 was mutated (R215E)
(from -0.1x10 to -4.5x10 ), and T„2was about 27-fold
shorter (from -333 to 12 min); while Control III antibody
exhibited a decreased aflinity when residue 237 was mutated
(K~ decreased from -0.6x10 to -5.9x10, and T„2
decreased from -481 to -43 min).
Binding specificity of 316P, 300N, and control anti-
hPCSK9 mAbs to hPCSK9 variants was tested using an
ELISA-based immunoassay. Anti-PCSK9 mAbs were
coated on a 96-well plate overnight at 4' C. Each mmh-
tagged variant hPCSK9 in CHO-kl transient transfection
316P 300N Control I Control H Control HI
KD Tt/r KD T r KD T r KD Tt/r Kr) Tt/r
WT
P70A
S127R
D129G
S147F
SI53R
EI59R
T162R
D192R
R194E
E197R
R215H
R215E
F216L
R237E
D238R
A341R
D343R
R357H
E366K
D374Y
V380M
P70A,
S147F
E366K,
V380M
l.00
1.42
2.40
1.27
1.29
5.64
6.96
0.98
1.35
0.38
1.42
0.86
0.90
1.83
2.48
410
l.54
7.88
6.26
2.92
2.04
0.48
1.18
37 0.69 120
32 1.68 80
36 1.87 110
36 1.40 88
32 9.07 24
4 0.56 141
5 0 82 94
43 0.58 140
28 0.75 119
71 0.65 129
27 0.67 115
41 1.03 98
43 1.81 77
32 0.99 121
15 1.03 109
I 078 123
21 0.34 190
6 1.18 89
30 6.53 66
13 360 2
15 0 66 83
63 2 82 28
34 7.87 24
30.6 16
19.0 16
25.0 18
22.9 18
21.1 15
36.6 17
31.7 16
29.0 17
30.2 15
31.4 16
30.2 17
37.8 17
44.0 16
21.2 15
29 6 15
25.9 19
28.7 18
27.0 16
26.4 13
28.8 18
25.0 17
25.9 17
23.5 18
0.10 333
0.24 168
0.26 288
0.19 257
0.22 178
0.09 322
0.08 350
0.09 322
0.09 326
0.07 389
0.09 339
065 49
4.48 12
1.35 39
0.07 481
0.24 144
0.08 340
0.08 402
0.63 165
0.46 69
0.08 285
0.15 177
0.23 164
0.60 481
0.90 325
0.55 550
0.75 445
0.23 1468
3.33 60
2.97 68
0.48 362
nb nb
nb nb
nb nb
0.74 272
0.78 276
0.33 880
5.89 43
0.14 1273
0.88 200
4.13 66
1.91 896
0.38 808
1.02 161
0.35 711
0.79 348
3 33 12 78 3 I 25.5 18 0.59 60 0.52 551
The results show that when residue D238 was mutated,
the binding aflinity of 316P for hPCSK9 was reduced
&400-fold, from a K~ of I x10 M to 410x10 M; and T„2
shortened about 30-fold, from 37 to I min, indicating that
316P binds an epitope on hPCSK9 comprising D238 of
hPCSK9 (SEQ ID NO:755). Additionally, BIACORE™
assays show that 316Pbinding affinity and T„2were reduced
about 5- to 10-fold when a residue at 153, 159 or 343 was
mutated. Specifically, K~ was reduced from about I x10 M
to between about 5-8x10 M when any one of S153, E159
or D343 were mutated; while T„2was decreased from about
37 min to between about 4-6 min.
300N binding to hPCSK9 was reduced about 50-fold
when the residue at position 366 was mutated, resulting in
a decreased K~ of from about 0.7x10 M to about 36x10
M and a shorter T„2from about 120 to 2 min. These results
indicate that 300N binds an epitope on hPCSK9 comprising
55
60
65
TABLE 28
hPCSK9 or Variant 316P 300N Control I Control H Control HI
IIPCSK9(WTi
hPCSK9(SI27Ri
hPCSK9(DI29Gi
hPCSK9(SI53Ri
hPCSK9(R215H1
hPCSK9(F216Li
++ ++ ++
++ ++ ++
++ ++ ++
++ ++ ++
++ ++ ++
++ ++ ++
++
++
++
++
++
++
++
++
++
++
++
++
lysate supernatants was added to the antibody-coated plate at
various concentrations ranging from 0 to 5 nM. After I hr
binding at RT, the plate was washed and bound variant
hPCSK9 was detected using HRP-conjugated anti-myc
polyclonal antibody (—=OD&0.7; +=OD 0.7—1.5;
++=OD&1.5).
41
TABLE 28-continued
US 9,550,837 B2
42
Example 17
hPCSK9 or Variant 316P 300N Control I Control H Control HI Efiect of 316P on Normolipemic and Hyperlipemic
Hamster
hPCSK9(R237E1
hPCSK9(D238Ri
hPCSK9(A34IRi
hPCSK9(D343Ri
hPCSK9(R357H1
hPCSK9(EI 59Ri
hPCSK9(TI 62Ri
HPCSK9(DI92Ri
hPCSK9(RI 94Ei
hPCSK9(EI 97Ri
hPCSK9(R215E1
hPCSK9(P70Ai
hPCSK9(SI47Fi
hPCSK9(E366Ki
hPCSK9(V380Mi
IIPCSK9(P70A,
S I47Fi
IIPCSK9(E366K,
V380Mi
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
++
5
The ability of anti-PCSK9 mAb 316P to reduce serum
LDL-C was tested in normolipemic or hyperlipemic Gold
Syrian hamsters (Mesocricetus auratus). Male Syrian Ham-
sters, age 6-8 weeks, weighing between 80-100 grams, were
10
allowed to acclimate for a period of 7 days before entry into
the study. All animals were placed on either a standard chow
diet or a hyperlipemic diet of chow supplemented with 0.1%
cholesterol and 10% coconut oil. The 316P mAb was
delivered to hamsters by a single subcutaneous injection at
doses of I, 3, or 10 mg/kg for normolipemic hamsters and
at doses of 3, 10, or 30 mg/kg for hyperlipemic hamsters.
Serum samples were taken from all groups at 24 hr and 7,
14, and 22 days post injection, at which time serum lipid
levels were assessed and compared to baseline levels taken
7 days prior to the administration of the mAbs. Circulating
20 total cholesterol and LDL-C in normolipemic hamsters was
significantly reduced in a dose-dependent manner compared
to vehicle injection. As shown in FIG. 14, administration of
316P efi'ectively reduced LDL-C levels by up to 60% seven
days post injection at the highest dose (10 mg/kg) tested.
Similar cholesterol reducing efi'ect of 316Pwas not observed
in hyperlipemic hamsters.
SEQUENCE LISTING
&160& NUMBER OF SEQ ID NOS: 763
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 1
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 1
caggtccagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt tactctaagt agttacgaca tgcactgggt ccgccaatct 120
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca 180
ggctccgtga agggccgatt caccatcacc agagaaaaag ccaagaactc cgtgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 300
gaggtaccct ttgactactg gggccaggga accctggtca ctgtctcctc a 351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 2
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 2
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cye Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Aep Met Hie Trp Val Arg Gln Ser Thr Gly Lye Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Aep Thr Tyr Tyr Pro Gly Ser Val Lye
50 88 60
43
US 9,550,837 B2
-continued
44
Gly Arg Phe Thr Ile Thr Arg Glu Lys Ala Lys Asn Ser Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 3
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 3
ggatttactc taagtagtta cgac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 4
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 4
Gly Phe Thr Leu Ser Ser Tyr Asp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 5
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 5
attggttcta ccggtgacac a 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 6
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 6
Ile Gly Ser Thr Gly Asp Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 7
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 7
gtaagagagg ggtgggaggt accctttgac tac 33
&210& SEQ ID NO 8
&211& LENGTH: 11
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
45
US 9,550,837 B2
-continued
46
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 8
Val Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 9
LENGTH: 327
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 9
gacatccaga tgacccagtc tccagccacc ctgtctgtgt ctccagggga aagagccgcc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca ccagaaacct
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc
120
180
aggttcagtg gcattgggtc tgggacagag ttcactctca ttatcagcag cctgcagtct 240
gaagattttg cattttattt ctgtcagcag tataataact ggcctccatt cactttcggc
cctgggacca aggtggagat caaacga
300
327
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 10
LENGTH: 109
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 10
Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Ala Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr His Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ile Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Phe Tyr Phe Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 11
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 11
cagagtgtta gcagcaac 18
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 12
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
47
US 9,550,837 B2
-continued
48
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 12
Gln Ser Val Ser Ser Asn
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 13
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 13
ggtgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 14
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 14
Gly Ala Ser
1
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 15
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 15
cagcagtata ataactggcc tccattcact 30
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 16
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 16
Gln Gln Tyr Asn Asn Trp Pro Pro Phe Thr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 17
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 17
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt tactctaagt agttacgaca tgcactgggt ccgccaatct 120
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca 180
ggctccgtga agggccgatt caccatcacc agagaaaaag ccaagaactc cgtgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 300
gaggtaccct ttgactactg gggccaggga accctggtca ccgtctcctc a 351
49
US 9,550,837 B2
-continued
50
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 18
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 18
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ser Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Thr Arg Glu Lys Ala Lys Asn Ser Val Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 19
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 19
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccgcc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca ccagaaacct
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc
120
180
aggttcagtg gcattgggtc tgggacagag ttcactctca ttatcagcag cctgcagtct
gaagattttg cattttattt ctgtcagcag tataataact ggcctccatt cactttcggc
240
300
cctgggacca aagtggatat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 20
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 20
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Ala Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr His Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ile Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Ser
51
US 9,550,837 B2
-continued
52
65 70 75 80
Glu Asp Phe Ala Phe Tyr Phe Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 21
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 21
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt tactctaagt agttacgaca tgcactgggt ccgccaagct
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca
120
180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg
gaggtaccct ttgactactg gggccaggga accctggtca ccgtctcctc a
300
351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 22
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 22
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val
85 90 95
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 23
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 23
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
53
US 9,550,837 B2
-continued
54
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataact ggcctccatt cactttcggc 300
cctgggacca aagtggatat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 24
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 24
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 25
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 25
caggtgcagc tggtgcagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatacattat
120
180
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat
ctggaaatga acagcctgag agccgaggac acggcaatgt actattgtgc gagagagaag
240
300
ggtttagact ggggccaggg aaccacggtc accgtctcct ca 342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 26
LENGTH: 114
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 26
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
55
US 9,550,837 B2
-continued
56
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile His Tyr Gly Asp Ser Val
80 88 60
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
68 70 78 80
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys
88 90 98
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Thr Val Thr Val
100 108 110
Ser Ser
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 27
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 27
ggattcacct tcagtagcta tggc 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 28
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 28
Gly Phe Thr Phe Ser Ser Tyr Gly
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 29
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 29
ataggatttg atggaagtaa tata 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 30
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 30
Ile Gly Phe Asp Gly Ser Asn Ile
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 31
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 31
gcgagagaga agggtttaga c 21
&210& SEQ ID NO 32
&211& LENGTH: 7
57
US 9,550,837 B2
-continued
58
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 32
Ala Arg Glu Lys Gly Leu Asp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 33
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 33
gccatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg
240
300
accaaggtgg aaatcaaacg a 321
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 34
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 34
Ala Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 35
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 35
cagagtatta gtagctgg 18
&210& SEQ ID NO 36
&211& LENGTH: 6
&212& TYPE: PRT
59
US 9,550,837 B2
-continued
60
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 36
Gln Ser Ile Ser Ser Trp
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 37
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 37
aaggcgtct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 38
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 38
Lys Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 39
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 39
caacagtata atagttatta cact 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 40
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 40
Gln Gln Tyr Asn Ser Tyr Tyr Thr
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 41
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 41
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatacattat 180
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 240
ctggaaatga acagcctgag agccgaggac acggcaatgt actattgtgc gagagagaag 300
61
US 9,550,837 B2
-continued
62
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 42
LENGTH: 114
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 42
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile His Tyr Gly Asp Ser Val
50 55 60
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
65 70 75 80
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 43
LENGTH: 318
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 43
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca
120
180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 300
accaagctgg agatcaaa 318
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 44
LENGTH: 106
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 44
Asp Ile Gln Met
1
Thr Gln Ser Pro Ser Thr Leu Ser Ala
10
Ser Val Gly
15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
63
US 9,550,837 B2
-continued
64
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 45
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 45
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
60
120
ccaggcaagg ggctggagtg ggtggcagtt ataggatttg atggaagtaa tatatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagagaag
ggtttagact ggggccaggg aaccctggtc accgtctcct ca
300
342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 46
LENGTH: 114
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 46
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 47
LENGTH: 319
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 47
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
65
US 9,550,837 B2
-continued
66
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 300
accaagctgg agatcaaac 319
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 48
LENGTH: 106
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 48
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 49
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 49
caggtgcagc tgcaggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatatattat
120
180
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat
ctggaaatga acagcctgag agccgaggac acggcagtgt attattgtgc gagagagaag
240
300
ggtttagact ggggccaggg aaccctggtc actgtctcct ca 342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 50
LENGTH: 114
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 50
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
67
US 9,550,837 B2
-continued
68
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Gly Asp Ser Val
50 55 60
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
65 70 75 80
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 51
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 51
ggattcacct tcagtagcta tggc 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 52
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 52
Gly Phe Thr Phe Ser Ser Tyr Gly
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 53
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 53
ataggatttg atggaagtaa tata 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 54
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 54
Ile Gly Phe Asp Gly Ser Asn Ile
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 55
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 55
gcgagagaga agggtttaga c 21
&210& SEQ ID NO 56
&211& LENGTH: 7
69
US 9,550,837 B2
-continued
70
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 56
Ala Arg Glu Lys Gly Leu Asp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 57
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 57
gccatccaga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagtt 120
tggtatcagc agaaaccagg acagcctcct aagttgctcc tttactgggc ctctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc
atcagcagcc tgcaggctga agatgtggca aattattact gtcaccaata ttacagtatt
240
300
ccgtggacgt tcggccaagg gaccaaggtg gagatcaaac ga 342
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 58
LENGTH: 114
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 58
Ala Ile Gln Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Thr
20 25 30
Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Asn Tyr Tyr Cys His Gln
85 90 95
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
Lys Arg
&210& SEQ ID NO 59
&211& LENGTH: 36
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 59
cagagtgttt ttcacacctc caacaataag aactac 36
&210& SEQ ID NO 60
71
US 9,550,837 B2
-continued
72
&211&
&212&
&213&
&220&
&223&
LENGTH: 12
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 60
Gln Ser Val Phe His Thr Ser Asn Asn Lys Asn Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 61
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 61
tgggcctct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 62
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 62
Trp Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 63
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 63
caccaatatt acagtattcc gtggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 64
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 64
His Gln Tyr Tyr Ser Ile Pro Trp Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 65
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 65
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatatattat 180
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 240
73
US 9,550,837 B2
-continued
74
ctggaaatga acagcctgag agccgaggac acggcagtgt attattgtgc gagagagaag 300
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 66
LENGTH: 114
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 66
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Gly Asp Ser Val
50 55 60
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr
65 70 75 80
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 67
LENGTH: 339
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 67
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagtt 120
tggtatcagc agaaaccagg acagcctcct aagttgctcc tttactgggc ctctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc
atcagcagcc tgcaggctga agatgtggca aattattact gtcaccaata ttacagtatt
240
300
ccgtggacgt tcggccaagg gaccaaggtg gaaatcaaa 339
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 68
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 68
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Thr
20 25 30
Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
75
US 9,550,837 B2
-continued
76
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Asn Tyr Tyr Cys His Gln
85 90 95
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
Lys
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 69
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 69
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
60
120
ccaggcaagg ggctggagtg ggtggcagtt ataggatttg atggaagtaa tatatactat 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagagaag
ggtttagact ggggccaggg aaccctggtc accgtctcct ca
300
342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 70
LENGTH: 114
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 70
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 71
LENGTH: 339
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 71
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
77
US 9,550,837 B2
-continued
78
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagct 120
tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc ctctacccgg
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc
180
240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaccaata ttacagtatt
ccgtggacgt tcggccaagg gaccaaggtg gaaatcaaa
300
339
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 72
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 72
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Thr
20 25 30
Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln
85 90 95
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
Lys
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 73
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 73
gaagtgcagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt cacctttaac aactatgcca tgaactgggt ccgccaggct
60
120
ccaggaaagg gactggactg ggtctcaact attagtggta gcggtggtac tacaaactac
gcagactccg tgaagggccg tttcattatt tcccgagaca gttccaaaca cacgctgtat
180
240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct
aactggggaa atttcgatct ctggggccgt ggcaccacgg tcactgtctc ctca
300
354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 74
LENGTH: 118
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 74
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
79
US 9,550,837 B2
-continued
80
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
35 40 45
Ser Thr Ile Ser Gly Ser Gly Gly Thr Thr Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Ile Ile Ser Arg Asp Ser Ser Lys His Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu Trp Gly Arg Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 75
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 75
ggattcacct ttaacaacta tgcc 24
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 76
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 76
Gly Phe Thr Phe Asn Asn Tyr Ala
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 77
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 77
attagtggta gcggtggtac taca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 78
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 78
Ile Ser Gly Ser Gly Gly Thr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 79
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
81
US 9,550,837 B2
-continued
82
&400& SEQUENCE: 79
gcgaaagatt ctaactgggg aaatttcgat ctc 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 80
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 80
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 81
LENGTH: 342
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 81
gacatccaga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttcttaggt
60
120
tggtaccagc agaaaccagg gcagcctcct aatctactca tttactgggc atctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact 300
ccgtacactt ttggccaggg gaccaaggtg gaaatcaaac ga 342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 82
LENGTH: 114
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 82
Asp Ile Gln Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg
20 25 30
Ser Asn Asn Arg Asn Phe Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Asn Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val
85
Ala Val Tyr Tyr Cys Gln Gln
90 95
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
100 105 110
Lys Arg
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 83
LENGTH: 36
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
83
US 9,550,837 B2
-continued
84
&400& SEQUENCE: 83
cagagtgttt tatacaggtc caacaatagg aacttc 36
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 84
LENGTH: 12
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 84
Gln Ser Val Leu Tyr Arg Ser Asn Asn Arg Asn Phe
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 85
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 85
tgggcatct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 86
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 86
Trp Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 87
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 87
caacaatatt atactactcc gtacact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 88
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 88
Gln Gln Tyr Tyr Thr Thr Pro Tyr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 89
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 89
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
85
US 9,550,837 B2
-continued
86
tcctgtgcag cctctggatt cacctttaac aactatgcca tgaactgggt ccgccaggct 120
ccaggaaagg gactggactg ggtctcaact attagtggta gcggtggtac tacaaactac
gcagactccg tgaagggccg tttcattatt tcccgagaca gttccaaaca cacgctgtat
180
240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct
aactggggaa atttcgatct ctggggccgt ggcaccctgg tcactgtctc ctca
300
354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 90
LENGTH: 118
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 90
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
35 40 45
Ser Thr Ile Ser Gly Ser Gly Gly Thr Thr Asn Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Ile Ile Ser Arg Asp Ser Ser Lys His Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu Trp Gly Arg Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 91
LENGTH: 339
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 91
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttcttaggt 120
tggtaccagc agaaaccagg gcagcctcct aatctactca tttactgggc atctacccgg 180
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact
240
300
ccgtacactt ttggccaggg gaccaagctg gagatcaaa 339
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 92
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 92
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
87
US 9,550,837 B2
-continued
88
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg
20 25 30
Ser Asn Asn Arg Asn Phe Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Asn Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 93
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 93
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt cacctttaac aactatgcca tgagctgggt ccgccaggct
60
120
ccagggaagg ggctggagtg ggtctcagct attagtggta gcggtggtac tacatactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct
aactggggaa atttcgatct ctggggccgt ggcaccctgg tcactgtctc ctca
300
354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 94
LENGTH: 118
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 94
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu Trp Gly Arg Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210& SEQ ID NO 95
89
US 9,550,837 B2
-continued
90
&211&
&212&
&213&
&220&
&223&
LENGTH: 339
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 95
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttcttagct 120
tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc atctacccgg
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc
180
240
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact
ccgtacactt ttggccaggg gaccaagctg gagatcaaa
300
339
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 96
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 96
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg
20 25 30
Ser Asn Asn Arg Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110
Lys
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 97
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 97
caggtgcagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag tctctggatt caccctcagt agctacgata tgcactgggt ccgccaacct 120
acaggaaaag gtctggagtg ggtctcagct attggttcta ctggtgacac atactatcca 180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggatgg 300
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351
&210& SEQ ID NO 98
&211& LENGTH: 117
&212& TYPE: PRT
91
US 9,550,837 B2
-continued
92
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 98
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Pro Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 99
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 99
ggattcaccc tcagtagcta cgat 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 100
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 100
Gly Phe Thr Leu Ser Ser Tyr Asp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 101
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 101
attggttcta ctggtgacac a 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 102
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 102
Ile Gly Ser Thr Gly Asp Thr
1 5
93
US 9,550,837 B2
-continued
94
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 103
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 103
gcaagagagg gatgggacgt accctttgac ttc 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 104
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 104
Ala Arg Glu Gly Trp Asp Val Pro Phe Asp Phe
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 105
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 105
gccatccagt tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca
gggaaagccc ctaagctcct gatctatgct gcatccagtt tacaaagtgg ggtcccatca
120
180
cggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa
240
300
gggaccaagg tggagatcaa acga 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 106
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 106
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp
20 25 30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
65 70 75
Gln Pro
80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
95
US 9,550,837 B2
-continued
96
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 107
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 107
caggacatta gaaatgat 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 108
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 108
Gln Asp Ile Arg Asn Asp
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 109
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 109
gctgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 110
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 110
Ala Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 111
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 111
ctacaagatt acaattaccc gtggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 112
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 112
Leu Gln Asp Tyr Asn Tyr Pro Trp Thr
1 8
&210& SEQ ID NO 113
&211& LENGTH: 381
&212& TYPE: DNA
97
US 9,550,837 B2
-continued
98
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 113
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag tctctggatt caccctcagt agctacgata tgcactgggt ccgccaacct
acaggaaaag gtctggagtg ggtctcagct attggttcta ctggtgacac atactatcca
120
180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggatgg
240
300
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 114
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 114
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Pro Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 115
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 115
gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctatgct gcatccagtt tacaaagtgg ggtcccatca 180
cggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
&210& SEQ ID NO 116
&211& LENGTH: 107
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
99
US 9,550,837 B2
-continued
100
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 116
Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp
20 25 30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 117
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 117
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccctcagt agctacgata tgcactgggt ccgccaagct
acaggaaaag gtctggagtg ggtctcagct attggttcta ctggtgacac atactatcca
120
180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggatgg
240
300
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 118
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 118
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly
50
Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Thr Leu
100 105 110
101
US 9,550,837 B2
-continued
102
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 119
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 119
gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca
gggaaagccc ctaagctcct gatctatgct gcatccagtt tacaaagtgg ggtcccatca
120
180
aggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa
240
300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 120
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 120
Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp
20 25 30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 121
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 121
caggtgcagc tgcaggagtc ggggccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctgggga ctccatcaat acttactact ggagctggtt ccggcagccc 120
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac 180
ccctccctca agagtcgagt caccatatca atagacacgc ccaggaacca gttctccctg 240
aagctgatct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgag agagaggatt 300
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa 360
gggaccacgg tcaccgtctc ctca 384
103
US 9,550,837 B2
-continued
104
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 122
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 122
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Thr Tyr
20 25 30
Tyr Trp Ser Trp Phe Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Ile Asp Thr Pro Arg Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 123
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 123
ggggactcca tcaatactta ctac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 124
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 124
Gly Asp Ser Ile Asn Thr Tyr Tyr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 125
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 125
atctattata gtggaaccac c 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 126
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
105
US 9,550,837 B2
-continued
106
&400& SEQUENCE: 126
Ile Tyr Tyr Ser Gly Thr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 127
LENGTH: 66
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 127
gcgagagaga ggattactat gattcgggga gttaccctct actattactc ctacggtatg
gacgtc
60
66
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 128
LENGTH: 22
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 128
Ala Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr
1 5 10 15
Ser Tyr Gly Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 129
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 129
gacatccaga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgct gggccagtca ggacattagc agttatttag cctggtatca gcaaaaacca 120
gggatagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca
aggttcggcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct
180
240
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa
gggaccaagg tggaaatcaa acga
300
324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 130
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 130
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly
50 55 60
107
US 9,550,837 B2
-continued
108
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 131
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 131
caggacatta gcagttat 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 132
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 132
Gln Asp Ile Ser Ser Tyr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 133
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 133
gctgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 134
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 134
Ala Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 135
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 135
caacagctta atagttaccc tcggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 136
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
109
US 9,550,837 B2
-continued
&400& SEQUENCE: 136
Gln Gln Leu Asn Ser Tyr Pro Arg Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 137
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 137
caggtgcagc tgcaggagtc ggggccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctgggga ctccatcaat acttactact ggagctggtt ccggcagccc
60
120
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac 180
ccctccctca agagtcgagt caccatatca atagacacgc ccaggaacca gttctccctg 240
aagctgatct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgag agagaggatt 300
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa
gggaccacgg tcaccgtctc ctca
360
384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 138
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 138
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Thr Tyr
20 25 30
Tyr Trp Ser Trp Phe Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Ile Asp Thr Pro Arg Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 139
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 139
gacatccaga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgct gggccagtca ggacattagc agttatttag cctggtatca gcaaaaacca 120
gggatagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca 180
111
US 9,550,837 B2
-continued
aggttcggcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 140
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 140
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 141
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 141
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60
acctgcactg tctctgggga ctccatcaat acttactact ggagctggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac
120
180
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agagaggatt 300
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa
gggaccacgg tcaccgtctc ctca
360
384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 142
LENGTH: 128
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 142
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Thr Tyr
20 25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
113
US 9,550,837 B2
-continued
35 40 45
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 143
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 143
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggcaagtca ggacattagc agttatttag gctggtatca gcagaaacca 120
gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct
180
240
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 144
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 144
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr
20 25 30
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
85
Gln Leu Asn Ser Tyr
90
Pro Arg
95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 145
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 145
115
US 9,550,837 B2
-continued
caggtgcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc
cctggacaag gacttgagtt aatgggatgg attagtggtt acaatggtaa cacaaactat
120
180
gcacaagaac tccaggccag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggaacctgag atctgacgac acggccgtat attactgtgc gagagataga 300
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 146
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 146
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Leu Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu
50 55 60
Gln Ala Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 147
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 147
ggttacacct ttaccaacta tggt 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 148
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 148
Gly Tyr Thr Phe Thr Asn Tyr Gly
1 5
&210& SEQ ID NO 149
&211& LENGTH: 24
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
117
US 9,550,837 B2
-continued
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 149
attagtggtt acaatggtaa caca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 150
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 150
Ile Ser Gly Tyr Asn Gly Asn Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 151
LENGTH: 57
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 151
gcgagagata gagtcgttgt agcagctgct aattactact tttattctat ggacgtc 57
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 152
LENGTH: 19
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 152
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser
1 5 10 15
Met Asp Val
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 153
LENGTH: 339
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 153
gccatccaga tgacccagtc tccactctcc ctgtccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg 120
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgctttcac actgaaaatc
180
240
agcggggtgg aggccgagga tgttggggtt tactactgca tgcaagctac acactggcct 300
cggacgttcg gccaagggac caaggtggaa atcaaacga 339
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 154
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 154
119
US 9,550,837 B2
-continued
120
Ala Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile
65 70 75 80
Ser Gly Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 155
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 155
caaagcctcg tatacagtga tggagacacc tac 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 156
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 156
Gln Ser Leu Val Tyr Ser Asp Gly Asp Thr Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 157
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 157
aaggtttct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 158
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 158
Lys Val Ser
1
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 159
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
121
US 9,550,837 B2
-continued
122
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 159
atgcaagcta cacactggcc tcggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 160
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 160
Met Gln Ala Thr His Trp Pro Arg Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 161
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 161
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc
cctggacaag gacttgagtt aatgggatgg attagtggtt acaatggtaa cacaaactat
120
180
gcacaagaac tccaggccag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggaacctgag atctgacgac acggccgtat attactgtgc gagagataga 300
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 162
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 162
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Leu Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu
50 55 60
Gln Ala Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210& SEQ ID NO 163
123
US 9,550,837 B2
-continued
124
&211&
&212&
&213&
&220&
&223&
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 163
gatgttgtga tgactcagtc tccactctcc ctgtccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg
60
120
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgctttcac actgaaaatc
180
240
agcggggtgg aggccgagga tgttggggtt tactactgca tgcaagctac acactggcct
cggacgttcg gccaagggac caaggtggaa atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 164
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 164
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile
65 70 75 80
Ser Gly Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 165
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 165
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc
60
120
cctggacaag ggcttgagtg gatgggatgg attagtggtt acaatggtaa cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagataga 300
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
&210& SEQ ID NO 166
&211& LENGTH: 126
&212& TYPE: PRT
125
US 9,550,837 B2
-continued
126
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 166
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 167
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 167
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac
120
180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaagctac acactggcct
240
300
cggacgttcg gccaagggac caaggtggaa atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 168
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 168
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
127
US 9,550,837 B2
-continued
128
Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 169
LENGTH: 375
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 169
caggtccact tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggattcgt
cagccccccg gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc
120
180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300
ataactgaaa ctagttacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 375
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 170
LENGTH: 125
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 170
Gln Val His Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 171
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 171
ggattctcac tcatcactag tggagtgggt 30
&210& SEQ ID NO 172
&211& LENGTH: 10
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
129
US 9,550,837 B2
-continued
130
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 172
Gly Phe Ser Leu Ile Thr Ser Gly Val Gly
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 173
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 173
atttattgga atggtgataa g 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 174
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 174
Ile Tyr Trp Asn Gly Asp Lys
1 5
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 175
LENGTH: 51
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 175
gcacacagga taactgaaac tagttactac ttctactacg gtatggacgt c
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 176
LENGTH: 17
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 176
Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met Asp
1 5 10 15
Val
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 177
LENGTH: 339
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 177
gacatccaga tgacccagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 300
131
US 9,550,837 B2
-continued
132
ctcactttcg gcggagggac caaggtggaa atcaaacga 339
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 178
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 178
Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
His Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 179
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 179
cagagcctcc tgcatagtca tggatacgac tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 180
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 180
Gln Ser Leu Leu His Ser His Gly Tyr Asp Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 181
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 181
ttgggttct
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 182
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
133
US 9,550,837 B2
-continued
134
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 182
Leu Gly Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 183
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 183
atgcaagctc tacaaactcc gctcact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 184
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 184
Met Gln Ala Leu Gln Thr Pro Leu Thr
1 5
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 185
LENGTH: 375
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 185
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggattcgt 120
cagccccccg gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300
ataactgaaa ctagttacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 375
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 186
LENGTH: 125
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 186
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
135
US 9,550,837 B2
-continued
136
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 187
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 187
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
120
180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg
240
300
ctcactttcg gcggagggac caaggtggag atcaaa 336
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 188
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 188
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
His Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210
&211
&212
&213
&220
&223
SEQ ID NO 189
LENGTH: 375
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 189
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggatccgt 120
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc 180
137
US 9,550,837 B2
-continued
138
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300
ataactgaaa ctagttacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 375
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 190
LENGTH: 125
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 190
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 191
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 191
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210& SEQ ID NO 192
&211& LENGTH: 112
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 192
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
139
US 9,550,837 B2
-continued
140
20 25 30
His Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 193
LENGTH: 375
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 193
cagatcacct tgaaggagtc tggtcctact ctggtgaaac cctcacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt 120
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaattc tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggta 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggatcacg 360
gtcaccgtct cctca 375
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 194
LENGTH: 125
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 194
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gln Gly Ile Thr Val Thr Val Ser Ser
115 120 125
&210& SEQ ID NO 195
&211& LENGTH: 30
&212& TYPE: DNA
141
US 9,550,837 B2
-continued
142
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 195
gggttctcac tcagcactag tggagtgggt 30
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 196
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 196
Gly Phe Ser Leu Ser Thr Ser Gly Val Gly
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 197
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 197
atttattgga attctgataa g 21
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 198
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 198
Ile Tyr Trp Asn Ser Asp Lys
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 199
LENGTH: 51
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 199
gcacacagac atgacagctc gtcctactac ttctactacg gtatggacgt c
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 200
LENGTH: 17
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 200
Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met Asp
1 5 10 15
Val
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 201
LENGTH: 339
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
143
US 9,550,837 B2
-continued
144
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 201
gacatccaga tgacccagtc tccgctctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttc taatcgggcc
tccggggtcc ctgacaggtt cagtggcggt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttgggatt tattactgca tgcaagctct acagactcct
ctcactttcg gcggagggac caaggtggag atcaaacga
300
339
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 202
LENGTH: 113
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 202
Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 203
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 203
cagagcctcc tccatagtca tggatacaac tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 204
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 204
Gln Ser Leu Leu His Ser His Gly Tyr Asn Tyr
1 5 10
&210& SEQ ID NO 205
&211& LENGTH: 9
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
145
US 9,550,837 B2
-continued
146
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 208
ttgggttct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 206
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 206
Leu Gly Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 207
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 207
atgcaagctc tacagactcc tctcact 27
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 208
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 208
Met Gln Ala Leu Gln Thr Pro Leu Thr
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 209
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 209
cagatcacct tgaaggagtc tggtcctact ctggtgaaac cctcacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaattc tgataagcgc
120
180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggta 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 210
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 210
147
US 9,550,837 B2
-continued
148
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 211
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 211
gatattgtga tgactcagtc tccgctctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttc taatcgggcc
tccggggtcc ctgacaggtt cagtggcggt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttgggatt tattactgca tgcaagctct acagactcct
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 212
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 212
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210& SEQ ID NO 213
149
US 9,550,837 B2
-continued
150
&211&
&212&
&213&
&220&
&223&
LENGTH: 375
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 213
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt 120
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaattc tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggaccacg 360
gtcaccgtct cctca 375
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 214
LENGTH: 125
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 214
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met
100 105 110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 215
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 215
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acagactcct 300
ctcactttcg gcggagggac caaggtggag atcaaa 336
151
US 9,550,837 B2
-continued
152
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 216
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 216
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 217
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 217
gagatgcaac tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagt agtcactgga tgaagtgggt ccgccaggct
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat
120
180
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgttt
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt
240
300
gtactaatgg tctatgatat ggactactac tactacggta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 218
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 218
Glu Met Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
10 15
Ser Leu Arg Leu Ser Cys Ala
20
Ala Ser Gly Phe Thr Phe Ser Ser His
3025
Trp Met Lys Trp Val Arg Gln
35
Ala Pro Gly Lys
40
Gly Leu Glu Trp Val
45
Ala Asn Ile Asn
50
Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
55 60
Lys Gly Arg Phe
65
Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
75 8070
153
US 9,550,837 B2
-continued
154
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
88 90 98
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr
100 108 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
118 120 128
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 219
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 219
ggattcacct ttagtagtca ctgg 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 220
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 220
Gly Phe Thr Phe Ser Ser His Trp
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 221
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 221
ataaaccaag atggaagtga gaaa 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 222
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 222
Ile Asn Gln Asp Gly Ser Glu Lys
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 223
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 223
gcgagagata ttgtactaat ggtctatgat atggactact actactacgg tatggacgtc 60
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 224
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
155
US 9,550,837 B2
-continued
156
&400& SEQUENCE: 224
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr
1 5 10 15
Gly Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 225
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 225
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
120
180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 226
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 226
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 227
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 227
cagagcctcc tgcatagtaa tggaaacaac tat 33
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 228
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
157
US 9,550,837 B2
-continued
158
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 228
Gln Ser Leu Leu His Ser Asn Gly Asn Asn Tyr
1 8 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 229
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 229
ttgggttct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 230
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 230
Leu Gly Ser
1
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 231
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 231
atgcaaactc tacaaactcc gctcact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 232
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 232
Met Gln Thr Leu Gln Thr Pro Leu Thr
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 233
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 233
gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagt agtcactgga tgaagtgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat 180
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgttt 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt 300
gtactaatgg tctatgatat ggactactac tactacggta tggacgtctg gggccaaggg 360
159
US 9,550,837 B2
-continued
160
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 234
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 234
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His
20 25 30
Trp Met Lys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 235
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 235
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 236
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 236
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln
20 25
Ser Leu Leu His Ser
30
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
161
US 9,550,837 B2
-continued
162
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 237
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 237
gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt cacctttagt agtcactgga tgagctgggt ccgccaggct
60
120
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat 180
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt
240
300
gtactaatgg tctatgatat ggactactac tactacggta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 238
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 238
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His
20 25 30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210& SEQ ID NO 239
&211& LENGTH: 336
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 239
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
163
US 9,550,837 B2
-continued
164
atctcctgca ggtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 240
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 240
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 241
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 241
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat
120
180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 242
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 242
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
165
US 9,550,837 B2
-continued
166
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys
85 90 95
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 243
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 243
ggattcacct tcagtagcta tggc 24
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 244
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 244
Gly Phe Thr Phe Ser Ser Tyr Gly
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 245
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 245
atatcatatg atggaagtaa taaa 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 246
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 246
Ile Ser Tyr Asp Gly Ser Asn Lys
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 247
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
167
US 9,550,837 B2
-continued
168
&400& SEQUENCE: 247
gcgaaaaata ttgtactagt gatgtatgat atagactatc actactatgg gatggacgtc 60
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 248
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 248
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
1 5 10 15
Gly Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 249
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 249
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct
ctcactttcg gcggagggac caaggtggag atcaga
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 250
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 250
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe
100
Gly Gly Gly Thr Lys Val Glu Ile Arg
105 110
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 251
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
169
US 9,550,837 B2
-continued
170
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 251
cagagcctcc tgcatagtaa tggatacaac tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 252
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 252
Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 253
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 253
ttgggtttt
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 254
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 254
Leu Gly Phe
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 255
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 255
atgcaagctc tacaaactcc tctcact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 256
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 256
Met Gln Ala Leu Gln Thr Pro Leu Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 257
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 257
171
US 9,550,837 B2
-continued
172
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
60
120
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg
300
360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 258
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 258
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys
85 90 95
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 259
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 259
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
ctcactttcg gcggagggac caaggtggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 260
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 260
173
US 9,550,837 B2
-continued
174
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 261
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 261
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactat
60
120
180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gaaaaatatt 300
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 262
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 262
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
175
US 9,550,837 B2
-continued
176
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 263
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 263
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 264
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 264
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 265
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 265
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 120
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
177
US 9,550,837 B2
-continued
178
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 266
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 266
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys
85 90 95
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 267
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 267
ggattcacct tcagtagcta tggc 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 268
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 268
Gly Phe Thr Phe Ser Ser Tyr Gly
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 269
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 269
atatcatatg atggaagtaa taaa 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 270
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 270
179
US 9,550,837 B2
-continued
180
Ile Ser Tyr Asp Gly Ser Asn Lys
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 271
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 271
gcgaaaaata ttgtactagt gatgtatgat atagactatc actactatgg gatggacgtc 60
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 272
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 272
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
1 5 10 15
Gly Met Asp Val
20
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 273
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 273
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct
ctcactttcg gcggagggac caaggtggag atcaga
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 274
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 274
Asp Ile Val Met
1
Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1510
Glu Pro Ala Ser Ile Ser Cys
20
Arg Ser Ser Gln Ser Leu
25
Leu His Ser
30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu
50
Ile Tyr Leu Gly Phe Asn Arg
55
Ala Ser Gly Val Pro
60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
181
US 9,550,837 B2
-continued
182
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 275
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 275
cagagcctcc tgcatagtaa tggatacaac tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 276
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 276
Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 277
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 277
ttgggtttt
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 278
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 278
Leu Gly Phe
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 279
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 279
atgcaagctc tacaaactcc tctcact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 280
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 280
Met Gln Ala Leu Gln Thr Pro Leu Thr
183
US 9,550,837 B2
-continued
184
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 281
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 281
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
60
120
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg
300
360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 282
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 282
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys
85 90 95
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 283
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 283
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 300
185
US 9,550,837 B2
-continued
186
ctcactttcg gcggagggac caaggtggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 284
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 284
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 285
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 285
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct
ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactat
120
180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gaaaaatatt 300
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 286
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 286
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
187
US 9,550,837 B2
-continued
188
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 287
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 287
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 288
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 288
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 289
LENGTH: 372
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 289
cagatcacct tgaaggagtc tggtcctacg ctggtaaaac ccacacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc gctagtggag tgggtgtggg ctggttccgt 120
189
US 9,550,837 B2
-continued
190
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgt 180
tacagcccat ctctaaagaa cagcctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
atacatctat ggtcctactt ctactacggt atggacgtct ggggccaagg gaccacggtc 360
accgtctcct ca 372
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 290
LENGTH: 124
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 290
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser
20 25 30
Gly Val Gly Val Gly Trp Phe Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Asn Ser Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 291
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 291
gggttctcac tcagcgctag tggagtgggt 30
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 292
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 292
Gly Phe Ser Leu Ser Ala Ser Gly Val Gly
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 293
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 293
191
US 9,550,837 B2
-continued
192
atttattgga atgatgataa g 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 294
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 294
Ile Tyr Trp Asn Asp Asp Lys
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 295
LENGTH: 48
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 295
gcacacagaa tacatctatg gtcctacttc tactacggta tggacgtc 48
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 296
LENGTH: 16
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 296
Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp Val
1 5 10 15
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 297
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 297
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttcgattgg
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
120
180
tccggggtcc ctgacagatt cagtggcagt ggatcaggca cagattttac actgaaaatc
agcagagtgg aggctgagga tgttggaatt tattactgca tgcaagctct acaaactcct
240
300
ctcactttcg gcggagggac caaggtggag atcaga 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 298
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 298
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser
20
Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser
25 30
193
US 9,550,837 B2
-continued
194
Asn Gly Tyr Asn Tyr Phe Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 299
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 299
cagactctcc tgcatagtaa tggatacaac tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 300
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 300
Gln Thr Leu Leu His Ser Asn Gly Tyr Asn Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 301
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 301
ttgggttct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 302
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 302
Leu Gly Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 303
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 303
atgcaagctc tacaaactcc tctcact 27
&210& SEQ ID NO 304
195
US 9,550,837 B2
-continued
196
&211&
&212&
&213&
&220&
&223&
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 304
Met Gln Ala Leu Gln Thr Pro Leu Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 305
LENGTH: 372
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 305
cagatcacct tgaaggagtc tggtcctacg ctggtaaaac ccacacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc gctagtggag tgggtgtggg ctggttccgt
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgt
120
180
tacagcccat ctctaaagaa cagcctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
atacatctat ggtcctactt ctactacggt atggacgtct ggggccaagg gaccacggtc 360
accgtctcct ca 372
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 306
LENGTH: 124
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 306
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser
20 25 30
Gly Val Gly Val Gly Trp Phe Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Asn Ser Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 307
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 307
197
US 9,550,837 B2
-continued
198
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttcgattgg
60
120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
tccggggtcc ctgacagatt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggaatt tattactgca tgcaagctct acaaactcct
ctcactttcg gcggagggac caaggtggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 308
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 308
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Phe Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 309
LENGTH: 372
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 309
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60
acctgcacct tctctgggtt ctcactcagc gctagtggag tgggtgtggg ctggatccgt 120
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgc 180
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300
atacatctat ggtcctactt ctactacggt atggacgtct gggggcaagg gaccacggtc 360
accgtctcct ca 372
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 310
LENGTH: 124
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 310
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15
199
US 9,550,837 B2
-continued
200
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser
20 25 30
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 311
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 311
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttggattgg
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
120
180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct
240
300
ctcactttcg gcggagggac caaggtggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 312
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 312
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser
20 25 30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 110
&210& SEQ ID NO 313
&211& LENGTH: 381
&212& TYPE: DNA
201
US 9,550,837 B2
-continued
202
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 313
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat
120
180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 314
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 314
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 315
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 315
ggttacacct ttaccaccta tggt 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 316
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 316
Gly Tyr Thr Phe Thr Thr Tyr Gly
1 5
203
US 9,550,837 B2
-continued
204
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 317
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 317
atcagcggtt acaatggtaa aaca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 318
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 318
Ile Ser Gly Tyr Asn Gly Lys Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 319
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 319
tcgagagatc gtttagtagt accacctgcc cttaattatt cctactacgt tatggacgtc 60
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 320
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 320
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr
1 5 10 15
Val Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 321
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 321
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
tctcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
&210& SEQ ID NO 322
&211& LENGTH: 112
&212& TYPE: PRT
205
US 9,550,837 B2
-continued
206
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 322
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Ser Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 323
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 323
caaagcctcg tatacagtga tggaaacacc tac 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 324
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 324
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 325
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 325
aaggtttct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 326
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 326
Lys Val Ser
1
&210& SEQ ID NO 327
207
US 9,550,837 B2
-continued
208
&211&
&212&
&213&
&220&
&223&
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 327
atgcaaggta cacactggcc gtacact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 328
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 328
Met Gln Gly Thr His Trp Pro Tyr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 329
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 329
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 330
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 330
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
209
US 9,550,837 B2
-continued
210
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 331
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 331
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
60
120
tctcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
180
240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
tacacttttg gccaggggac caagctggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 332
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 332
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Ser Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 333
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 333
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
211
US 9,550,837 B2
-continued
212
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 334
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 334
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 335
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 335
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac
120
180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
240
300
tacacttttg gccaggggac caagctggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 336
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 336
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
213
US 9,550,837 B2
-continued
214
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 337
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 337
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatagca tggactgggt ccgccaggct
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac
120
180
gcagactctg tgaagggccg attcaccatc tccagagaca ccgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agacgaggac acggctgttt attactgtgc gagagagggc
agtagcagac tttttgacta ctggggccag ggaaccctgg tcaccgtctc ctca
300
354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 338
LENGTH: 118
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 338
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 339
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 339
ggattcacct tcagtagcta tagc 24
&210& SEQ ID NO 340
&211& LENGTH: 8
215
US 9,550,837 B2
-continued
216
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 340
Gly Phe Thr Phe Ser Ser Tyr Ser
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 341
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 341
attagtagta gtagtagtta cata 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 342
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 342
Ile Ser Ser Ser Ser Ser Tyr Ile
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 343
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 343
gcgagagagg gcagtagcag actttttgac tac 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 344
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 344
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr
1 8 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 348
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 348
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagagacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaggtgg agtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gaggattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag 300
217
US 9,550,837 B2
-continued
218
gggaccaagc tggagatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 346
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 346
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 347
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 347
cagagtatta gtagctgg 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 348
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 348
Gln Ser Ile Ser Ser Trp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 349
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 349
aaggcgtct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 350
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
219
US 9,550,837 B2
-continued
220
&400& SEQUENCE: 350
Lys Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 351
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 351
caacagtata atagttattg gtacact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 352
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 352
Gln Gln Tyr Asn Ser Tyr Trp Tyr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 353
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 353
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatagca tggactgggt ccgccaggct
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac
120
180
gcagactctg tgaagggccg attcaccatc tccagagaca ccgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agacgaggac acggctgttt attactgtgc gagagagggc 300
agtagcagac tttttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 354
LENGTH: 118
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 354
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
221
US 9,550,837 B2
-continued
222
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 355
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 355
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagagacca
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaggtgg agtcccatca
120
180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct
gaggattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag
240
300
gggaccaagc tggagatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 356
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 356
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Gly Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 357
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 357
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagagggc 300
223
US 9,550,837 B2
-continued
224
agtagcagac tttttgacta ctggggccaa ggaaccctgg tcaccgtctc ctca 354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 358
LENGTH: 118
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 358
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 359
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 359
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct
gatgattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag
240
300
gggaccaagc tggagatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 360
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 360
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
225
US 9,550,837 B2
-continued
226
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 361
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 361
caggtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat
120
180
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag
240
300
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa
gggaccacgg tcaccgtcgc ctca
360
384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 362
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 362
Gln Val His Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His
20 25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val
50 55 60
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ala Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 363
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 363
227
US 9,550,837 B2
-continued
228
ggattcacct tcagtgacca ctac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 364
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 364
Gly Phe Thr Phe Ser Asp His Tyr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 365
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 365
attagtaatg atggtggtac caaa 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 366
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 366
Ile Ser Asn Asp Gly Gly Thr Lys
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 367
LENGTH: 63
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 367
gcgagagatc agggatatat tggctacgac tcgtattatt actattccta cggtatggac 60
gtc 63
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 368
LENGTH: 21
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 368
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
1 5 10 15
Tyr Gly Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 369
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 369
229
US 9,550,837 B2
-continued
230
aaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 60
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
120
180
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tctcggcgga
240
300
gggaccaagg tggagatcaa g 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 370
LENGTH: 107
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 370
Lys Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu
65 70 75 80
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 371
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 371
cagagtgtta acaacaaatt c 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 372
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 372
Gln Ser Val Asn Asn Lys Phe
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 373
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 373
231
US 9,550,837 B2
-continued
232
ggtgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 374
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 374
Gly Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 375
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 375
caagtatatg gtaactcact cact 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 376
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 376
Gln Val Tyr Gly Asn Ser Leu Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 377
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 377
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct
60
120
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat
180
240
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa
300
360
gggaccacgg tcaccgtctc ctca 384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 378
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 378
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His
20 25 30
233
US 9,550,837 B2
-continued
234
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val
50 55 60
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 379
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 379
gaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 60
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
120
180
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 240
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tctcggcgga 300
gggaccaagg tggagatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 380
LENGTH: 107
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 380
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu
65 70 75 80
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 381
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
235
US 9,550,837 B2
-continued
236
&400& SEQUENCE: 381
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct
60
120
ccagggaagg ggctggagtg ggtttcatac attagtaatg atggtggtac caaatactac 180
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gagagatcag
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctgggggcaa
300
360
gggaccacgg tcaccgtctc ctca 384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 382
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 382
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His
20 25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 383
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 383
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 240
cctgaagatt ttgcagtgta ttactgtcaa gtatatggta actcactcac tttcggcgga 300
gggaccaagg tggagatcaa a 321
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 384
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
237
US 9,550,837 B2
-continued
238
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 384
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 385
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 385
gaggtgcaga aggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca
300
360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 386
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 386
Glu Val Gln Lys Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
239
US 9,550,837 B2
-continued
240
120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 387
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 387
ggattcacct tcagtactta taac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 388
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 388
Gly Phe Thr Phe Ser Thr Tyr Asn
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 389
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 389
attaggagta gtagtaatta cata 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 390
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 390
Ile Arg Ser Ser Ser Asn Tyr Ile
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 391
LENGTH: 39
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 391
gcgagagatg gcagcagttg gtacgactac tctgactac 39
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 392
LENGTH: 13
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 392
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr
1 5 10
&210& SEQ ID NO 393
241
US 9,550,837 B2
-continued
242
&211&
&212&
&213&
&220&
&223&
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 393
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
180
240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa
gggaccaagg tggaaatcaa a
300
321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 394
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 394
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 395
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 395
cagagtatta gtagctgg 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 396
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 396
Gln Ser Ile Ser Ser Trp
1 5
&210& SEQ ID NO 397
&211& LENGTH: 9
243
US 9,550,837 B2
-continued
244
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 397
aaggcgtct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 398
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 398
Lys Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 399
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 399
caacagtata ttagttattc tcggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 400
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 400
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 401
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 401
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct
60
120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 402
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 402
245
US 9,550,837 B2
-continued
246
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 403
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 403
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
180
240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa
gggaccaagg tggaaatcaa a
300
321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 404
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 404
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210& SEQ ID NO 405
247
US 9,550,837 B2
-continued
248
&211&
&212&
&213&
&220&
&223&
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 405
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct
60
120
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca
300
360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 406
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 406
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 407
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 407
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
&210& SEQ ID NO 408
&211& LENGTH: 107
249
US 9,550,837 B2
-continued
250
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 408
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 409
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 409
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct
60
120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca
300
360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 410
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 410
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
251
US 9,550,837 B2
-continued
252
100 108 110
Gly Thr Leu Val Thr Val Ser Ser
118 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 411
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 411
ggattcacct tcagtactta taac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 412
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 412
Gly Phe Thr Phe Ser Thr Tyr Asn
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 413
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 413
attaggagta gtagtaatta cata 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 414
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 414
Ile Arg Ser Ser Ser Asn Tyr Ile
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 418
LENGTH: 39
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 418
gcgagagatg gcagcagttg gtacgactac tctgactac 39
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 416
LENGTH: 13
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 416
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr
1 8 10
253
US 9,550,837 B2
-continued
254
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 417
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 417
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
180
240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa
gggaccaagg tggaaatcaa a
300
321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 418
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 418
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 419
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 419
cagagtatta gtagctgg 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 420
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 420
Gln Ser Ile Ser Ser Trp
1 5
255
US 9,550,837 B2
-continued
256
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 421
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 421
aaggcgtct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 422
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 422
Lys Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 423
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 423
caacagtata ttagttattc tcggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 424
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 424
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 428
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 428
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac
120
180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 426
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
257
US 9,550,837 B2
-continued
258
&400& SEQUENCE: 426
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 427
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 427
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
120
180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa
240
300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 428
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 428
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
259
US 9,550,837 B2
-continued
260
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 429
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 429
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct
60
120
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca
300
360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 430
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 430
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 431
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 431
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
261
US 9,550,837 B2
-continued
262
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 432
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 432
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 433
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 433
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac
120
180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagag ttcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 434
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 434
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
263
US 9,550,837 B2
-continued
264
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 435
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 435
ggattcacct tcagtactta taac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 436
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 436
Gly Phe Thr Phe Ser Thr Tyr Asn
1 5
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 437
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 437
attaggagta gtagtaatta cata 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 438
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 438
Ile Arg Ser Ser Ser Asn Tyr Ile
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 439
LENGTH: 39
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 439
gcgagagatg gcagcagttg gtacgactac tctgactac 39
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 440
LENGTH: 13
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 440
265
US 9,550,837 B2
-continued
266
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 441
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 441
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acaggtacca
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
120
180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa
240
300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 442
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 442
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Val Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 443
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 443
cagagtatta gtagctgg 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 444
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 444
267
US 9,550,837 B2
-continued
268
Gln Ser Ile Ser Ser Trp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 445
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 445
aaggcgtct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 446
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 446
Lys Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 447
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 447
caacagtata ttagttattc tcggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 448
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 448
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 449
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 449
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagag ttcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
&210& SEQ ID NO 450
&211& LENGTH: 120
&212& TYPE: PRT
269
US 9,550,837 B2
-continued
270
ial Sequence&213& ORGANISM: Artific
&220& FEATURE:
&223& OTHER INFORMATION Synthetic
&400& SEQUENCE: 450
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 451
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 451
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acaggtacca
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
120
180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa
240
300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 452
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 452
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Val Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
271
US 9,550,837 B2
-continued
272
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 453
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 453
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac
120
180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 454
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 454
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 455
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 455
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
273
US 9,550,837 B2
-continued
274
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 456
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 456
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 457
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 457
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac
120
180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 458
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 458
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
275
US 9,550,837 B2
-continued
276
68 70 78 80
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
88 90 98
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 108 110
Gly Thr Leu Val Thr Val Ser Ser
118 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 489
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 489
ggattcacct tcagtactta taac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 460
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 460
Gly Phe Thr Phe Ser Thr Tyr Asn
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 461
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 461
attaggagta gtagtaatta cata 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 462
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 462
Ile Arg Ser Ser Ser Asn Tyr Ile
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 463
LENGTH: 39
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 463
gcgagagatg gcagcagttg gtacgactac tctgactac 39
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 464
LENGTH: 13
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
277
US 9,550,837 B2
-continued
278
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 464
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 465
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 465
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
120
180
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa
240
300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 466
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 466
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 467
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 467
cagagtatta gtagctgg 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 468
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
279
US 9,550,837 B2
-continued
280
&400& SEQUENCE: 468
Gln Ser Ile Ser Ser Trp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 469
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 469
aaggcgtct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 470
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 470
Lys Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 471
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 471
caacagtata ttagttattc tcggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 472
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 472
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 473
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 473
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 120
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360
281
US 9,550,837 B2
-continued
282
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 474
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 474
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212 &
&213&
&220&
&223&
SEQ ID NO 475
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 475
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct
180
240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 476
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 476
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro
65 70 75 80
283
US 9,550,837 B2
-continued
284
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 477
LENGTH: 360
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 477
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac
120
180
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca 360
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 478
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 478
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 479
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 479
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 180
285
US 9,550,837 B2
-continued
286
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 480
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 480
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 481
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 481
gaggtgcaac tagtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgtag tctctggatt caccttcggt gactacgaca tgcactgggt ccgtcaagct
60
120
acaggaagag gtctggagtg ggtctcaggt attgctcctg ctggtgacac atcctataca 180
ggctccgtga agggccgatt caccatctcc agagagaatg ccaagaactc cttgcatctt
caaatgaaca gcctgacaac cggggacacg gctatatatt attgtgctag agaggatata
240
300
gcagtgcctg gttttgatta ctggggccag ggaaccctgg tcaccgtctc ctca 354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 482
LENGTH: 118
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 482
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asp Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Arg Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ala Pro Ala Gly Asp Thr Ser Tyr Thr Gly Ser Val Lys
287
US 9,550,837 B2
-continued
288
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu His Leu
65 70 75 80
Gln Met Asn Ser Leu Thr Thr Gly Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 483
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 483
ggattcacct tcggtgacta cgac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 484
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 484
Gly Phe Thr Phe Gly Asp Tyr Asp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 485
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 485
attgctcctg ctggtgacac a 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 486
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 486
Ile Ala Pro Ala Gly Asp Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 487
LENGTH: 36
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 487
gctagagagg atatagcagt gcctggtttt gattac 36
&210& SEQ ID NO 488
&211& LENGTH: 12
289
US 9,550,837 B2
-continued
290
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 488
Ala Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 489
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 489
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga acgaggcacc
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct
60
120
ggccaggctc ccagactcct catctatggt gcatccacga gggccactgg cttcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
gaagattttg cagtttatta ctgtcagcag tataataagt ggcctccgtt cactttcggc
240
300
cctgggacca aagtggattt caaa 324
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 490
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 490
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Gly Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Phe Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Lys Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 491
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 491
cagagtgtta gcagcaac 18
&210& SEQ ID NO 492
&211& LENGTH: 6
&212& TYPE: PRT
291
US 9,550,837 B2
-continued
292
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 492
Gln Ser Val Ser Ser Asn
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 493
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 493
ggtgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 494
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 494
Gly Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 495
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 495
cagcagtata ataagtggcc tccgttcact 30
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 496
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 496
Gln Gln Tyr Asn Lys Trp Pro Pro Phe Thr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 497
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 497
gaggtgcaac tagtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgtag tctctggatt caccttcggt gactacgaca tgcactgggt ccgtcaagct 120
acaggaagag gtctggagtg ggtctcaggt attgctcctg ctggtgacac atcctataca 180
ggctccgtga agggccgatt caccatctcc agagagaatg ccaagaactc cttgcatctt 240
caaatgaaca gcctgacaac cggggacacg gctatatatt attgtgctag agaggatata 300
293
US 9,550,837 B2
-continued
294
gcagtgcctg gttttgatta ctggggccag ggaaccctgg tcaccgtctc ctca 354
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 498
LENGTH: 118
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 498
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asp Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Arg Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Ala Pro Ala Gly Asp Thr Ser Tyr Thr Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu His Leu
65 70 75 80
Gln Met Asn Ser Leu Thr Thr Gly Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 499
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 499
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga acgaggcacc
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct
60
120
ggccaggctc ccagactcct catctatggt gcatccacga gggccactgg cttcccagcc
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
180
240
gaagattttg cagtttatta ctgtcagcag tataataagt ggcctccgtt cactttcggc
cctgggacca aagtggatat caaa
300
324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 500
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 500
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Gly Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Phe Pro Ala Arg Phe Ser Gly
50 55 60
295
US 9,550,837 B2
-continued
296
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Lys Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 501
LENGTH: 354
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 501
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccttcggt gactacgaca tgcactgggt ccgccaagct
60
120
acaggaaaag gtctggagtg ggtctcagct attgctcctg ctggtgacac atactatcca 180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgctag agaggatata
240
300
gcagtgcctg gttttgatta ctggggccaa ggaaccctgg tcaccgtctc ctca 354
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 502
LENGTH: 118
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 502
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ala Pro Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 503
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 503
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 120
297
US 9,550,837 B2
-continued
298
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
gaagattttg cagtttatta ctgtcagcag tataataagt ggcctccgtt cactttcggc
240
300
cctgggacca aagtggatat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 504
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 504
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Lys Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 505
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 505
caaattctgc tggtgcaatc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc
60
120
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc
300
360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 506
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 506
Gln Ile Leu Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
299
US 9,550,837 B2
-continued
300
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 507
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 507
ggttacacct ttaccaacta cgct 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 508
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 508
Gly Tyr Thr Phe Thr Asn Tyr Ala
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 509
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 509
gtcagcgctt acaatggtca caca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 510
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 510
Val Ser Ala Tyr Asn Gly His Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 511
LENGTH: 57
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 511
301
US 9,550,837 B2
-continued
302
gcgagagggg gtgtagtcgt gccagttgct ccccacttct acaacggtat ggacgtc 57
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 512
LENGTH: 19
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 512
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
1 5 10 15
Met Asp Val
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 513
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 513
gatattgtga tgactcagtt tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg
60
120
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 300
tggacgttag gccaagggac caaggtggaa atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 514
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 514
Asp Ile Val Met Thr Gln Phe Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Leu
100
Gly Gln Gly Thr Lys Val Glu Ile Lys
105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 515
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 515
303
US 9,550,837 B2
-continued
304
cagagcctcc tgcatattaa tgaatacaac tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 516
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 516
Gln Ser Leu Leu His Ile Asn Glu Tyr Asn Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 517
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 517
ttgggtttt
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 518
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 518
Leu Gly Phe
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 519
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 519
atgcaagctc ttcaaactcc gtggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 520
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 520
Met Gln Ala Leu Gln Thr Pro Trp Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 521
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 521
caggttcagc tggtgcagtc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 120
305
US 9,550,837 B2
-continued
306
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 522
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 522
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 523
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 523
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc
120
180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg
240
300
tggacgttag gccaagggac caaggtggaa atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 524
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 524
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
307
US 9,550,837 B2
-continued
308
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Leu Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 525
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 525
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggcc
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat
120
180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg gcaagggacc 360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 526
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 526
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210& SEQ ID NO 527
309
US 9,550,837 B2
-continued
310
&211&
&212&
&213&
&220&
&223&
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 527
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg
60
120
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
180
240
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct tcaaactccg
tggacgttcg gccaagggac caaggtggaa atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 528
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 528
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 529
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 529
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca
60
120
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaggga gcccgggtca ccgtctcctc a 351
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 530
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
311
US 9,550,837 B2
-continued
312
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 530
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu
65 70 75 80
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Ala Arg
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 531
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 531
ggattcaccc taagtagcta cgac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 532
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 532
Gly Phe Thr Leu Ser Ser Tyr Asp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 533
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 533
attggcagta ctggtgacac a 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 534
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 534
Ile Gly Ser Thr Gly Asp Thr
1 5
313
US 9,550,837 B2
-continued
314
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 535
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 535
gcaagagagg gaataagaac accctatgat tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 536
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 536
Ala Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 537
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 537
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct
60
120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct
180
240
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc
cctgggacca aagtggatat caaa
300
324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 538
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 538
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210& SEQ ID NO 539
315
US 9,550,837 B2
-continued
316
&211&
&212&
&213&
&220&
&223&
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 539
cagagtgtta gcagcaat 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 540
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 540
Gln Ser Val Ser Ser Asn
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 541
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 541
ggtgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 542
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 542
Gly Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 543
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 543
cagcagtata ataattggcc tccattcact 30
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 544
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 544
Gln Gln Tyr Asn Asn Trp Pro Pro Phe Thr
1 5 10
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 545
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
317
US 9,550,837 B2
-continued
318
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 545
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca
60
120
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata
agaacaccct atgattattg gggccaggga accctggtca ccgtctcctc a
300
351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 546
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 546
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu
65 70 75 80
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 547
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 547
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc
120
180
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 300
cctgggacca aagtggatat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 548
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
319
US 9,550,837 B2
-continued
320
&400& SEQUENCE: 548
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 549
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 549
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagct
60
120
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactatcca
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt
180
240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaagga accctggtca ccgtctcctc a 351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 550
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 550
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
321
US 9,550,837 B2
-continued
322
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 551
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 551
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcaatttag cctggtacca gcagaaacct
60
120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
180
240
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc
cctgggacca aagtggatat caaa
300
324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 552
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 552
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 553
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 553
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca 120
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300
agaacaccct atgattattg gggccaggga gcccgggtca ccgtctcctc a 351
&210& SEQ ID NO 554
&211& LENGTH: 117
323
US 9,550,837 B2
-continued
324
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 554
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu
65 70 75 80
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Ala Arg
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 555
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 555
ggattcaccc taagtagcta cgac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 556
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 556
Gly Phe Thr Leu Ser Ser Tyr Asp
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 557
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 557
attggcagta ctggtgacac a 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 558
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 558
Ile Gly Ser Thr Gly Asp Thr
325
US 9,550,837 B2
-continued
326
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 559
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 559
gcaagagagg gaataagaac accctatgat tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 560
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 560
Ala Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 561
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 561
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc
120
180
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc
240
300
cctgggacca aagtggatat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 562
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 562
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
327
US 9,550,837 B2
-continued
328
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 563
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 563
cagagtgtta gcagcaat 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 564
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 564
Gln Ser Val Ser Ser Asn
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 565
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 565
ggtgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 566
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 566
Gly Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 567
LENGTH: 30
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 567
cagcagtata ataattggcc tccattcact 30
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 568
LENGTH: 10
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 568
Gln Gln Tyr Asn Asn Trp Pro Pro Phe Thr
1 5 10
&210& SEQ ID NO 569
&211& LENGTH: 351
329
US 9,550,837 B2
-continued
330
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 569
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca
60
120
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata
agaacaccct atgattattg gggccaggga accctggtca ccgtctcctc a
300
351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 570
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 570
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu
65 70 75 80
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 571
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 571
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 180
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 240
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 300
cctgggacca aagtggatat caaa 324
&210& SEQ ID NO 572
&211& LENGTH: 108
&212& TYPE: PRT
331
US 9,550,837 B2
-continued
332
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 572
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 573
LENGTH: 351
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 573
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagct
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactatcca
120
180
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggaata
240
300
agaacaccct atgattattg gggccaagga accctggtca ccgtctcctc a 351
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 574
LENGTH: 117
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 574
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
333
US 9,550,837 B2
-continued
334
Val Thr Val Ser Ser
115
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 575
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 575
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agcaatttag cctggtacca gcagaaacct
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc
120
180
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc
240
300
cctgggacca aagtggatat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 576
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 576
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro
85 90 95
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 577
LENGTH: 363
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 577
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 120
ccagggaagg gcctggagtg ggtctcaggt attaattgga acagtggtag cataggctat 180
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagca ctccctgtat 240
ctgcaaatga acagtctgag acctgaggac acggccttgt attactgtgt aaaagaggtg 300
actacgggat actactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc 360
335
US 9,550,837 B2
-continued
336
tca 363
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 578
LENGTH: 121
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 578
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asn Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys His Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 579
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 579
ggattcacct ttgatgatta tgcc 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 580
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 580
Gly Phe Thr Phe Asp Asp Tyr Ala
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 581
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 581
attaattgga acagtggtag cata 24
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 582
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
337
US 9,550,837 B2
-continued
338
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 582
Ile Asn Trp Asn Ser Gly Ser Ile
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 583
LENGTH: 42
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 583
gtaaaagagg tgactacggg atactactac ggtatggacg tc 42
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 584
LENGTH: 14
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 584
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val
1 5 10
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 585
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 585
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgct gggccagtca gggcattagc agttatttag cctggtatca gaaaaaacca 120
gggaaagccc ctaacctcct gatctatgat gcatccactt tgcaaagtgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca cactcagcag cctgcagcct
180
240
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tttcggccct 300
gggaccaaag tggatatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 586
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 586
Asp Ile Gln Leu
1
Thr Gln Ser Pro Ser Phe Leu Ser Ala
10
Ser Val Gly
15
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Gly Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Lys Lys Pro Gly Lys Ala
35 40
Pro Asn Leu Leu Ile
45
Tyr Asp Ala Ser
50
Thr Leu Gln Ser Gly Val Pro
55
Ser Arg Phe Ser Gly
60
Ser Gly Ser Gly Thr Glu Phe Thr Leu
65 70 75 80
Thr Leu Ser Ser Leu Gln Pro
339
US 9,550,837 B2
-continued
340
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ile Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 587
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 587
cagggcatta gcagttat 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 588
LENGTH: 6
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 588
Gln Gly Ile Ser Ser Tyr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 589
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 589
gatgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 590
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 590
Asp Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 591
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 591
caacagctta atatttaccc attcact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 592
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 592
Gln Gln Leu Asn Ile Tyr Pro Phe Thr
341
US 9,550,837 B2
-continued
342
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 593
LENGTH: 363
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 593
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct
60
120
ccagggaagg gcctggagtg ggtctcaggt attaattgga acagtggtag cataggctat 180
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagca ctccctgtat 240
ctgcaaatga acagtctgag acctgaggac acggccttgt attactgtgt aaaagaggtg
actacgggat actactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc
300
360
tca 363
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 594
LENGTH: 121
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 594
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asn Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys His Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 595
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 595
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgct gggccagtca gggcattagc agttatttag cctggtatca gaaaaaacca 120
gggaaagccc ctaacctcct gatctatgat gcatccactt tgcaaagtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagaa ttcactctca cactcagcag cctgcagcct 240
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tttcggccct 300
343
US 9,550,837 B2
-continued
344
gggaccaaag tggatatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 596
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 596
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Gly Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Lys Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Leu Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ile Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 597
LENGTH: 363
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 597
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct
ccagggaagg gcctggagtg ggtctcaggt attaattgga acagtggtag cataggctat
120
180
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctccctgtat 240
ctgcaaatga acagtctgag agctgaggac acggccttgt attactgtgt aaaagaggtg 300
actacgggat actactacgg tatggacgtc tgggggcaag ggaccacggt caccgtctcc 360
tca 363
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 598
LENGTH: 121
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 598
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Gly Ile Asn Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60
345
US 9,550,837 B2
-continued
346
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 599
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 599
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca 120
gggaaagccc ctaagctcct gatctatgat gcatccactt tgcaaagtgg ggtcccatca
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct
180
240
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tttcggccct 300
gggaccaaag tggatatcaa a 321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 600
LENGTH: 107
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 600
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ile Tyr Pro Phe
85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 601
LENGTH: 366
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 601
gaggtgcagt tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgaactgggt ccgccaggct 120
347
US 9,550,837 B2
-continued
348
ccagggaagg ggctggattg ggtctcaggt atcagtggta atggtggtag cacctactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca tttccaagaa cacgctgtat
gtgcaaatgc acagcctgag agtcgaggac acggccgttt actactgtgc gaaagcccgt
240
300
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccca ggtcactgtc 360
tcctca 366
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 602
LENGTH: 122
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 602
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
35 40 45
Ser Gly Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ile Ser Lys Asn Thr Leu Tyr
65 70 75 80
Val Gln Met His Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu Trp
100 105 110
Gly Arg Gly Thr Gln Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 603
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 603
ggattcacgt ttagtagcta tgcc 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 604
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 604
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 605
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 605
349
US 9,550,837 B2
-continued
350
atcagtggta atggtggtag cacc 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 606
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 606
Ile Ser Gly Asn Gly Gly Ser Thr
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 607
LENGTH: 48
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 607
gcgaaagccc gttattacga tttttggggg gggaatttcg atctc 48
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 608
LENGTH: 18
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 608
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu
1 8 10 18
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 609
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 609
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc atcaggtact tagcctggta tcagcagaaa
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
120
180
gacaggttca gtgtcagtgt gtctgggaca gacttcactc tcaccatcac tagactggag
cctgaagatt ttgcagtcta ttactgtcag caatatggta gttcaccgct cactttcggc
240
300
ggagggacca aggtggagat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 610
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 610
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
8 10 18
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg
20 28 30
351
US 9,550,837 B2
-continued
352
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Val Ser Val Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 611
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 611
cagagtgtta gcatcaggta c 21
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 612
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 612
Gln Ser Val Ser Ile Arg Tyr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 613
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 613
ggtgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 614
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 614
Gly Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 615
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 615
cagcaatatg gtagttcacc gctcact 27
&210& SEQ ID NO 616
353
US 9,550,837 B2
-continued
354
&211&
&212&
&213&
&220&
&223&
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 616
Gln Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 617
LENGTH: 366
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 617
gaggtgcagt tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgaactgggt ccgccaggct
ccagggaagg ggctggattg ggtctcaggt atcagtggta atggtggtag cacctactac
120
180
gcagactccg tgaagggccg gttcaccatc tccagagaca tttccaagaa cacgctgtat
gtgcaaatgc acagcctgag agtcgaggac acggccgttt actactgtgc gaaagcccgt
240
300
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccct ggtcactgtc 360
tcctca 366
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 618
LENGTH: 122
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 618
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
35 40 45
Ser Gly Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ile Ser Lys Asn Thr Leu Tyr
65 70 75 80
Val Gln Met His Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu Trp
100 105 110
Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 619
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 619
355
US 9,550,837 B2
-continued
356
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc atcaggtact tagcctggta tcagcagaaa
60
120
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
gacaggttca gtgtcagtgt gtctgggaca gacttcactc tcaccatcac tagactggag
180
240
cctgaagatt ttgcagtcta ttactgtcag caatatggta gttcaccgct cactttcggc
ggagggacca aggtggagat caaa
300
324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 620
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 620
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Val Ser Val Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 621
LENGTH: 366
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 621
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgagctgggt ccgccaggct
60
120
ccagggaagg ggctggagtg ggtctcagct atcagtggta atggtggtag cacctactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagcccgt
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccct ggtcactgtc
300
360
tcctca 366
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 622
LENGTH: 122
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 622
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
357
US 9,550,837 B2
-continued
358
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu Trp
100 105 110
Gly Arg Gly Thr Leu Val Thr Val Ser Ser
115 120
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 623
LENGTH: 324
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 623
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc atcaggtact tagcctggta ccagcagaaa
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
120
180
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
cctgaagatt ttgcagtgta ttactgtcag caatatggta gttcaccgct cactttcggc
240
300
ggagggacca aggtggagat caaa 324
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 624
LENGTH: 108
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 624
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210& SEQ ID NO 625
&211& LENGTH: 381
&212& TYPE: DNA
359
US 9,550,837 B2
-continued
360
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 625
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat
120
180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 626
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 626
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 627
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 627
ggttacacct ttaccaccta tggt 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 628
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 628
Gly Tyr Thr Phe Thr Thr Tyr Gly
1 5
361
US 9,550,837 B2
-continued
362
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 629
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 629
atcagcggtt acaatggtaa aaca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 630
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 630
Ile Ser Gly Tyr Asn Gly Lys Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 631
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 631
tcgagagatc gtttagtagt accacctgcc ctttattatt cctactacgt tatggacgtc 60
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 632
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 632
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr
1 5 10 15
Val Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 633
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 633
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
&210& SEQ ID NO 634
&211& LENGTH: 112
&212& TYPE: PRT
363
US 9,550,837 B2
-continued
364
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 634
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 635
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 635
caaagcctcg tatacagtga tggaaacacc tac 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 636
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 636
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 637
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 637
aaggtttct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 638
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 638
Lys Val Ser
1
&210& SEQ ID NO 639
365
US 9,550,837 B2
-continued
366
&211&
&212&
&213&
&220&
&223&
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 639
atgcaaggta cacactggcc gtacact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 640
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 640
Met Gln Gly Thr His Trp Pro Tyr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 641
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 641
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 642
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 642
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
367
US 9,550,837 B2
-continued
368
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 643
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 643
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
60
120
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
180
240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
tacacttttg gccaggggac caagctggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 644
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 644
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 645
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 645
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
369
US 9,550,837 B2
-continued
370
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 646
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 646
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 647
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 647
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac
120
180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
240
300
tacacttttg gccaggggac caagctggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 648
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 648
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
371
US 9,550,837 B2
-continued
372
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 649
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 649
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat
120
180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg gggccaaggg
300
360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 650
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 650
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 651
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 651
ggttacacct ttaccaccta tggt 24
373
US 9,550,837 B2
-continued
374
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 652
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 652
Gly Tyr Thr Phe Thr Thr Tyr Gly
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 653
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 653
atcagcggtt acaatggtaa aaca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 654
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 654
Ile Ser Gly Tyr Asn Gly Lys Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 655
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 655
tcgagagatc gtttagtagt accacctgcc cttaattatt actactacgt tatggacgtc 60
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 656
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 656
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr
1 5 10 15
Val Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 657
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 657
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
375
US 9,550,837 B2
-continued
376
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
180
240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
tacacttttg gccaggggac caagctggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 658
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 658
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 659
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 659
caaagcctcg tatacagtga tggaaacacc tac 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 660
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 660
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 661
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 661
aaggtttct
&210& SEQ ID NO 662
&211& LENGTH: 3
377
US 9,550,837 B2
-continued
378
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 662
Lys Val Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 663
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 663
atgcaaggta cacactggcc gtacact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 664
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 664
Met Gln Gly Thr His Trp Pro Tyr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 665
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 665
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat
120
180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg gggccaaggg
300
360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 666
LENGTH: 127
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 666
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
379
US 9,550,837 B2
-continued
380
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 667
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 667
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac
120
180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
240
300
tacacttttg gccaggggac caagctggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 668
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 668
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 669
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 669
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
381
US 9,550,837 B2
-continued
382
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat
120
180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 670
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 670
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 671
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 671
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac
120
180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
240
300
tacacttttg gccaggggac caagctggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 672
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 672
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
383
US 9,550,837 B2
-continued
384
10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 673
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 673
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc
60
120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac
180
240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg gggccaaggg
300
360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 674
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 674
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
385
US 9,550,837 B2
-continued
386
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 678
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 678
ggttacacct ttaccaccta tggt 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 676
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 676
Gly Tyr Thr Phe Thr Thr Tyr Gly
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 677
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 677
atcagcggtt acaatggtaa aaca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 678
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 678
Ile Ser Gly Tyr Asn Gly Lys Thr
1 8
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 679
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 679
tcgagagatc gtttagtagt accacctgcc ctttattatt actactacgt tatggacgtc 60
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 680
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 680
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr
1 8 10 18
Val Met Asp Val
20
&210& SEQ ID NO 681
387
US 9,550,837 B2
-continued
388
&211&
&212&
&213&
&220&
&223&
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 681
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
60
120
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
180
240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
tacacttttg gccaggggac caagctggag atcaaa
300
336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 682
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 682
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 683
LENGTH: 33
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 683
caaagcctcg tatacagtga tggaaacacc tac 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 684
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 684
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr
1 5 10
&210& SEQ ID NO 685
&211& LENGTH: 9
389
US 9,550,837 B2
-continued
390
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 685
aaggtttct
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 686
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 686
Lys Val Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 687
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 687
atgcaaggta cacactggcc gtacact 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 688
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 688
Met Gln Gly Thr His Trp Pro Tyr Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 689
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 689
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc
60
120
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg gggccaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 690
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
391
US 9,550,837 B2
-continued
392
&400& SEQUENCE: 690
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe
50 55 60
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 691
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 691
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac
120
180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg
240
300
tacacttttg gccaggggac caagctggag atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 692
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 692
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn
35
Trp Phe Gln Gln Arg Pro Gly Gln Ser
40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
393
US 9,550,837 B2
-continued
394
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 693
LENGTH: 381
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 693
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat
120
180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg ggggcaaggg 360
accacggtca ccgtctcctc a 381
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 694
LENGTH: 127
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 694
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr
100 105 110
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 695
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 695
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 180
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300
tacacttttg gccaggggac caagctggag atcaaa 336
395
US 9,550,837 B2
-continued
396
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 696
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 696
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
20 25 30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
35 40 45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213 &
&220&
&223&
SEQ ID NO 697
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 697
caggtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct
60
120
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat
180
240
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa
300
360
gggaccacgg tcaccgtcgc ctca 384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 698
LENGTH: 128
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 698
Gln Val His Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His
20 25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val
50 55 60
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
397
US 9,550,837 B2
-continued
398
65 70 75 80
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ala Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 699
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 699
ggattcacct tcagtgacca ctac 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 700
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 700
Gly Phe Thr Phe Ser Asp His Tyr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 701
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 701
attagtaatg atggtggtac caaa 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 702
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 702
Ile Ser Asn Asp Gly Gly Thr Lys
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 703
LENGTH: 63
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 703
gcgagagatc agggatatat tggctacgac tcgtattatt actattccta cggtatggac 60
gtc 63
&210& SEQ ID NO 704
&211& LENGTH: 21
&212& TYPE: PRT
399
US 9,550,837 B2
-continued
400
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 704
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
1 5 10 15
Tyr Gly Met Asp Val
20
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 705
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 705
aaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 60
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag
180
240
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tttcggcgga
gggaccaagg tggagatcaa g
300
321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 706
LENGTH: 107
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 706
Lys Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu
65 70 75 80
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 707
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 707
cagagtgtta acaacaaatt c 21
&210& SEQ ID NO 708
401
US 9,550,837 B2
-continued
402
&211&
&212&
&213&
&220&
&223&
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 708
Gln Ser Val Asn Asn Lys Phe
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 709
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 709
ggtgcatcc
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 710
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 710
Gly Ala Ser
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 711
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 711
caagtatatg gtaactcact cact 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 712
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 712
Gln Val Tyr Gly Asn Ser Leu Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 713
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 713
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 120
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 180
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 240
403
US 9,550,837 B2
-continued
404
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 300
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa 360
gggaccacgg tcaccgtctc ctca 384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 714
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 714
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His
20 25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val
50 55 60
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 715
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 715
gaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa
60
120
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag
180
240
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tttcggcgga
gggaccaagg tggagatcaa a
300
321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 716
LENGTH: 107
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 716
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu
405
US 9,550,837 B2
-continued
406
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu
65 70 75 80
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 717
LENGTH: 384
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 717
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcatac attagtaatg atggtggtac caaatactac
120
180
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gagagatcag 300
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctgggggcaa
gggaccacgg tcaccgtctc ctca
360
384
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 718
LENGTH: 128
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 718
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His
20 25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser
100 105 110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 719
LENGTH: 321
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
407
US 9,550,837 B2
-continued
408
&400& SEQUENCE: 719
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
180
240
cctgaagatt ttgcagtgta ttactgtcaa gtatatggta actcactcac tttcggcgga
gggaccaagg tggagatcaa a
300
321
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 720
LENGTH: 107
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 720
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys
20 25 30
Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 721
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 721
caaattctgc tggtgcaatc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat
120
180
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc 360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 722
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 722
409
US 9,550,837 B2
-continued
410
Gln Ile Leu Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 723
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 723
ggttacacct ttaccaacta cgct 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 724
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 724
Gly Tyr Thr Phe Thr Asn Tyr Ala
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 725
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 725
gtcagcgctt acaatggtca caca 24
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 726
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 726
Val Ser Ala Tyr Asn Gly His Thr
1 5
&210& SEQ ID NO 727
&211& LENGTH: 57
&212& TYPE: DNA
411
US 9,550,837 B2
-continued
412
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 727
gcgagagggg gtgtagtcgt gccagttgct ccccacttct acaacggtat ggacgtc 57
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 728
LENGTH: 19
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 728
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
1 5 10 15
Met Asp Val
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 729
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 729
gatattgtga tgactcagtt tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 120
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg
240
300
tggacgttcg gccaagggac caaggtggaa atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 730
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 730
Asp Ile Val Met Thr Gln Phe Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu
50
Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Phe
100
Gly Gln Gly Thr Lys Val Glu Ile Lys
105 110
&210& SEQ ID NO 731
&211& LENGTH: 33
413
US 9,550,837 B2
-continued
414
&212& TYPE: DNA
&213& ORGANISM: Artificial Sequence
&220& FEATURE:
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 731
cagagcctcc tgcatattaa tgaatacaac tat 33
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 732
LENGTH: 11
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 732
Gln Ser Leu Leu His Ile Asn Glu Tyr Asn Tyr
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 733
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 733
ttgggtttt
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 734
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 734
Leu Gly Phe
1
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 735
LENGTH: 27
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 735
atgcaagctc ttcaaactcc gtggacg 27
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 736
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 736
Met Gln Ala Leu Gln Thr Pro Trp Thr
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 737
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
415
US 9,550,837 B2
-continued
416
&400& SEQUENCE: 737
caggttcagc tggtgcagtc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc
60
120
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc
300
360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 738
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 738
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
100 105 110
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 739
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 739
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg
60
120
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 300
tggacgttcg gccaagggac caaggtggaa atcaaa 336
&210&
&211&
&212&
&213&
&220&
SEQ ID NO 740
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
417
US 9,550,837 B2
-continued
418
&223& OTHER INFORMATION: Synthetic
&400& SEQUENCE: 740
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 741
LENGTH: 378
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 741
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagggggt
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg gcaagggacc
300
360
acggtcaccg tctcctca 378
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 742
LENGTH: 126
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 742
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly
100 105 110
419
US 9,550,837 B2
-continued
420
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 743
LENGTH: 336
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 743
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc
120
180
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct tcaaactccg
240
300
tggacgttcg gccaagggac caaggtggaa atcaaa 336
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 744
LENGTH: 112
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
&400& SEQUENCE: 744
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile
20 25 30
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85 90 95
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
&210&
&211&
&212&
&213&
&220&
&223&
&220&
&221&
&222&
&223&
SEQ ID NO 745
LENGTH: 8
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
FEATURE:
NAME)KEY: VARIANT
LOCATION: (1) . . . (8)
OTHER INFORMATION: Xaa = Any amino acid
&400& SEQUENCE: 745
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
&210& SEQ ID NO 746
&211& LENGTH: 8
&212& TYPE: PRT
&213& ORGANISM: Artificial Sequence
421
US 9,550,837 B2
-continued
422
&220&
&223&
&220&
&221&
&222&
&223&
FEATURE:
OTHER INFORMATION: Synthetic
FEATURE:
NAME)KEY: VARIANT
LOCATION: (1) . . . (8)
OTHER INFORMATION: Xaa — Any amino acid
&400& SEQUENCE: 746
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5
&210&
&211&
&212&
&213&
&220&
&223&
&220&
&221&
&222&
&223&
SEQ ID NO 747
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
FEATURE:
NAME)KEY: VARIANT
LOCATION: (1) . . . (20)
OTHER INFORMATION: Xaa = Any amino acid
&400& SEQUENCE: 747
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20
&210&
&211&
&212&
&213 &
&220&
&223&
&220&
&221&
&222&
&223&
SEQ ID NO 748
LENGTH: 12
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
FEATURE:
NAME)KEY: VARIANT
LOCATION: (1) . . . (12)
OTHER INFORMATION: Xaa = Any amino acid
&400& SEQUENCE: 748
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10
&210&
&211&
&212&
&213&
&220&
&223&
&220&
&221&
&222&
&223&
SEQ ID NO 749
LENGTH: 3
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
FEATURE:
NAME)KEY: VARIANT
LOCATION: (1).. . (3)
OTHER INFORMATION: Xaa = Any amino acid
&400& SEQUENCE: 749
Xaa Xaa Xaa
1
&210&
&211&
&212&
&213&
&220&
&223&
&220&
&221&
&222&
&223&
SEQ ID NO 750
LENGTH: 9
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
FEATURE:
NAME)KEY: VARIANT
LOCATION: (1) . . . (9)
OTHER INFORMATION: Xaa = Any amino acid
&400& SEQUENCE: 750
423
US 9,550,837 B2
-continued
424
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 751
LENGTH: 330
TYPE: PRT
ORGANISM: Artific
FEATURE:
OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 751
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225 230 235 240
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
&210& SEQ ID NO 752
425
US 9,550,837 B2
-continued
426
&211& LENGTH: 327
&212& TYPE: PRT
&213& ORGANISM: Artific
&220& FEATURE:
&223& OTHER INFORMATION
ial Sequence
Synthetic
&400& SEQUENCE: 752
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
100 105 110
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met
305
His Glu Ala Leu His
310
Asn His Tyr Thr Gln Lys Ser
315 320
Leu Ser Leu Ser Leu Gly Lys
325
&210&
&211&
&212&
&213&
&220&
&223&
SEQ ID NO 753
LENGTH: 327
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
427
US 9,550,837 B2
-continued
428
&400& SEQUENCE: 753
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
325
&210& SEQ ID NO 754
&211& LENGTH: 2076
&212& TYPE: DNA
&213& ORGANISM: Homo sapiens
&400& SEQUENCE: 754
atgggcaccg tcagctccag gcggtcctgg tggccgctgc cactgctgct gctgctgctg 60
ctgctcctgg gtcccgcggg cgcccgtgcg caggaggacg aggacggcga ctacgaggag 120
ctggtgctag ccttgcgttc cgaggaggac ggcctggccg aagcacccga gcacggaacc 180
429
US 9,550,837 B2
-continued
430
acagccacct tccaccgctg cgccaaggat ccgtggaggt tgcctggcac ctacgtggtg 240
gtgctgaagg aggagaccca cctctcgcag tcagagcgca ctgcccgccg cctgcaggcc 300
caggctgccc gccggggata cctcaccaag atcctgcatg tcttccatgg ccttcttcct 360
ggcttcctgg tgaagatgag tggcgacctg ctggagctgg ccttgaagtt gccccatgtc 420
gactacatcg aggaggactc ctctgtcttt gcccagagca tcccgtggaa cctggagcgg 480
attacccctc cacggtaccg ggcggatgaa taccagcccc ccgacggagg cagcctggtg 540
gaggtgtatc tcctagacac cagcatacag agtgaccacc gggaaatcga gggcagggtc 600
atggtcaccg acttcgagaa tgtgcccgag gaggacggga cccgcttcca cagacaggcc 660
agcaagtgtg acagtcatgg cacccacctg gcaggggtgg tcagcggccg ggatgccggc 720
gtggccaagg gtgccagcat gcgcagcctg cgcgtgctca actgccaagg gaagggcacg 780
gttagcggca ccctcatagg cctggagttt attcggaaaa gccagctggt ccagcctgtg 840
gggccactgg tggtgctgct gcccctggcg ggtgggtaca gccgcgtcct caacgccgcc 900
tgccagcgcc tggcgagggc tggggtcgtg ctggtcaccg ctgccggcaa cttccgggac 960
gatgcctgcc tctactcccc agcctcagct cccgaggtca tcacagttgg ggccaccaat 1020
gcccaggacc agccggtgac cctggggact ttggggacca actttggccg ctgtgtggac 1080
ctctttgccc caggggagga catcattggt gcctccagcg actgcagcac ctgctttgtg 1140
tcacagagtg ggacatcaca ggctgctgcc cacgtggctg gcattgcagc catgatgctg 1200
tctgccgagc cggagctcac cctggccgag ttgaggcaga gactgatcca cttctctgcc 1260
aaagatgtca tcaatgaggc ctggttccct gaggaccagc gggtactgac ccccaacctg 1320
gtggccgccc tgccccccag cacccatggg gcaggttggc agctgttttg caggactgtg 1380
tggtcagcac actcggggcc tacacggatg gccacagcca tcgcccgctg cgccccagat 1440
gaggagctgc tgagctgctc cagtttctcc aggagtggga agcggcgggg cgagcgcatg 1500
gaggcccaag ggggcaagct ggtctgccgg gcccacaacg cttttggggg tgagggtgtc 1560
tacgccattg ccaggtgctg cctgctaccc caggccaact gcagcgtcca cacagctcca 1620
ccagctgagg ccagcatggg gacccgtgtc cactgccacc aacagggcca cgtcctcaca 1680
ggctgcagct cccactggga ggtggaggac cttggcaccc acaagccgcc tgtgctgagg 1740
ccacgaggtc agcccaacca gtgcgtgggc cacagggagg ccagcatcca cgcttcctgc 1800
tgccatgccc caggtctgga atgcaaagtc aaggagcatg gaatcccggc ccctcaggag 1860
caggtgaccg tggcctgcga ggagggctgg accctgactg gctgcagtgc cctccctggg 1920
acctcccacg tcctgggggc ctacgccgta gacaacacgt gtgtagtcag gagccgggac 1980
gtcagcacta caggcagcac cagcgaagag gccgtgacag ccgttgccat ctgctgccgg 2040
agccggcacc tggcgcaggc ctcccaggag ctccag 2076
&210& SEQ ID NO 755
&211& LENGTH: 692
&212& TYPE: PRT
&213& ORGANISM: Homo sapiens
&400& SEQUENCE: 755
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp
1 5 10
Pro Leu Pro Leu Leu
Leu Leu Leu Leu Leu Leu Leu Gly
20
Pro Ala Gly Ala Arg Ala Gln Glu
25 30
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
431
US 9,550,837 B2
-continued
432
35 40 45
Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe
50 55 60
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65 70 75 80
Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg
85 90 95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
100 105 110
His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
115 120 125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu
130 135 140
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg
145 150 155 160
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly
165 170 175
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
180 185 190
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val
195 200 205
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp
210 215 220
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225 230 235 240
Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn Cys Gln
245 250 255
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
260 265 270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln Arg Leu
290 295 300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp
305 310 315 320
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
325 330 335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly
370 375 380
Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu
385 390 395 400
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
405 410 415
His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp
420 425 430
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr
435 440 445
His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His
450 455 460
433
US 9,550,837 B2
-continued
434
Ser Gly Pro Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala Pro Asp
465 470 475 480
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
485 490 495
Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His
500 505 510
Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
515 520 525
Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala Glu Ala
530 535 540
Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr
545 550 555 560
Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro
565 570 575
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg
580 585 590
Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys
595 600 605
Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Thr Val
610 615 620
Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly
625 630 635 640
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
645 650 655
Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val
660 665 670
Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser
675 680 685
Gln Glu Leu Gln
690
&210& SEQ ID NO 756
&211& LENGTH: 692
&212& TYPE: PRT
&213& ORGANISM: Macaca mulata
&400& SEQUENCE: 756
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Pro
1 5 10 15
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu
20 25 30
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
35 40 45
Glu Asp Gly Leu Ala Asp Ala Pro Glu His Gly Ala Thr Ala Thr Phe
50 55 60
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65 70 75 80
Val Leu Lys Glu Glu Thr His Arg Ser Gln Ser Glu Arg Thr Ala Arg
85 90 95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
100 105 110
His Val Phe His His Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
115 120 125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu
435
US 9,550,837 B2
-continued
436
130 135 140
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg
145 150 155 160
Ile Thr Pro Ala Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Lys Gly
165 170 175
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
180 185 190
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Ser Val
195 200 205
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp
210 215 220
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225 230 235 240
Val Ala Lys Gly Ala Gly Leu Arg Ser Leu Arg Val Leu Asn Cys Gln
245 250 255
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
260 265 270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Val Phe Asn Ala Ala Cys Gln Arg Leu
290 295 300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp
305 310 315 320
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
325 330 335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Arg Ser Gly
370 375 380
Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu
385 390 395 400
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
405 410 415
His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp
420 425 430
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr
435 440 445
His Arg Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His
450 455 460
Ser Gly Pro Thr Arg Met Ala Thr Ala Val Ala Arg Cys Ala Gln Asp
465 470 475 480
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
485 490 495
Gly Glu Arg Ile Glu Ala Gln Gly Gly Lys Arg Val Cys Arg Ala His
500 505 510
Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
515 520 525
Leu Pro Gln Val Asn Cys Ser Val His Thr Ala Pro Pro Ala Gly Ala
530 535 540
Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr
545 550 555 560
437
US 9,550,837 B2
-continued
438
Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro
565 570 575
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg
580 585 590
Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys
595 600 605
Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Ile Val
610 615 620
Ala Cys Glu Asp Gly Trp Thr Leu Thr Gly Cys Ser Pro Leu Pro Gly
625 630 635 640
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
645 650 655
Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Lys Glu Ala Val
660 665 670
Ala Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Val Gln Ala Ser
675 680 685
Gln Glu Leu Gln
690
&210& SEQ ID NO 757
&211& LENGTH: 694
&212& TYPE: PRT
&213& ORGANISM: Mus muscular
&400& SEQUENCE: 757
Met Gly Thr His Cys Ser Ala Trp Leu Arg Trp Pro Leu Leu Pro Leu
1 5 10 15
Leu Pro Pro Leu Leu Leu Leu Leu Leu Leu Leu Cys Pro Thr Gly Ala
20 25 30
Gly Ala Gln Asp Glu Asp Gly Asp Tyr Glu Glu Leu Met Leu Ala Leu
35 40 45
Pro Ser Gln Glu Asp Gly Leu Ala Asp Glu Ala Ala His Val Ala Thr
50 55 60
Ala Thr Phe Arg Arg Cys Ser Lys Glu Ala Trp Arg Leu Pro Gly Thr
65 70 75 80
Tyr Ile Val Val Leu Met Glu Glu Thr Gln Arg Leu Gln Ile Glu Gln
85 90 95
Thr Ala His Arg Leu Gln Thr Arg Ala Ala Arg Arg Gly Tyr Val Ile
100 105 110
Lys Val Leu His Ile Phe Tyr Asp Leu Phe Pro Gly Phe Leu Val Lys
115 120 125
Met Ser Ser Asp Leu Leu Gly Leu Ala Leu Lys Leu Pro His Val Glu
130 135 140
Tyr Ile Glu Glu Asp Ser Phe Val Phe Ala Gln Ser Ile Pro Trp Asn
145 150 155 160
Leu Glu Arg Ile Ile Pro Ala Trp His Gln Thr Glu Glu Asp Arg Ser
165 170 175
Pro Asp Gly Ser Ser Gln Val Glu Val Tyr Leu Leu Asp Thr Ser Ile
180 185 190
Gln Gly Ala His Arg Glu Ile Glu Gly Arg Val Thr Ile Thr Asp Phe
195 200 205
Asn Ser Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser
210 215 220
Lys Cys Asp Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg
439
US 9,550,837 B2
-continued
440
225 230 235 240
Asp Ala Gly Val Ala Lys Gly Thr Ser Leu His Ser Leu Arg Val Leu
245 250 255
Asn Cys Gln Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu
260 265 270
Phe Ile Arg Lys Ser Gln Leu Ile Gln Pro Ser Gly Pro Leu Val Val
275 280 285
Leu Leu Pro Leu Ala Gly Gly Tyr Ser Arg Ile Leu Asn Ala Ala Cys
290 295 300
Arg His Leu Ala Arg Thr Gly Val Val Leu Val Ala Ala Ala Gly Asn
305 310 315 320
Phe Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val
325 330 335
Ile Thr Val Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly
340 345 350
Thr Leu Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly
355 360 365
Lys Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Met Ser
370 375 380
Gln Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Val Ala
385 390 395 400
Arg Met Leu Ser Arg Glu Pro Thr Leu Thr Leu Ala Glu Leu Arg Gln
405 410 415
Arg Leu Ile His Phe Ser Thr Lys Asp Val Ile Asn Met Ala Trp Phe
420 425 430
Pro Glu Asp Gln Gln Val Leu Thr Pro Asn Leu Val Ala Thr Leu Pro
435 440 445
Pro Ser Thr His Glu Thr Gly Gly Gln Leu Leu Cys Arg Thr Val Trp
450 455 460
Ser Ala His Ser Gly Pro Thr Arg Thr Ala Thr Ala Thr Ala Arg Cys
465 470 475 480
Ala Pro Glu Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly
485 490 495
Arg Arg Arg Gly Asp Trp Ile Glu Ala Ile Gly Gly Gln Gln Val Cys
500 505 510
Lys Ala Leu Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Val Ala Arg
515 520 525
Cys Cys Leu Val Pro Arg Ala Asn Cys Ser Ile His Asn Thr Pro Ala
530 535 540
Ala Arg Ala Gly Leu Glu Thr His Val His Cys His Gln Lys Asp His
545 550 555 560
Val Leu Thr Gly Cys Ser Phe His Trp Glu Val Glu Asp Leu Ser Val
565 570 575
Arg Arg Gln Pro Ala Leu Arg Ser Arg Arg Gln Pro Gly Gln Cys Val
580 585 590
Gly His Gln Ala Ala Ser Val Tyr Ala Ser Cys Cys His Ala Pro Gly
595 600 605
Leu Glu Cys Lys Ile Lys Glu His Gly Ile Ser Gly Pro Ser Glu Gln
610 615 620
Val Thr Val Ala Cys Glu Ala Gly Trp Thr Leu Thr Gly Cys Asn Val
625 630 635 640
Leu Pro Gly Ala Ser Leu Thr Leu Gly Ala Tyr Ser Val Asp Asn Leu
645 650 655
441
US 9,550,837 B2
-continued
442
Cys Val Ala Arg Val His Asp Thr Ala Arg Ala Asp Arg Thr Ser Gly
660 665 670
Glu Ala Thr Val Ala Ala Ala Ile Cys Cys Arg Ser Arg Pro Ser Ala
675 680 685
Lys Ala Ser Trp Val Gln
690
&210& SEQ ID NO 758
&211& LENGTH: 653
&212& TYPE: PRT
&213& ORGANISM: Homo sapiens
&400& SEQUENCE: 758
Glu Phe Arg Cys His Asp Gly Lys Cys Ile Ser Arg Gln Phe Val Cys
1 5 10 15
Asp Ser Asp Arg Asp Cys Leu Asp Gly Ser Asp Glu Ala Ser Cys Pro
20 25 30
Val Leu Thr Cys Gly Pro Ala Ser Phe Gln Cys Asn Ser Ser Thr Cys
35 40 45
Ile Pro Gln Leu Trp Ala Cys Asp Asn Asp Pro Asp Cys Glu Asp Gly
50 55 60
Ser Asp Glu Trp Pro Gln Arg Cys Arg Gly Leu Tyr Val Phe Gln Gly
65 70 75 80
Asp Ser Ser Pro Cys Ser Ala Phe Glu Phe His Cys Leu Ser Gly Glu
85 90 95
Cys Ile His Ser Ser Trp Arg Cys Asp Gly Gly Pro Asp Cys Lys Asp
100 105 110
Lys Ser Asp Glu Glu Asn Cys Ala Val Ala Thr Cys Arg Pro Asp Glu
115 120 125
Phe Gln Cys Ser Asp Gly Asn Cys Ile His Gly Ser Arg Gln Cys Asp
130 135 140
Arg Glu Tyr Asp Cys Lys Asp Met Ser Asp Glu Val Gly Cys Val Asn
145 150 155 160
Val Thr Leu Cys Glu Gly Pro Asn Lys Phe Lys Cys His Ser Gly Glu
165 170 175
Cys Ile Thr Leu Asp Lys Val Cys Asn Met Ala Arg Asp Cys Arg Asp
180 185 190
Trp Ser Asp Glu Pro Ile Lys Glu Cys Gly Thr Asn Glu Cys Leu Asp
195 200 205
Asn Asn Gly Gly Cys Ser His Val Cys Asn Asp Leu Lys Ile Gly Tyr
210 215 220
Glu Cys Leu Cys Pro Asp Gly Phe Gln Leu Val Ala Gln Arg Arg Cys
225 230 235 240
Glu Asp Ile Asp Glu Cys Gln Asp Pro Asp Thr Cys Ser Gln Leu Cys
245 250 255
Val Asn Leu Glu Gly Gly Tyr Lys Cys Gln Cys Glu Glu Gly Phe Gln
260 265 270
Leu Asp Pro His Thr Lys Ala Cys Lys Ala Val Gly Ser Ile Ala Tyr
275 280 285
Leu Phe Phe Thr Asn Arg
290
His Glu Val Arg Lys
295
Met Thr Leu Asp Arg
300
Ser Glu Tyr Thr Ser Leu Ile Pro Asn Leu Arg Asn Val Val Ala Leu
305 310 315 320
Asp Thr Glu Val Ala Ser Asn Arg Ile Tyr Trp Ser Asp Leu Ser Gln
443
US 9,550,837 B2
-continued
444
325 330 335
Arg Met Ile Cys Ser Thr Gln Leu Asp Arg Ala His Gly Val Ser Ser
340 345 350
Tyr Asp Thr Val Ile Ser Arg Asp Ile Gln Ala Pro Asp Gly Leu Ala
355 360 365
Val Asp Trp Ile His Ser Asn Ile Tyr Trp Thr Asp Ser Val Leu Gly
370 375 380
Thr Val Ser Val Ala Asp Thr Lys Gly Val Lys Arg Lys Thr Leu Phe
385 390 395 400
Arg Glu Asn Gly Ser Lys Pro Arg Ala Ile Val Val Asp Pro Val His
405 410 415
Gly Phe Met Tyr Trp Thr Asp Trp Gly Thr Pro Ala Lys Ile Lys Lys
420 425 430
Gly Gly Leu Asn Gly Val Asp Ile Tyr Ser Leu Val Thr Glu Asn Ile
435 440 445
Gln Trp Pro Asn Gly Ile Thr Leu Asp Leu Leu Ser Gly Arg Leu Tyr
450 455 460
Trp Val Asp Ser Lys Leu His Ser Ile Ser Ser Ile Asp Val Asn Gly
465 470 475 480
Gly Asn Arg Lys Thr Ile Leu Glu Asp Glu Lys Arg Leu Ala His Pro
485 490 495
Phe Ser Leu Ala Val Phe Glu Asp Lys Val Phe Trp Thr Asp Ile Ile
500 505 510
Asn Glu Ala Ile Phe Ser Ala Asn Arg Leu Thr Gly Ser Asp Val Asn
515 520 525
Leu Leu Ala Glu Asn Leu Leu Ser Pro Glu Asp Met Val Leu Phe His
530 535 540
Asn Leu Thr Gln Pro Arg Gly Val Asn Trp Cys Glu Arg Thr Thr Leu
545 550 555 560
Ser Asn Gly Gly Cys Gln Tyr Leu Cys Leu Pro Ala Pro Gln Ile Asn
565 570 575
Pro His Ser Pro Lys Phe Thr Cys Ala Cys Pro Asp Gly Met Leu Leu
580 585 590
Ala Arg Asp Met Arg Ser Cys Leu Thr Glu Ala Glu Ala Ala Val Ala
595 600 605
Thr Gln Glu Thr Ser Thr Val Arg Leu Lys Val Ser Ser Thr Ala Val
610 615 620
Arg Thr Gln His Thr Thr Thr Arg Pro Val Pro Asp Thr Ser Arg Leu
625 630 635 640
Pro Gly Ala Thr Pro Gly Leu Thr Thr Val Glu Ile Val
645 650
&210& SEQ ID NO 759
&211& LENGTH: 753
&212& TYPE: PRT
&213& ORGANISM: Homo sapiens
&400& SEQUENCE: 759
Met Glu Arg Arg Ala Trp Ser Leu Gln Cys Thr
1 5 10
Ala Phe Val Leu Phe
15
Cys Ala Trp Cys Ala Leu Asn Ser Ala Lys Ala Lys Arg Gln Phe Val
20 25 30
Asn Glu Trp
35
Ala Ala Glu Ile Pro Gly Gly Pro Glu Ala Ala Ser Ala
4540
445
US 9,550,837 B2
-continued
446
Ile Ala Glu Glu Leu Gly Tyr Asp Leu Leu Gly Gln Ile Gly Ser Leu
50 55 60
Glu Asn His Tyr Leu Phe Lys His Lys Asn His Pro Arg Arg Ser Arg
65 70 75 80
Arg Ser Ala Phe His Ile Thr Lys Arg Leu Ser Asp Asp Asp Arg Val
85 90 95
Ile Trp Ala Glu Gln Gln Tyr Glu Lys Glu Arg Ser Lys Arg Ser Ala
100 105 110
Leu Arg Asp Ser Ala Leu Asn Leu Phe Asn Asp Pro Met Trp Asn Gln
115 120 125
Gln Trp Tyr Leu Gln Asp Thr Arg Met Thr Ala Ala Leu Pro Lys Leu
130 135 140
Asp Leu His Val Ile Pro Val Trp Gln Lys Gly Ile Thr Gly Lys Gly
145 150 155 160
Val Val Ile Thr Val Leu Asp Asp Gly Leu Glu Trp Asn His Thr Asp
165 170 175
Ile Tyr Ala Asn Tyr Asp Pro Glu Ala Ser Tyr Asp Phe Asn Asp Asn
180 185 190
Asp His Asp Pro Phe Pro Arg Tyr Asp Pro Thr Asn Glu Asn Lys His
195 200 205
Gly Thr Arg Cys Ala Gly Glu Ile Ala Met Gln Ala Asn Asn His Lys
210 215 220
Cys Gly Val Gly Val Ala Tyr Asn Ser Lys Val Gly Gly Ile Arg Met
225 230 235 240
Leu Asp Gly Ile Val Thr Asp Ala Ile Glu Ala Ser Ser Ile Gly Phe
245 250 255
Asn Pro Gly His Val Asp Ile Tyr Ser Ala Ser Trp Gly Pro Asn Asp
260 265 270
Asp Gly Lys Thr Val Glu Gly Pro Gly Arg Leu Ala Gln Lys Ala Phe
275 280 285
Glu Tyr Gly Val Lys Gln Gly Arg Gln Gly Lys Gly Ser Ile Phe Val
290 295 300
Trp Ala Ser Gly Asn Gly Gly Arg Gln Gly Asp Asn Cys Asp Cys Asp
305 310 315 320
Gly Tyr Thr Asp Ser Ile Tyr Thr Ile Ser Ile Ser Ser Ala Ser Gln
325 330 335
Gln Gly Leu Ser Pro Trp Tyr Ala Glu Lys Cys Ser Ser Thr Leu Ala
340 345 350
Thr Ser Tyr Ser Ser Gly Asp Tyr Thr Asp Gln Arg Ile Thr Ser Ala
355 360 365
Asp Leu His Asn Asp Cys Thr Glu Thr His Thr Gly Thr Ser Ala Ser
370 375 380
Ala Pro Leu Ala Ala Gly Ile Phe Ala Leu Ala Leu Glu Ala Asn Pro
385 390 395 400
Asn Leu Thr Trp Arg Asp Met Gln His Leu Val Val Trp Thr Ser Glu
405 410 415
Tyr Asp Pro Leu Ala Asn Asn Pro Gly Trp Lys Lys Asn Gly Ala Gly
420 425 430
Leu Met Val Asn Ser Arg Phe Gly Phe Gly Leu Leu Asn Ala Lys Ala
435 440 445
Leu Val Asp Leu Ala Asp Pro Arg Thr Trp Arg Ser Val Pro Glu Lys
450 455 460
Lys Glu Cys Val Val Lys Asp Asn Asp Phe Glu Pro Arg Ala Leu Lys
447
US 9,550,837 B2
-continued
448
465 470 475 480
Ala Asn Gly Glu Val Ile Ile Glu Ile Pro Thr Arg Ala Cys Glu Gly
485 490 495
Gln Glu Asn Ala Ile Lys Ser Leu Glu His Val Gln Phe Glu Ala Thr
500 505 510
Ile Glu Tyr Ser Arg Arg Gly Asp Leu His Val Thr Leu Thr Ser Ala
515 520 525
Ala Gly Thr Ser Thr Val Leu Leu Ala Glu Arg Glu Arg Asp Thr Ser
530 535 540
Pro Asn Gly Phe Lys Asn Trp Asp Phe Met Ser Val His Thr Trp Gly
545 550 555 560
Glu Asn Pro Ile Gly Thr Trp Thr Leu Arg Ile Thr Asp Met Ser Gly
565 570 575
Arg Ile Gln Asn Glu Gly Arg Ile Val Asn Trp Lys Leu Ile Leu His
580 585 590
Gly Thr Ser Ser Gln Pro Glu His Met Lys Gln Pro Arg Val Tyr Thr
595 600 605
Ser Tyr Asn Thr Val Gln Asn Asp Arg Arg Gly Val Glu Lys Met Val
610 615 620
Asp Pro Gly Glu Glu Gln Pro Thr Gln Glu Asn Pro Lys Glu Asn Thr
625 630 635 640
Leu Val Ser Lys Ser Pro Ser Ser Ser Ser Val Gly Gly Arg Arg Asp
645 650 655
Glu Leu Glu Glu Gly Ala Pro Ser Gln Ala Met Leu Arg Leu Leu Gln
660 665 670
Ser Ala Phe Ser Lys Asn Ser Pro Pro Lys Gln Ser Pro Lys Lys Ser
675 680 685
Pro Ser Ala Lys Leu Asn Ile Pro Tyr Glu Asn Phe Tyr Glu Ala Leu
690 695 700
Glu Lys Leu Asn Lys Pro Ser Gln Leu Lys Asp Ser Glu Asp Ser Leu
705 710 715 720
Tyr Asn Asp Tyr Val Asp Val Phe Tyr Asn Thr Lys Pro Tyr Lys His
725 730 735
Arg Asp Asp Arg Leu Leu Gln Ala Leu Val Asp Ile Leu Asn Glu Glu
740 745 750
Asn
&210& SEQ ID NO 760
&211& LENGTH: 785
&212& TYPE: PRT
&213& ORGANISM: Homo sapiens
&400& SEQUENCE: 760
Met Pro Lys Gly Arg Gln Lys Val Pro His Leu Asp Ala Pro Leu Gly
1 5 10 15
Leu Pro Thr Cys Leu Trp Leu Glu Leu Ala Gly Leu Phe Leu Leu Val
20 25 30
Pro Trp Val Met Gly Leu Ala Gly Thr Gly Gly Pro Asp Gly Gln Gly
35 40 45
Thr Gly Gly Pro Ser Trp Ala Val His Leu Glu Ser Leu Glu Gly Asp
50 55 60
Gly Glu Glu Glu Thr Leu Glu Gln Gln Ala Asp Ala Leu Ala Gln Ala
65 70 75 80
Ala Gly Leu Val Asn Ala Gly Arg Ile Gly Glu Leu Gln Gly His Tyr
449
US 9,550,837 B2
-continued
450
85 90 95
Leu Phe Val Gln Pro Ala Gly His Arg Pro Ala Leu Glu Val Glu Ala
100 105 110
Ile Arg Gln Gln Val Glu Ala Val Leu Ala Gly His Glu Ala Val Arg
115 120 125
Trp His Ser Glu Gln Arg Leu Leu Arg Arg Ala Lys Arg Ser Val His
130 135 140
Phe Asn Asp Pro Lys Tyr Pro Gln Gln Trp His Leu Asn Asn Arg Arg
145 150 155 160
Ser Pro Gly Arg Asp Ile Asn Val Thr Gly Val Trp Glu Arg Asn Val
165 170 175
Thr Gly Arg Gly Val Thr Val Val Val Val Asp Asp Gly Val Glu His
180 185 190
Thr Ile Gln Asp Ile Ala Pro Asn Tyr Ser Pro Glu Gly Ser Tyr Asp
195 200 205
Leu Asn Ser Asn Asp Pro Asp Pro Met Pro His Pro Asp Val Glu Asn
210 215 220
Gly Asn His His Gly Thr Arg Cys Ala Gly Glu Ile Ala Ala Val Pro
225 230 235 240
Asn Asn Ser Phe Cys Ala Val Gly Val Ala Tyr Gly Ser Arg Ile Ala
245 250 255
Gly Ile Arg Val Leu Asp Gly Pro Leu Thr Asp Ser Met Glu Ala Val
260 265 270
Ala Phe Asn Lys His Tyr Gln Ile Asn Asp Ile Tyr Ser Cys Ser Trp
275 280 285
Gly Pro Asp Asp Asp Gly Lys Thr Val Asp Gly Pro His Gln Leu Gly
290 295 300
Lys Ala Ala Leu Gln His Gly Val Ile Ala Gly Arg Gln Gly Phe Gly
305 310 315 320
Ser Ile Phe Val Val Ala Ser Gly Asn Gly Gly Gln His Asn Asp Asn
325 330 335
Cys Asn Tyr Asp Gly Tyr Ala Asn Ser Ile Tyr Thr Val Thr Ile Gly
340 345 350
Ala Val Asp Glu Glu Gly Arg Met Pro Phe Tyr Ala Glu Glu Cys Ala
355 360 365
Ser Met Leu Ala Val Thr Phe Ser Gly Gly Asp Lys Met Leu Arg Ser
370 375 380
Ile Val Thr Thr Asp Trp Asp Leu Gln Lys Gly Thr Gly Cys Thr Glu
385 390 395 400
Gly His Thr Gly Thr Ser Ala Ala Ala Pro Leu Ala Ala Gly Met Ile
405 410 415
Ala Leu Met Leu Gln Val Arg Pro Cys Leu Thr Trp Arg Asp Val Gln
420 425 430
His Ile Ile Val Phe Thr Ala Thr Arg Tyr Glu Asp Arg Arg Ala Glu
435 440 445
Trp Val Thr Asn Glu Ala Gly Phe Ser His Ser His Gln His Gly Phe
450 455 460
Gly Leu Leu Asn Ala Trp Arg Leu Val Asn Ala Ala Lys Ile Trp Thr
465 470 475 480
Ser Val Pro Tyr Leu Ala Ser Tyr Val Ser Pro Val Leu Lys Glu Asn
485 490 495
Lys Ala Ile Pro Gln Ser Pro Arg Ser Leu Glu Val Leu Trp Asn Val
500 505 510
451
US 9,550,837 B2
-continued
452
Ser Arg Met Asp Leu Glu Met Ser Gly Leu Lys Thr Leu Glu His Val
515 520 525
Ala Val Thr Val Ser Ile Thr His Pro Arg Arg Gly Ser Leu Glu Leu
530 535 540
Lys Leu Phe Cys Pro Ser Gly Met Met Ser Leu Ile Gly Ala Pro Arg
545 550 555 560
Ser Met Asp Ser Asp Pro Asn Gly Phe Asn Asp Trp Thr Phe Ser Thr
565 570 575
Val Arg Cys Trp Gly Glu Arg Ala Arg Gly Thr Tyr Arg Leu Val Ile
580 585 590
Arg Asp Val Gly Asp Glu Ser Phe Gln Val Gly Ile Leu Arg Gln Trp
595 600 605
Gln Leu Thr Leu Tyr Gly Ser Val Trp Ser Ala Val Asp Ile Arg Asp
610 615 620
Arg Gln Arg Leu Leu Glu Ser Ala Met Ser Gly Lys Tyr Leu His Asp
625 630 635 640
Asp Phe Ala Leu Pro Cys Pro Pro Gly Leu Lys Ile Pro Glu Glu Asp
645 650 655
Gly Tyr Thr Ile Thr Pro Asn Thr Leu Lys Thr Leu Val Leu Val Gly
660 665 670
Cys Phe Thr Val Phe Trp Thr Val Tyr Tyr Met Leu Glu Val Tyr Leu
675 680 685
Ser Gln Arg Asn Val Ala Ser Asn Gln Val Cys Arg Ser Gly Pro Cys
690 695 700
His Trp Pro His Arg Ser Arg Lys Ala Lys Glu Glu Gly Thr Glu Leu
705 710 715 720
Glu Ser Val Pro Leu Cys Ser Ser Lys Asp Pro Asp Glu Val Glu Thr
725 730 735
Glu Ser Arg Gly Pro Pro Thr Thr Ser Asp Leu Leu Ala Pro Asp Leu
740 745 750
Leu Glu Gln Gly Asp Trp Ser Leu Ser Gln Asn Lys Ser Ala Leu Asp
755 760 765
Cys Pro His Gln His Leu Asp Val Pro His Gly Lys Glu Glu Gln Ile
770 775 780
Cys
785
&210& SEQ ID NO 761
&211& LENGTH: 692
&212& TYPE: PRT
&213& ORGANISM: Macaca fascicularis
&400& SEQUENCE: 761
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Pro
1 5 10 15
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu
20 25 30
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu
35 40 45
Glu Asp Gly Leu Ala Asp Ala Pro Glu His Gly Ala Thr Ala Thr Phe
50 55 60
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65 70 75 80
Val Leu Lys Glu Glu Thr His Arg Ser Gln Ser Glu Arg Thr Ala Arg
453
US 9,550,837 B2
-continued
454
85 90 95
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
100 105 110
His Val Phe His His Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly
115 120 125
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu
130 135 140
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg
145 150 155 160
Ile Thr Pro Ala Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Lys Gly
165 170 175
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp
180 185 190
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Ser Val
195 200 205
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp
210 215 220
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly
225 230 235 240
Val Ala Lys Gly Ala Gly Leu Arg Ser Leu Arg Val Leu Asn Cys Gln
245 250 255
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
260 265 270
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Val Phe Asn Ala Ala Cys Gln Arg Leu
290 295 300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp
305 310 315 320
Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
325 330 335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Arg Ser Gly
370 375 380
Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu
385 390 395 400
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile
405 410 415
His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp
420 425 430
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr
435 440 445
His Arg Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His
450 455 460
Ser Gly Pro Thr Arg Met Ala Thr Ala Val Ala Arg Cys Ala Gln Asp
465 470 475 480
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
485 490 495
Gly Glu Arg Ile Glu Ala Gln Gly Gly Lys Arg Val Cys Arg Ala His
500 505 510
455
US 9,550,837 B2
-continued
456
Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
515 520 525
Leu Pro Gln Val Asn Cys Ser Val His Thr Ala Pro Pro Ala Gly Ala
530 535 540
Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr
545 550 555 560
Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro
565 570 575
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg
580 585 590
Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys
595 600 605
Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Ile Val
610 615 620
Ala Cys Glu Asp Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly
625 630 635 640
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
645 650 655
Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val
660 665 670
Ala Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Val Gln Ala Ser
675 680 685
Gln Glu Leu Gln
690
&210& SEQ ID NO 762
&211& LENGTH: 698
&212& TYPE: PRT
&213& ORGANISM: Mesocricetus auratus
&400& SEQUENCE: 762
Met Gly Thr Ser Cys Ser Ala Arg Pro Arg Trp Leu Leu Ser Pro Leu
1 5 10 15
Leu Leu Leu Leu Leu Leu Leu Arg Tyr Met Gly Ala Ser Ala Gln Asp
20 25 30
Glu Asp Ala Glu Tyr Glu Glu Leu Met Leu Thr Leu Gln Ser Gln Asp
35 40 45
Asp Gly Leu Ala Asp Glu Thr Asp Glu Ala Pro Gln Gly Ala Thr Ala
50 55 60
Ala Phe His Arg Cys Pro Glu Glu Ala Trp Arg Val Pro Gly Thr Tyr
65 70 75 80
Ile Val Met Leu Ala Glu Glu Ala Gln Trp Val His Ile Glu Gln Thr
85 90 95
Met His Arg Leu Gln Thr Gln Ala Ala Arg Arg Gly Tyr Val Ile Lys
100 105 110
Ile Gln His Ile Phe Tyr Asp Phe Leu Pro Ala Phe Val Val Lys Met
115 120 125
Ser Ser Asp Leu Leu Asp Leu Ala Leu Lys Leu
130 135
Pro His Val Lys Tyr
140
Ile Glu Glu Asp Ser Leu Val Phe Ala Gln Ser Ile Pro Trp Asn Leu
145 150 155 160
Asp Arg Ile Ile Pro Ala Gly Arg Gln Ala Gln Glu Tyr Ser Ser Ser
165 170 175
Arg Lys Val Pro Ser Gly Ser Gly Gln Val Glu Val Tyr Leu Leu Asp
180 185 190
457
US 9,550,837 B2
-continued
458
Thr Ser Ile Gln Ser Asp His Arg Glu Ile Glu Gly Arg Val Thr Val
195 200 205
Thr Asp Phe Asn Ser Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg
210 215 220
Gln Ala Ser Lys Cys Asp Ser His Gly Thr His Leu Ala Gly Val Val
225 230 235 240
Ser Gly Arg Asp Ala Gly Val Ala Lys Gly Thr Ile Leu His Gly Leu
245 250 255
Arg Val Leu Asn Cys Gln Gly Lys Gly Ile Val Ser Gly Ile Leu Thr
260 265 270
Gly Leu Glu Phe Ile Trp Lys Ser Gln Leu Met Gln Pro Ser Gly Pro
275 280 285
Gln Val Val Leu Leu Pro Leu Ala Gly Arg Tyr Ser Arg Val Leu Asn
290 295 300
Thr Ala Cys Gln His Leu Ala Arg Thr Gly Val Val Leu Val Ala Ala
305 310 315 320
Ala Gly Asn Phe Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala
325 330 335
Pro Glu Val Ile Thr Val Gly Ala Thr Asp Val Gln Asp Gln Pro Val
340 345 350
Thr Leu Gly Thr Leu Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe
355 360 365
Ala Pro Gly Lys Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Ala Cys
370 375 380
Phe Met Ser Gln Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly
385 390 395 400
Ile Val Ala Met Met Leu Thr Leu Glu Pro Glu Leu Thr Leu Thr Glu
405 410 415
Leu Arg Gln Arg Leu Ile His Phe Ser Thr Lys Asp Ala Ile Asn Met
420 425 430
Ala Trp Phe Pro Glu Asp Gln Arg Val Leu Thr Pro Asn Leu Val Ala
435 440 445
Thr Leu Pro Pro Ser Thr His Gly Thr Gly Gly Gln Leu Leu Cys Arg
450 455 460
Thr Val Trp Ser Ala His Ser Gly Pro Thr Arg Ala Ala Thr Ala Thr
465 470 475 480
Ala Arg Cys Ala Pro Gly Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser
485 490 495
Arg Ser Gly Arg Arg Arg Gly Asp Arg Ile Glu Ala Ala Gly Thr Gln
500 505 510
Gln Val Cys Lys Ala Leu Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala
515 520 525
Val Ala Arg Cys Cys Leu Leu Pro Arg Ala Asn Cys Ser Ile His Thr
530 535 540
Thr Pro Ala Ala Arg Thr Ser Leu Glu Thr His Ala His Cys His Gln
545 550 555 560
Lys Asp His Val Leu Thr Gly Cys Ser Leu His Trp Glu Val Glu Gly
565 570 575
Ile Gly Val Gln Pro Leu Ala Val Leu Arg Ser Arg His Gln Pro Gly
580 585 590
Gln Cys Thr Gly His Arg Glu Ala Ser Val His Ala Ser Cys Cys His
595 600 605
459
US 9,550,837 B2
-continued
460
Ala Pro Gly Leu Glu Cys Lys Ile Lys Glu His Gly Ile Ser Gly Pro
610 615 620
Ala Glu Gln Val Thr Val Ala Cys Glu Ala Gly Trp Thr Leu Thr Gly
625 630 635 640
Cys Asn Val Leu Pro Gly Ala Phe Ile Thr Leu Gly Ala Tyr Ala Val
645 650 655
Asp Asn Thr Cys Val Ala Arg Ser Arg Val Thr Asp Thr Ala Gly Arg
660 665 670
Thr Gly Glu Glu Ala Thr Val Ala Ala Ala Ile Cys Cys Arg Asn Arg
675 680 685
Pro Ser Ala Lys Ala Ser Trp Val His Gln
690 695
&210& SEQ ID NO 763
&211& LENGTH: 691
&212& TYPE: PRT
&213& ORGANISM: Rattus norvegicus
&400& SEQUENCE: 763
Met Gly Ile Arg Cys Ser Thr Trp Leu Arg Trp Pro Leu Ser Pro Gln
1 5 10 15
Leu Leu Leu Leu Leu Leu Leu Cys Pro Thr Gly Ser Arg Ala Gln Asp
20 25 30
Glu Asp Gly Asp Tyr Glu Glu Leu Met Leu Ala Leu Pro Ser Gln Glu
35 40 45
Asp Ser Leu Val Asp Glu Ala Ser His Val Ala Thr Ala Thr Phe Arg
50 55 60
Arg Cys Ser Lys Glu Ala Trp Arg Leu Pro Gly Thr Tyr Val Val Val
65 70 75 80
Leu Met Glu Glu Thr Gln Arg Leu Gln Val Glu Gln Thr Ala His Arg
85 90 95
Leu Gln Thr Trp Ala Ala Arg Arg Gly Tyr Val Ile Lys Val Leu His
100 105 110
Val Phe Tyr Asp Leu Phe Pro Gly Phe Leu Val Lys Met Ser Ser Asp
115 120 125
Leu Leu Gly Leu Ala Leu Lys Leu Pro His Val Glu Tyr Ile Glu Glu
130 135 140
Asp Ser Leu Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg Ile
145 150 155 160
Ile Pro Ala Trp Gln Gln Thr Glu Glu Asp Ser Ser Pro Asp Gly Ser
165 170 175
Ser Gln Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Gly His
180 185 190
Arg Glu Ile Glu Gly Arg Val Thr Ile Thr Asp Phe Asn Ser Val Pro
195 200 205
Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp Ser
210 215 220
His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly Val
225 230 235 240
Ala Lys Gly Thr Ser Leu His Ser Leu
245
Arg Val Leu Asn Cys Gln Gly
250 255
Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg Lys
260 265 270
Ser Gln Leu Ile Gln Pro Ser Gly Pro Leu Val Val Leu Leu Pro Leu
275 280 285
461
US 9,550,837 B2
-continued
462
Ala Gly Gly Tyr Ser Arg Ile Leu Asn Thr Ala Cys Gln Arg Leu Ala
290 295 300
Arg Thr Gly Val Val Leu Val Ala Ala Ala Gly Asn Phe Arg Asp Asp
305 310 315 320
Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val Gly
325 330 335
Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly Thr
340 345 350
Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Lys Asp Ile Ile
355 360 365
Gly Ala Ser Ser Asp Cys Ser Thr Cys Tyr Met Ser Gln Ser Gly Thr
370 375 380
Ser Gln Ala Ala Ala His Val Ala Gly Ile Val Ala Met Met Leu Asn
385 390 395 400
Arg Asp Pro Ala Leu Thr Leu Ala Glu Leu Arg Gln Arg Leu Ile Leu
405 410 415
Phe Ser Thr Lys Asp Val Ile Asn Met Ala Trp Phe Pro Glu Asp Gln
420 425 430
Arg Val Leu Thr Pro Asn Arg Val Ala Thr Leu Pro Pro Ser Thr Gln
435 440 445
Glu Thr Gly Gly Gln Leu Leu Cys Arg Thr Val Trp Ser Ala His Ser
450 455 460
Gly Pro Thr Arg Thr Ala Thr Ala Thr Ala Arg Cys Ala Pro Glu Glu
465 470 475 480
Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Arg Arg Arg Gly
485 490 495
Asp Arg Ile Glu Ala Ile Gly Gly Gln Gln Val Cys Lys Ala Leu Asn
500 505 510
Ala Phe Gly Gly Glu Gly Val Tyr Ala Val Ala Arg Cys Cys Leu Leu
515 520 525
Pro Arg Val Asn Cys Ser Ile His Asn Thr Pro Ala Ala Arg Ala Gly
530 535 540
Pro Gln Thr Pro Val His Cys His Gln Lys Asp His Val Leu Thr Gly
545 550 555 560
Cys Ser Phe His Trp Glu Val Glu Asn Leu Arg Ala Gln Gln Gln Pro
565 570 575
Leu Leu Arg Ser Arg His Gln Pro Gly Gln Cys Val Gly His Gln Glu
580 585 590
Ala Ser Val His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys Lys
595 600 605
Ile Lys Glu His Gly Ile Ala Gly Pro Ala Glu Gln Val Thr Val Ala
610 615 620
Cys Glu Ala Gly Trp Thr Leu Thr Gly Cys Asn Val Leu Pro Gly Ala
625 630 635 640
Ser Leu Pro Leu Gly Ala Tyr Ser Val Asp Asn Val Cys Val Ala Arg
645 650 655
Ile Arg Asp Ala Gly Arg Ala Asp Arg Thr Ser Glu Glu Ala Thr Val
660 665 670
Ala Ala Ala Ile Cys Cys Arg Ser Arg Pro Ser Ala Lys Ala Ser Trp
675 680 685
Val His Gln
690
463
US 9,550,837 B2
464
We claim:
1.A method for treating a subject selected from the group
consisting of: a subject indicated for LDL apheresis, a
subject with a PCSK9 gain of function mutation, and a
subject with primary hypercholesterolemia who is statin
intolerant or statin uncontrolled, the method comprising
administering to the subject a therapeutically efiective
amount of a pharmaceutical composition comprising an
antibody or antigen-binding fragment thereof which specifi-
cally binds hPCSK9, wherein the antibody or antigen-
binding fragment comprises the heavy and light chain CDRs
of a HCVR/LCVR amino acid sequence pair selected from
the group consisting of SEQ ID NOs:90/92 and 218/226.
2. The method of claim 1, wherein the antibody or
antigen-binding fragment comprises heavy and light chain
CDR amino acid sequences having SEQ ID NOs:220, 222,
224, 228, 230 and 232.
3. The method of claim 2, wherein the antibody or
antigen-binding fragment comprises an HCVR having the
amino acid sequence of SEQ ID NO:218 and an LCVR
having the amino acid sequence of SEQ ID NO:226.
4. The method of claim 1, wherein the antibody or
antigen-binding fragment comprises heavy and light chain
CDR amino acid sequences having SEQ ID NOs:76, 78, 80,
84, 86 and 88.
5
10
15
20
5. The method of claim 4, wherein the antibody or
antigen-binding fragment comprises an HCVR having the
amino acid sequence of SEQ ID NO:90 and an LCVR
having the amino acid sequence of SEQ ID NO:92.
6. The method of claim 1, wherein the antibody or
antigen-binding fragment binds to the same epitope on
hPCSK9 as an antibody comprising heavy and light chain
CDR amino acid sequences having SEQ ID NOs:220, 222,
224, 228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86
and 88.
7. The method of claim 1, wherein the antibody or
antigen-binding fragment competes for binding to hPCSK9
with an antibody comprising heavy and light chain CDR
amino acid sequences having SEQ ID NOs:220, 222, 224,
228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86 and
88.
S. The method of claim 1, wherein the subject has familial
hypercholesterolemia (FH).
9. The method of claim S, wherein the familial hyperc-
holesterolemia is heterozygous familial hypercholester-
olemia (heFH).
10. The method of claim S, wherein the familial hyperc-
holesterolemia is homozygous familial hypercholester-
olemia (hoFH).

